Novel biomarkers in two gastrointestinal malignancies - the potential of early detection and identification of new therapies by Sagar, Vandana Mridhu
 1 
Novel biomarkers in two gastrointestinal 
malignancies - the potential of early 
detection and identification of new 
therapies 
 
By 
 
Vandana Mridhu Sagar 
MRCP (UK) (Gastroenterology), MBChB 
 
A thesis submitted to the University of Birmingham for the degree of  
 
DOCTOR OF MEDICINE 
 
 
Centre for Liver and Gastroenterology Research 
Institute of Immunology and Immunotherapy 
College of Medical and Dental Sciences 
University of Birmingham 
May 2019 
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 
of the copyright holder.  
 
 
 
 2 
Abstract 
Currently, there are no sufficient biomarkers that can be utilised in 
hepatocellular cancer (HCC) and neuroendocrine tumours (NETs) that can help 
in making an early diagnosis, or recognise serious complications that can be 
associated with the tumour. HCC is usually diagnosed at an advanced stage 
when curative treatment options are limited. There is no recommended 
biomarker to use in clinical practice to diagnose early HCC at present. NETs 
can occur in different sites, but the gastroenteropancreatic NETs are the 
commonest sites of origin. Serious complications can be associated with this 
cancer due to the underlying gastrointestinal and cardiac valve fibrosis, 
including intestinal obstruction and ischaemia, and carcinoid heart disease 
(CHD).  
Within this thesis the suitability of prothrombin induced by vitamin K absence-II 
(PIVKA-II) as a biomarker in HCC will be presented. The aims of this study are 
to compare PIVKA-II to the traditional marker alpha-fetoprotein (AFP) in 
diagnosing early HCC, as well as a combination of both biomarkers, assess 
PIVKA-II levels in patients undergoing ablation therapy, and assess if levels of 
PIVKA-II increase with disease progression of HCC. The second project in this 
thesis describes the suitability of vascular adhesion-protein 1 (VAP-1) as a 
biomarker in NETs and CHD. The aims of this project are to compare the levels 
of soluble VAP-1 (sVAP-1) in different NET cohorts and healthy volunteers and 
compare levels of sVAP-1 pre- and post-treatment in midgut NETs. I also aim to 
study the tissue expression of VAP-1 in midgut NET tissue and CHD.  
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AFP has been the traditional marker used in HCC surveillance. PIVKA-II was 
not found to be a superior marker to AFP in diagnosing early HCC, and the 
combination of both markers was only slightly better compared to AFP alone. 
However, on explant histology, pre-transplant serum PIVKA-II levels were found 
to be significantly higher in the presence of microvascular invasion and also in 
moderately- or poorly- differentiated HCC. This was not seen with AFP. In the 
longitudinal data analysis, PIVKA-II shows a promising role in the surveillance 
of recurrent HCC post-ablation.  
Tissue expression of VAP-1 was present in midgut NETs and in the CHD 
valves, associated with the presence of a dense stromal and collagen network. 
Significantly higher % area of tissue expression of VAP-1 was seen in CHD 
valves compared to control valves. Across the healthy controls, midgut NETs 
and CHD groups, significantly higher levels of circulating sVAP-1 was seen with 
highest levels found in CHD. The longitudinal data analysis did not show any 
significant change in the sVAP-1 levels between the pre- and post-treatment 
samples, similar to the markers currently used in clinical practice (chromogranin 
A, 24 hour urinary 5-hydroxyindole acetic acid and N-terminal pro b-type 
natriuretic peptide).  
PIVKA-II could therefore be a prognostic marker in HCC and may support 
patient stratification for therapy. Despite a small number in the longitudinal data 
analysis, PIVKA-II shows a promising role in the surveillance of recurrent HCC 
post-ablation therapy. The VAP-1 study identifies the presence of VAP-1, both 
in a circulating form and tissue expression in midgut NETs and in CHD, and 
therefore could be a potential biomarker and treatment target in NETs. 
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1. Introduction 
Increasing knowledge on the biology of cancer, in addition to a greater 
understanding in the pathophysiology of the disease, has led to a significant 
interest in the use of biomarkers.(1) A biomarker is defined by the National  
Cancer Institute as ‘a biological molecule found in blood, other body fluids, or 
tissues that is a sign of a normal or abnormal process, or of a condition or 
disease.’(2)  
 
Biomarkers can help diagnose cancer at an early stage allowing curative 
treatment options to be considered, as well as being implemented as a 
surveillance and treatment response marker. Biomarkers can also be used to 
help detect complications early when treatment can then be offered. 
In this thesis two markers will be discussed, one in hepatocellular carcinoma 
(HCC) and one in neuroendocrine tumours (NETs), where there are unmet 
needs in both these cancers, with an overall aim of diagnosing cancer or 
detecting complications early to allow the initiation of treatment. The markers 
that will be discussed in this thesis are prothrombin induced by vitamin K 
absence-II (PIVKA-II) in HCC and vascular adhesion protein-1 (VAP-1) in NETs. 
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1.1 Epidemiology, aetiology and pathogenesis of hepatocellular 
carcinoma 
Incidence of HCC varies according to geographic regions, with high incidence 
of disease found in Asian countries including China, Southeast Asia, and Sub-
Saharan Western and Eastern Africa.(3) In 2016, a total of 5933 cases of HCC 
were diagnosed in the United Kingdom (UK). The age-standardised incidence 
rate for males in 2016 in the UK was 14.1 per 100,000 population, and 6.1 per 
100,000 population for females.(4) A variety of risk factors for HCC exist, with 
viral infections showing a strong association with HCC development worldwide. 
Other common risk factors that can cause HCC include alcohol, smoking, non-
alcoholic fatty liver disease and hereditary haemochromatosis.(3) Around 90% 
of cases occur in the presence of underlying liver cirrhosis.(5, 6) In addition to 
the extrinsic risk factors, genetic mutations also can lead to the development of 
HCC.(3) 
Chronic liver inflammation and fibrosis are present in the background liver 
occurring as a result of continuous liver insult and injury to common causes 
including alcohol and viral infections. These hepatotoxic agents target the 
hepatocytes which leads to the release of reactive oxygen species (ROS) and 
cytokines (including platelet derived growth factor, transforming growth factor , 
TGF-, tumour necrosis factor-, interleukins and interferons), and activation of 
hepatic stellate cells resulting in the onset of fibrosis and extracellular matrix 
(ECM) production. The presence of chronic inflammation and fibrosis influences 
certain changes to take place in the microenvironment, including hepatocyte 
proliferation and chromosomal instability (by telomere shortening), thereby 
 24 
predisposing to HCC development.(7) Alterations in genomes have been found 
to drive HCC progression including mutations affecting telomere maintenance, 
activation of Wnt/-catenin, mechanistic target of rapamycin (mTOR) and ROS 
pathways, inactivation of p53, and activation of the Ras signalling pathway.(8)  
Another change in the microenvironment is hypoxia-induced reactive nitrogen 
species production, and upregulation of angiogenic factors such as vascular 
endothelial growth factor (VEGF), leading to tumour angiogenesis and 
growth.(9) Gut microbiota and lipopolysachharides are also a driver to HCC 
development, by promoting inflammatory reactions in the hepatic 
microenvironment and activating Kupffer cells and endothelial cells to trigger the 
release of pro-inflammatory chemokines leading to liver inflammation and 
fibrosis.(10) Additionally, changes in the innate and adaptive immune system 
influences tumour progression by causing the immune system to become 
tolerant to cancer.(7) 
 
1.2 Background of hepatocellular carcinoma 
Worldwide, HCC is the fifth most common cause of cancer, and is the second 
leading cause of deaths related to cancer.(11) The American Cancer Society 
has recently shown that the overall 5-year relative survival rate in all cancers 
combined has improved, and the overall cancer mortality rate has also reduced. 
A large reduction in the mortality associated with the 4 major cancers (lung, 
breast, prostate and colorectal) has also been witnessed, largely because of an 
improvement in early diagnosis and effective treatments being offered.(12) 
However, in contrast to the reduced mortality observed in these cancers, HCC 
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has shown an increase in mortality rate.(12) Liver cancer mortality rates have 
increased by approximately 55% over the last decade, and between 2014 and 
2035, mortality rates are estimated to rise by 58% in the UK.(4) The 5-year 
survival without treatment for patients with HCC is 10 – 12%.(13) However, with 
early detection and diagnosis of the cancer, the 5-year survival rate improves 
markedly to >70%.(11) This therefore highlights the importance of developing 
markers that will contribute towards an earlier diagnosis of cancer, to enable 
more effective and potentially curative treatment to be provided.  
 
1.3 Biomarkers in hepatocellular carcinoma 
The presence of liver inflammation and cirrhosis may complicate the early 
diagnosis of HCC.(11) Hence, the use of biomarkers is increasingly being 
required to assist in making the diagnosis. If HCC is diagnosed at an early 
stage, curative treatment options including liver resection, ablative techniques 
and liver transplantation can be offered, thereby improving the overall morbidity 
and mortality associated with this cancer.  
 
Three biomarkers used in clinical practice in Japan include alpha-fetoprotein 
(AFP), Lens-culinaris agglutinin-reactive alpha-fetoprotein (AFP-L3) and des - 
carboxy-prothrombin (DCP).(14) The diagnostic accuracy of the combination of 
these three biomarkers has been shown to be greater in diagnosing both HCC 
and early HCC compared to each marker alone.(15) AFP is used in combination 
with ultrasound (US) imaging in high-risk patients in Asia, but a high level of 
uncertainty in the clinical effectiveness of this marker does remain.(14) 
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However, in Western Countries, including the United Kingdom (UK), guidelines 
do not include the utilisation of this marker.(16, 17)  
 
An ideal biomarker is one that is non-invasive, is tumour-specific, can be used 
as a screening marker in asymptomatic patients, has a high sensitivity and 
specificity (≥ 90%), and finally is cost-effective.(11) 
 
1.3.1 Alpha-fetoprotein in hepatocellular carcinoma 
Traditionally, AFP has been used as the main biomarker in detecting the 
presence of HCC. However, a number of investigations looking at the diagnostic 
utility of this marker have been undertaken.(18)  
 
A meta-analysis showed a combined sensitivity of 66% and specificity of 95% 
for AFP.(19) One study showed a relationship between high serum AFP with 
the presence of important HCC features, including a larger tumour size, bilobar 
involvement, and evidence of portal vein thrombosis (PVT). However, there was 
no correlation identified between an increased AFP level and other tumour 
characteristics including degree of tumour differentiation or the presence of 
extrahepatic metastasis.(20) Another study conducted in a Sicilian population, 
showed a sensitivity of 65% and a specificity of 89% with an AFP cut-off value 
of 30 nanograms/millilitres (ng/mL) to differentiate HCC from liver cirrhosis.(21) 
Marrero et al found the optimal cut-off value for AFP to be 10.9 ng/mL in 
diagnosing early HCC in a cohort of patients with cirrhosis, yielding a sensitivity 
of 66%.(22) A Chinese group reported that AFP is an independent risk predictor 
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in tumour differentiation, size and survival.(23) These results therefore show 
varying results on the suitability of AFP as an ideal biomarker in diagnosing 
HCC.  
 
The European Association for the Study of the Liver - European Organisation 
for Research and Treatment of Cancer clinical practice guidelines (EASL-
EORTC CPG) has provided guidance in the surveillance of HCC, advising that 
surveillance should involve using 6-monthly abdominal ultrasound imaging in all 
at-risk groups without the measurement of the traditional tumour marker, 
AFP.(17) Interestingly, a recent meta-analysis showed that the addition of AFP 
to US imaging significantly increased the sensitivity in diagnosing early HCC. 
US alone diagnosed early stage HCC with a sensitivity of 45% compared to a 
sensitivity of 63% with the addition of AFP (P=0.002).(24) 
 
Table 1 shows the sensitivities and specificities associated with AFP in 
diagnosing HCC in different clinical scenarios found in various studies. 
Regarding AFP, the optimal cut-off value ranged from 10.9 ng/mL to 200 ng/mL. 
The sensitivity and specificity ranged from 40% to 95.2%, and 47.1% to 100%, 
respectively.  
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Study Clinical scenario AFP Cut-off 
value 
Sensitivity Specificity 
Taketa et al(25) HCC from cirrhosis 30 ng/mL 65% 89% 
Taketa at al(25) HCC 200 ng/mL 70% 100% 
Marrero et al(22) Early-stage HCC 10.9 ng/mL 65% 82% 
Sung et al(26) HCC among 
cirrhosis 
20 ng/mL 55% 90% 
Hippo et al (27) HCC from non-
malignant liver 
diseases 
20 ng/mL 73% 77% 
Marrero et al (28) HCC from chronic 
cirrhosis 
13.6 ng/mL 95.2% 47.1% 
Muramatsu(29) HCC 20 ng/mL 51.9% 86.3% 
Muramatsu(29) Early stage HCC 20 ng/mL 40% NA 
Zhu et al (30) HCC 20 ng/mL 62.5% 53.3% 
Zhu et al (30) Early stage HCC 20 ng/mL 40% NA 
Fouad et al(31) HCC from cirrhosis 20 ng/mL 53% 93% 
Fouad et al(31) Early stage HCC 
from cirrhosis 
20 ng/mL 46% 93% 
Zhang et al(32) HCC 14.88 ng/mL 63.4% 79.7% 
Zhang et al(32) Early stage HCC 15.64 ng/mL 55% 81.3% 
Mao et al (33) HCC 35 ng/mL 58% 85% 
Giannelli et al (34) HCC 18.8 ng/mL 41% 94% 
Hussein et al (35) HCC 7.7 ng/mL 90% 93% 
      
Table 1: Sensitivities and specificities of the biomarker, AFP, in various 
clinical applications. AFP, alpha-fetoprotein. HCC, hepatocellular carcinoma. 
(Adapted from Lou et al. (18) and Witjes et al. (36)). 
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In addition to AFP and PIVKA-II, there are various biomarkers currently being 
assessed and used in diagnosing early HCC, including AFP-L3, glypican-3 
(GPC3), osteopontin (OPN), golgi-protein-73 (GP73), nucleic acids and 
microRNAs (miRNAs).(11)  
 
AFP-L3 is a glycoform of AFP and is increased specifically in HCC with AFP-L3 
levels correlating with AFP levels.(11) A multicentre study showed that AFP-L3 
had a sensitivity of 28% and a specificity of 97% in diagnosing early HCC.(22) 
When total AFP levels are <20 ng/mL, AFP-L3 is not usually detected, and 
therefore AFP-L3 cannot be used as a biomarker for HCC when total AFP 
concentrations are <20 ng/mL. The sensitivity of AFP-L3 is therefore limited by 
overall AFP levels.(11)  
 
GPC3 is a member of the glypican family and binds to the cell surface 
membrane. It is involved in cellular proliferation and survival, as well as tumour 
suppression, and is usually not present in healthy and non-cancerous 
hepatocytes.(11) GP73 has been found to be upregulated in HCC.(26) A meta-
analysis showed the pooled sensitivity and specificity of serum GPC3 in the 
early diagnosis of HCC was 55.1% and 97% respectively, compared to 34.7% 
and 87.6% respectively for AFP.(37) 
 
OPN is an integrin-binding glycophosphoprotein that is overexpressed in 
various malignancies and is involved in tumour growth, progression and 
metastasis.(11, 38) Increased expression of serum OPN has been seen in HCC 
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compared to normal liver / chronic hepatitis / cirrhosis patients.(39, 40) One 
study showed that OPN had a sensitivity and specificity for early HCC of 75% 
and 62% respectively compared to 46% and 93% respectively for AFP.(39) 
 
GP73 is a type II golgi-specific membrane protein usually expressed in epithelial 
cells of different human tissue types excluding hepatocytes. However, serum 
GP73 is found in patients with liver disease especially in HCC.(11, 41) One 
study showed a higher sensitivity of serum GP73 in diagnosing early HCC 
compared to AFP.(42) Another study showed GP73 had a significantly higher 
sensitivity for diagnosing early HCC compared to AFP, 62% and 25% 
respectively.(28) 
 
Molecular biomarkers for disease diagnosis by probing nucleic acids using 
microarray technology is an alternative method of detecting disease.(43) Three 
separate genes have been found associated with HCC by Shi et al and showed 
that the combination of all three gene markers increased the accuracy in 
detecting early HCC compared to individual gene markers, with a sensitivity of 
72% and specificity of 95%. The study also showed that the addition of AFP 
improved the accuracy and sensitivity in detecting early HCC.(44)     
 
MicroRNAs have been found to play a role both as oncogenes as well as 
tumour suppressor genes in human cancer.(45) Serum miR-15b and miR-130b 
are found to be upregulated in HCC.(46) Both miRNA markers have a high 
sensitivity in early HCC which may be beneficial when AFP levels are low.(46)  
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1.4 GALAD and BALAD-2 Score 
The gender, age, AFP-L3, AFP, and DCP (GALAD) score and bilirubin, 
albumin, AFP-L3, AFP, and DCP (BALAD-2) score are two validated models in 
diagnosing HCC and predicting patient survival respectively in international 
patient cohorts.(47) The BALAD-2 score is very similar to the BALAD score that 
was originally developed in Japan, but has been shown to have a slightly better 
performance incorporating a more detailed statistical analysis.(48, 49)The 
GALAD score was found to have a superior area under the receiver operating 
characteristic curve (AUROC) in diagnosing HCC in the UK, German and Japan 
cohorts compared to each individual marker, as well in diagnosing early HCC in 
the UK and Japan cohorts. The BALAD-2 score reflects both the severity of liver 
dysfunction by incorporating the bilirubin and albumin levels into the score, as 
well as tumour associated factors by including the AFP-L3, AFP and DCP. The 
score  showed a clear differentiation in the four different score categories in the 
median survival in the UK, German, Japan and Hong Kong cohorts, irrespective 
of tumour size and liver disease aetiology.(47, 48) The GALAD score was also 
shown to significantly improve the detection of early HCC according to the 
BCLC staging, with a sensitivity of 85.6% and a specificity of 93.3%.(50) 
Given that these scores were applied to various international cohorts, they have 
the ability to be utilised in an international setting.(47) 
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1.5 Radiological diagnosis of hepatocellular carcinoma  
It is thought that early diagnosis of HCC is possible in 30-60% of cases in 
developed countries, therefore enabling curative interventions to be applied.(17) 
Liver biopsy remained the standard test to be performed to diagnose HCC until 
2000. However, improvements in radiological investigations and technique 
meant that diagnosis could be based on imaging alone. EASL and American 
Association for the Study of Liver Diseases (AASLD) adopted a specific HCC 
radiological feature: evidence of contrast uptake in the arterial phase (arterial 
hypervascularity) with washout in the venous/late phase.(17) 
 
Patients who should be entered into the surveillance programme to screen for 
liver lesions include patients with underlying liver cirrhosis, non-cirrhotic 
hepatitis B virus (HBV) carriers with active hepatitis or have a family history of 
HCC, and non-cirrhotic patients with chronic hepatitis C virus (HCV) and 
advanced liver fibrosis.(17) There is variation in the surveillance interval. 
Japanese guidelines propose a three to four month interval for patients falling in 
the extremely high risk category (cirrhosis secondary to viral hepatitis).(14, 51) 
However one study did not show any difference between three-monthly and six-
monthly interval scans.(52) A meta-analysis of prospective studies showed the 
combined sensitivity of US based surveillance falls from 70% with the six-month 
programme to 50% with the twelve-month programme.(53) Cost-effectiveness 
studies have in fact shown that six-monthly surveillance scans do improve 
quality-adjusted life expectancy at an acceptable cost.(54) Therefore in view of 
this, EASL-EORTC CPG recommend six-monthly US surveillance scans.(17) 
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The diagnostic pathway for HCC using radiology is in accordance to the size of 
the mass identified on the surveillance ultrasound scan (USS), and this is 
explained below, with Figure 1 summarising this pathway. 
 
1.5.1  Lesions <1cm in diameter 
Lesions <1cm in size have a low risk of being malignant; however, there is a 
high probability that small liver nodules may turn cancerous over time. 
Therefore, close surveillance of these lesions needs to be undertaken.(55) A 
repeat USS should be performed after 4 months: if this is stable, then repeat 
imaging every 4 months should be done. However, if the lesion is growing or 
the appearance is changing, further investigation should then be carried out 
according to the size.(17) 
 
1.5.2  Lesions 1-2cm in diameter 
Lesions within this size group have a high likelihood of being HCC.(55) 
Following the detection of a lesion between 1-2cm in size on USS, a 4-phase 
computed tomography (CT) or dynamic contrast enhanced magnetic resonance 
imaging (MRI) scan should then be performed. Both techniques should be 
undertaken in this group of patients, and only a one imaging technique is 
recommended in centres of excellence with advanced radiological equipment. If 
HCC radiological hallmarks are present then a diagnosis of HCC can be made. 
However, if there are no definite HCC radiological hallmarks present then a liver 
biopsy is recommended.(17) 
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1.5.3  Lesions >2cm in diameter 
Identification of a hepatic mass >2cm in size is highly suspicious of HCC.(55) 
Following detection of this lesion, imaging using 4-phase CT or dynamic 
contrast enhanced MRI scan should be done. For this group, only one imaging 
technique is required for diagnosis. A diagnosis is made if radiological hallmarks 
for HCC are seen; a liver biopsy is required if radiological hallmarks are not 
identified.(17) 
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Figure 1: Radiological pathway following liver lesion identification on US imaging. (Adapted from EASL-EORTC CPG, (17)).  
US, ultrasound. CT, computed tomography. MRI, magnetic resonance imaging.  
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1.6 Pathological diagnosis of hepatocellular carcinoma 
The sensitivity of liver biopsy ranges from 70-90% across all tumour size 
groups, and is dependent on a number of factors including location and size of 
the tumour, and operator expertise. For lesions between 1-2cm in size, 
pathological diagnosis remains challenging.(17, 56) One study reported a 
positive first liver biopsy for HCC in 70% of tumours 2cm or less in size.(57) 
Therefore, a positive liver biopsy is clinically useful in identifying HCC cases, 
but a negative biopsy does not rule out the diagnosis.(17) There is a 2.7% risk 
of needle tract tumour seeding after a median time of 17 months from the time 
of biopsy to the presence of seeding, and therefore patients undergoing liver 
biopsy need to be appropriately selected.(58) 
 
Differentiating high-grade dysplastic nodules from early HCC by solely using the 
classical morphological criteria can be difficult, particularly because the most 
important pathological hallmark of stromal invasion seen in HCC is frequently 
found to be absent or difficult to identify in biopsy specimens.(17, 56) Therefore, 
additional markers used in staining methods have been validated for their use in 
diagnosing early HCC on molecular profiling. These include GPC3, heat shock 
protein 70 and glutamine synthetase.(56) The combination of these three 
markers showed good sensitivity and specificity in diagnosing HCC (72% and 
100% respectively with two positive markers) and have also been validated in 
two large series.(59-62)  
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Significant poor prognostic factors on histological diagnosis of HCC include the 
presence of microvascular invasion (MVI) and nuclear grade 3, with the 
combination of these parameters providing good prognostic stratification.(63) 
Other prognostic factors of HCC include tumour size and number.(64) 
 
1.7 Staging of hepatocellular carcinoma 
Staging systems are used in cancer aids in predicting prognosis and allocating 
treatment appropriately. Additionally, they enable exchange of information in the 
research environment and clinical trials to be developed with comparable 
criteria.(17) Prognostic assessments are further complicated in HCC, as two 
independent variables can both result in death: cancer and liver function 
associated with cirrhosis.(65, 66) 
 
The staging of HCC commonly follows the Barcelona Clinic Liver Cancer 
(BCLC) staging system that stages the cancer (Stage 0, A, B, C and D) after 
taking into account several factors including the tumour status, the patient’s 
performance status (PS) and assessment of liver function (Child-Pugh’s score). 
This staging system allows appropriate treatment allocation in accordance to 
cancer stage.(17)  
 
BCLC stage 0 represents the very early cancer where there is a single lesion 
<2cm in diameter with no evidence of vascular invasion or satellite lesions in 
patients who have a PS of 0 and preserved liver function (Child-Pugh A), or if 
there is carcinoma in situ.(17) Data has shown that resection and liver 
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transplantation provide a five-year survival of around 70-90% and 70% with liver 
ablation.(67-69) 
 
BCLC stage A represents the early HCC where there is a single nodule 
between 2-5cm in size or if there are 3 nodules 3cm in diameter, in patients 
who have a PS of 0 and Child-Pugh A or B.(17) Median survival with early HCC 
at five years after resection, liver transplantation or ablation reaches 50-
70%.(17) 
 
Curative treatment options are possible for stage 0 and A, which includes 
hepatic resection, ablation therapies and liver transplantation.(17) 
 
BCLC stage B represents the intermediate stage where there is multinodular 
disease, PS 0 and Child-Pugh A or B. Transarterial chemoembolisation (TACE) 
treatment is possible for this stage with a median overall survival (OS) of 20 
months.(17) TACE has also been shown to improve the two year survival of 
patients.(17, 70) 
 
BCLC stage C represents the advanced stage where there is now evidence of 
macrovascular invasion (portal invasion), lymph node involvement or 
metastases, PS 1-2 and Child-Pugh A or B. Treatment with Sorafenib can be 
considered for this stage of disease and has a median OS of 11 months.(17, 
71)  
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BCLC stage D represents the terminal stage where the PS is >2 and evidence 
of poor liver function (Child-Pugh C). Best supportive care is the management 
plan for this group of patients with a median OS of <3 months.(17, 72)  Figure 2 
summarises the BCLC staging system. 
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Figure 2: Barcelona Clinic Liver Cancer staging system in HCC. (Taken from EASL-EORTC CPG, (17)). 
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1.8 Milan criteria  
The Milan criteria (MC) was introduced in 1996 by Mazzaferro et al who showed 
the overall four-year survival for patients transplanted for HCC was 75% with a 
recurrence free survival of 83%.(73) This was found to be highly promising 
given the three-year survival for small untreated HCCs occurring on a 
background of liver cirrhosis is only 21%.(74) The four-year survival reported by 
Mazzaferro et al was found to be similar to patients transplanted without 
HCC.(73) The defined MC is a single hepatic lesion 5cm, or up to 3 lesions 
each 3cm, without evidence of tumour vascular invasion or extra-hepatic 
metastases.(73, 75) 
 
The principal aim for performing liver transplantation (LT) in HCC, is to provide 
a similar rate of disease-free survival to those transplanted for benign liver 
disease. Therefore, it is imperative that an agreed set of criteria is followed to 
ensure appropriate patients are selected for LT. Agreed criteria also allow 
prioritisation of accepted candidates on the waiting list, and to set out clear 
indications for bridging and downstaging therapy to be offered with the goal of 
reducing the risk of disease progression and allowing continued activation on 
the waiting list.(13, 76) 
 
The MC has been adopted worldwide for selecting patients with HCC for LT. 
Fifteen years following the introduction of the MC good outcomes following LT is 
still being seen with a 5-year survival of at least 70% when the criteria are 
met.(77)  
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Current UK selection criteria for patients with HCC to undergo LT represent a 
modification of the MC.(78) The Liver Advisory Group state that an AFP >1000 
ng/mL is a contraindication to LT, given that a higher risk of recurrence was 
seen when the AFP was found to be higher than this.(79) A solitary lesion 
measuring between 5-7cm may also be an indication for LT if this has not grown 
>20% over a period of 6 months.(78, 80) 
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1.9  Downstaging hepatocellular carcinoma 
For patients who are outside the MC for liver transplantation, downstaging can 
assist in bringing this group within criteria for possible transplantation.(81) One 
large study showed that around a third of patients with HCC were within 
MC.(82) In the UK, despite the expansion of selection criteria for LT, less than 
10% of patients with HCC met this criteria.(83) Downstaging is achieved by 
performing liver-targeted therapy, such as liver ablation, TACE and stereotactic 
ablative radiotherapy (SABR). The response to these downstaging treatments is 
defined radiologically as per the modified Response Evaluation Criteria in Solid 
Tumours (mRECIST).(84)  
 
The Duvoux criteria are used in listing for HCC following downstaging 
treatment.(79) This takes into account the largest diameter of the HCC, number 
of nodules and the AFP. A score of 2 is required for eligibility to be assessed 
for liver transplantation. An interval of 6 months following downstaging 
treatment to imaging, or an interval of 3 months after the first imaging has 
demonstrated the patient is within selection criteria, is required.(85) 
  
The five-year survival rate in those transplanted following successful 
downstaging of HCC is comparable to patients transplanted within the MC.(86) 
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1.10 Introduction to prothrombin induced by vitamin K absence-II 
PIVKA-II (also known as des--carboxyprothrombin, DCP) was first detected in 
1984 by Liebman et al as an independent serum biomarker for primary HCC.(87, 
88)  
 
Abnormal prothrombin was first purified in 1972 and compared to normal 
prothrombin production.(89, 90) Both prothrombins were seen to have the same 
structure of amino acids and carbohydrates; however, the abnormal prothrombin 
was unable to bind calcium ions and the functional prothrombin activity was 
absent. Two years later, it was found that the normal prothrombin contained 
residues of carboxylated glutamic acid, -carboxyglutamic acid, and further 
studies showed the presence of 10 -carboxyglutamic acid residues in normal 
prothrombin that were absent in abnormal prothrombin. The carboxylated 
glutamic acid is required for the high affinity binding of calcium ions, leading to 
the activation and functioning of prothrombin.(91-93) PIVKA-II is therefore an 
abnormal form of the coagulation prothrombin protein, found to be raised in the 
sera of HCC patients.  
 
1.10.1 Production of PIVKA-II 
Vitamin K is a fat-soluble vitamin and an important co-factor in the carboxylation 
reaction of glutamic acid residues (Glu) to form -carboxyglutamic (Gla) acid 
residues.(94, 95) The vitamin K-dependent carboxylase enzyme, -
glutamylcarboxylase uses vitamin K hydroxyquinone as the energy source for the 
carboxylation, which is oxidised to vitamin K, 2-3 epoxide.(96) In normal 
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prothrombin production, the vitamin K-dependent carboxylase enzyme catalyses 
the conversion of 10 Glu residues present in the Gla domain at positions 6, 7, 14, 
16, 19, 20, 25, 26, 29 and 32 to Gla residues.(97) The vitamin K-dependent 
carboxylase responsible for the post-translational carboxylation of prothrombin is 
impaired in many HCC cells, and an abnormal prothrombin with all or some of 
unconverted glutamic acid is secreted.(98-101) Another factor involved in the 
production of PIVKA-II is vitamin K deficiency given that the activity of the 
carboxylase enzyme is dependent on the presence of vitamin K as a co-
factor.(88) One study showed that vitamin K levels were significantly lower in 
cancerous tissue in patients with HCC compared to non-malignant tissue.(102) 
Naraki et al identified that the abnormal prothombin contained less than 4 Gla 
residues in HCC, but chronic liver disease including cirrhosis contained PIVKA-II 
with more than 5 Gla residues.(97)   
 
Therefore, this non-carboxylated form (PIVKA-II) could be considered a HCC 
biomarker, and a summary of PIVKA-II production is shown in Figure 3. 
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Figure 3: Schematic representation summarising PIVKA-II production. PIVKA-II, prothrombin induced by vitamin K 
absence-II. Glu, glutamic acid.  Gla , -carboxyglutamic. 
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1.10.2 PIVKA-II signaling pathways 
A number of studies have looked at the role and mechanism of PIVKA-II/ DCP in 
tumour survival, growth and metastasis.  
 
It has been shown that PIVKA-II binds to a membrane spanning tyrosine kinase 
receptor, cellular mesenchymal-epithelium transition factor (c-Met), leading to 
Met autophosphorylation of tyrosines 1234 and 1235 of the tyrosine kinase 
domain and tyrosine 1349 and 1356 of the multifunctional docking site.(103-105) 
Hepatocyte growth factor (HGF) is the ligand for c-Met and is known to have a 
significant role in tumour growth, including in HCC.(106, 107) DCP was found to 
phosphorylate only tyrosine 1234 and 1235, whereas HGF phosphorylated all 
residues in both sites.(108) The difference in phosphorylation may lead to 
alternative biological effect on cellular proliferation.(108) Following the binding of 
DCP to c-Met, this then led to downstream activation of the Janus kinase 1 / 
Signal transducer and activator of transcription 3 (JAK-1/STAT3) signaling 
pathway, resulting in cell proliferation and tumour growth.(108, 109) STAT3 and 
c-Met small interfering RNA (siRNA), as well as functional inhibition of c-MET by 
the c-Met inhibitor SU11274, suppressed the PIVKA-II induced HCC cell 
growth.(108, 110) It has been noted that high levels of PIVKA-II are a risk factor 
for extrahepatic HCC metastasis.(111) Another study showed that PIVKA-II 
increased the expression and secretion of matrix metalloproteinase (MMP) 2 and 
9 (MMP-2 and MMP-9) following c-Met binding and subsequent activation of the 
epidermal growth factor receptor (EGFR). This then stimulated activation of the 
extracellular signal-regulated kinase/mitogen activated protein kinase (ERK 1/2 
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MAPK) pathway, leading to MMP-2 and MMP-9 secretion and promotion of HCC 
growth and metastasis. Blocking this pathway with an ERK 1/2 inhibitor, 
PD98059, removed the DCP induced MMP-2 and MMP-9 activity.(112) PIVKA-II 
is also associated with the onset of angiogenesis in HCC, and angiogenesis is 
an important process in tumour growth given that HCC is a highly hypervascular 
tumour.(113) Tumour cells release angiogenic factors that stimulate vascular 
endothelial cells and infiltrating cells. These angiogenic factors including VEGF, 
fibroblast growth factor (FGF) and MMPs, stimulate the migration and 
proliferation of vascular endothelial cells which lead to a dense vascular network 
in the stromal space.(114-116) DCP was found to bind directly with the kinase 
domain receptor (KDR), a VEGF receptor 2, leading to activation of the 
phospholipase C-gamma-mitogen activated protein kinase (PLC--MAPK) 
pathway and promoting angiogenesis in HCC.(117) Exposing vascular 
endothelial cells to KDR siRNA, KDR kinase inhibitor or MAPK inhibitor stops the 
DCP-induced angiogenesis from taking place.(115) 
 
Figure 4 outlines the pathways involved by PIVKA-II in HCC growth, metastasis 
and angiogenesis. 
 
 
 
 
 
 
 49 
 
Figure 4: Schematic diagram of the various signaling pathways involved by PIVKA-II in promoting HCC growth, 
metastasis and angiogenesis. Some components of this diagram were obtained from Servier (118). JAK1 STAT3, Janus 
kinase 1 / Signal transducer and activator of transcription 3. MMP, matrix metalloproteinase. EGFR, epidermal growth factor 
receptor. ERK 1/2 MAPK, extracellular signal-regulated kinase/mitogen activated protein kinase. KDR, kinase domain receptor. 
PLC-, phospholipase C-gamma.
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1.10.3 What is already known of prothrombin induced by vitamin K absence-
II and hepatocellular carcinoma  
PIVKA-II is mainly used in Asia as a diagnostic and surveillance marker for HCC, 
and has also been shown to be a predictor of MVI, an important prognostic factor 
in HCC. However, there is limited experience in Europe with PIVKA-II.(11, 119) 
The majority of studies looking into PIVKA-II have taken place in Asia, where the 
patient cohort differs from the UK. There have been no studies conducted in the 
UK comparing AFP with PIVKA-II and PIVKA-II’s association with prognosis, nor 
the response of PIVKA-II with ablation treatment.  
 
Studies have shown variable results in the efficacy of PIVKA-II in HCC both as 
a single biomarker and also as a combination with AFP. In addition to this, a 
high proportion of studies looking at the role of PIVKA-II in HCC, have involved 
patients with viral hepatitis being the main aetiology of underlying liver disease.  
 
A recent study conducted in China has shown that PIVKA-II is superior to AFP 
in diagnosing early HCC versus liver cirrhosis with an area under the curve 
(AUC) of 0.73 (95% CI 0.70 – 0.85) and 0.62 (95% CI 0.60 – 0.77) respectively. 
Comparing HCC as a whole versus liver cirrhosis, PIVKA-II performed better 
than AFP, AUC 0.78 (95% CI 0.64 – 0.81) and 0.67 (95% CI 0.68 – 0.80) 
respectively. In early stage AFP-positive HCC, AFP-L3 was found to be a 
superior diagnostic marker compared to PIVKA-II, whereas PIVKA-II was the 
better marker compared to AFP-L3 in early stage AFP-negative HCC. The 
combination of AFP and PIVKA-II showed a better diagnostic performance 
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compared to either marker alone in diagnosing early HCC versus liver cirrhosis 
(AUC 0.75, 95% CI 0.71 – 0.87). (120) 
 
One European study showed that a high percentage of non-alcoholic 
steatohepatitis had positive PIVKA-II tumours, and the combination of both AFP 
and PIVKA-II increases the overall sensitivity of diagnosing HCC, even in the 
early stages.(121) Previous studies in Egypt and France have shown a higher 
sensitivity and specificity of PIVKA-II in comparison with AFP.(98, 119) Zakhary 
et al showed a sensitivity of 44% and specificity of 73% using the best cut-off 
value of >28 for AFP and 100% sensitivity and specificity with cut-off value of 
>53.7 for PIVKA-II, in detecting and diagnosing HCC at an earlier stage when 
curative treatment options are possible. The plasma level of PIVKA-II also 
showed a significant gradual rise correlating with progressive tumour 
burden.(98) Poté et al showed the AUC for PIVKA-II was better for diagnosing 
early HCC compared to AFP (0.81 vs 0.582). For very early HCC, PIVKA-II was 
found to be a better marker than AFP (AUC 0.716 vs 0.5 for PIVKA-II and AFP 
respectively). The PIVKA-II serum level was found to be significantly higher in 
tumours >2cm, in moderately / poorly differentiated HCC and in HCC with MVI. 
The AFP serum level was significantly higher only in tumours >2cm. The 
combination of AFP and PIVKA-II did not improve the diagnostic performance 
for overall or very early HCC. A slight improved performance of early HCC 
diagnosis was found when combining the two markers (AUC 0.826).(119)  
A Chinese group showed that between the different BCLC stages (excluding 
between BCLC stage B and C), PIVKA-II levels significantly increased (p<0.05) 
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whereas AFP showed no difference. PIVKA-II levels >40 milli arbitrary unit 
(mAU)/mL independently predicted the presence of MVI, similar to another 
study showing that high serum PIVKA-II levels was an independent risk factor 
for MVI.(122, 123) Another group in China showed that PIVKA-II correlates with 
tumour size, tumour differentiation and BCLC staging but had a negative 
correlation with serum hepatitis B viral load.(124) A recent study performed in 
Italy showed that PIVKA-II has a higher accuracy than AFP in differentiating 
HCC from patients with benign chronic liver disease (CLD).(125) A recent meta-
analysis conducted by Caviglia et al summarised the performance of both 
markers across three different groups: HCC, liver cirrhosis and CLD. Viral 
hepatitis, in particular chronic hepatitis B, accounted for the vast majority of the 
underlying liver disease aetiology. The weighted summary AUC of PIVKA-II was 
0.791 in diagnosing HCC compared to 0.767 for AFP, and this showed no 
significant difference (p=0.524). The combination of AFP and PIVKA-II however 
was seen to be significantly better and had a weighted summary AUC of 0.859, 
(p<0.001).(126) 
 
In a study in South Korea, the AUC for diagnosing HCC was slightly better with 
AFP compared to PIVKA-II (0.879 vs 0.801 respectively). In the multivariate 
analysis, PIVKA-II correlated with laboratory tests including aspartate 
aminotransferase, bilirubin, platelets and albumin levels.(127) Marrero et al also 
showed that AFP had a better sensitivity than PIVKA-II for diagnosing very early 
and early HCC.(22) Park et al compared the diagnostic accuracy of AFP, AFP-
L3 and PIVKA-II in HCC and found that AFP had the best diagnostic 
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performance in diagnosing HCC as a single biomarker.(128) A Korean study 
recently showed that AFP and AFP-L3 started to show an increase in levels 6 
months prior to HCC diagnosis (very early stage) (p<0.05). AFP was superior to 
AFP-L3 and PIVKA-II at HCC diagnosis with AUROCs of 0.77, 0.73 and 0.71 
respectively. The sensitivity of US alone at HCC diagnosis was 48.6% and 
improved to 88.6% with the addition of AFP and 94.3% with both AFP and AFP-
L3.(129) A group in America recruited patients with viral hepatitis and showed 
that PIVKA-II was the superior marker compared to either AFP and AFP-L3 in 
diagnosing HCC, had a direct correlation with tumour size and was not elevated 
in non-HCC patients.(130)  
 
Yu et al have recently shown that liver cirrhosis accounted for the largest part of 
the PIVKA-II positive non-HCC group. They showed that PIVKA-II had a better 
diagnostic effectiveness in differentiating HCC from non-HCC cases, with an 
improved AUC when both markers are combined in differentiating HCC from 
cirrhosis, and HCC from cirrhosis and hepatitis. Both AFP and PIVKA-II could 
barely differentiate early HCC from cirrhosis, with AFP having a better (non-
significant) AUC compared with PIVKA-II (0.635 vs 0.607 respectively). The 
study also showed an increase in PIVKA-II levels with HCC progression.(131)  
Table 2 shows the differences between AFP, PIVKA-II and the combination of 
both markers in diagnosing HCC in different clinical scenarios found in various 
studies. 
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However, results from previous studies do not necessarily apply to UK patients 
as the patient cohorts are different in some studies compared to the UK, with 
hepatitis B or C viral hepatitis being the cause of liver cirrhosis. In the UK the 
commonest causes of cirrhosis are alcohol, hepatitis C and obesity. Since 
demographics and causes of liver disease differ significantly between 
geographical regions it is important to assess the relevance of potential 
biomarkers in specific populations. 
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Study Clinical 
scenario 
AFP 
 
AUC (95% CI) 
PIVKA-II 
 
AUC (95% CI) 
AFP and 
PIVKA-II 
combination 
 
AUC (95% CI) 
Cut-off 
PIVKA-II 
Cut-off 
AFP 
Combinatio
n of AFP 
and PIVKA-
II sensitivity 
Combinatio
n of AFP 
and PIVKA-
II specificity 
AFP 
Sensitivity 
AFP 
Specificity 
PIVKA-II 
Sensitivity 
PIVKA-II 
Specific
ity 
Chen H 
et al 
(110) 
Early 
HCC 
from 
cirrhosis 
0.62 (0.60 – 
0.77) 
0.73 (0.70 – 
0.85) 
0.75 (0.71 – 
0.87) 
NR NR 52.6% 90% 30.6% 90% 48.3% 90% 
Chen H 
et al 
(110) 
HCC 
from 
cirrhosis 
0.67 (0.68 – 
0.80) 
0.78 (0.64 – 
0.81) 
0.83 (0.68 – 
0.84) 
NR NR 64.2% 90% 40.1% 90% 57.2% 90% 
Ertle JM 
et al 
(111) 
HCC 
from 
controls* 
0.88 0.87 0.91 5 ng/mL 10 
ng/mL 
78% 89.3% 54.9% 94.5% 63.4% 94.5% 
Ertle JM 
et al 
(111) 
Early 
HCC 
from 
controls* 
0.84 0.81 0.87 5 ng/mL 10 
ng/mL 
58.3% 89.3% 38.9% 94.5% 45.8% 94.5% 
Pote et 
al (109) 
Early 
HCC 
from 
cirrhosis 
0.582 (0.443 – 
0.722) 
0.81 (0.697 – 
0.924) 
0.826 (0.722 – 
0.929) 
42 
mAU/mL 
5.5 
ng/mL 
NR NR 61% 50% 77% 82% 
Wang X 
et al 
(113) 
HCC 
from 
chronic 
hepatitis 
B 
0.781 0.756 0.868 32.1 
mAU/mL 
17.6 
ng/mL 
NR NR 64.6% 73.3% 52.2% 81.5% 
Caviglia 
GP et al 
(116) 
HCC 
from CLD 
or 
cirrhosis 
0.767 0.791 0.859 NR NR NR NR NR NR NR NR 
Choi JY 
et al 
(117) 
HCC 
from CLD 
0.879 0.801 NR 40 
AU/mL 
10 
ng/mL 
NR NR 78.9% 84.6% 62.2% 94.9% 
Marrero 
JA et al 
(22) 
Early 
HCC 
from 
cirrhosis 
0.80 (0.77 – 
0.84) 
0.72 (0.68 – 
0.81) 
0.83 (0.8 – 
0.87) 
150 
mAU/mL 
20 
ng/mL 
78% 62% 53% 90% 61% 70% 
Choi JY 
et all 
(119) 
Early or 
very early 
HCC 
from 
cirrhosis 
+/or CHB 
0.77 (0.68 – 
0.86) 
0.71 (0.61 – 
0.80) 
0.77 (0.67 – 
0.87) 
20 
mAU/mL 
5 ng/mL 62% 78% 62% 87% 48% 86% 
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Park SJ 
et al 
(118) 
HCC 
from 
cirrhosis 
0.751 (0.683 – 
0.818) 
0.705 (0.633 – 
0.777) 
0.765 (0.708 – 
0.823) 
40 
mAU/mL 
10 
ng/mL 
55.7% 97.4% 68.4% 81.8% 70.9% 70.1% 
Yu R et 
al (121) 
Early 
HCC 
from 
cirrhosis 
0.635 (0.595 – 
0.674) 
0.607 (0.566 – 
0.646) 
0.641 (0.601 – 
0.679) 
NR NR NR NR NR NR NR NR 
Table 2: Comparisons between AFP, PIVKA-II and as a combination of both markers, in diagnosing HCC in 
various clinical applications. AUC, area under the curve. CLD, chronic liver disease. NR, not reported, CHB, chronic 
hepatitis B. *Controls were patients with chronic liver disease, cirrhosis, or viral hepatitis  
 
 
 
 
 57 
Previous studies have also looked at immunohistochemical staining of PIVKA-II 
in HCC. Poté et al assessed PIVKA-II tissue expression in HCC cases and 
showed that high PIVKA-II expression (50% stained cells) was significantly 
associated with moderately/poorly differentiated HCC (p=0.03) and in the 
presence of MVI (p=0.001). They also showed that early HCC cases had low 
PIVKA-II expression. In non-HCC tissue, PIVKA-II expression was negative in 
76% of cases (53/70), weakly positive in 20% of cases (14/70) and strongly 
positive in 4% of cases (3/70). The combination of serum PIVKA-II levels with 
the PIVKA-II staining improved the sensitivity and specificity of diagnosing 
MVI.(119) These findings are in keeping with previous studies showing that 
positive PIVKA-II tumour expression influences prognosis.(132-134) It has also 
been shown that PIVKA-II expression is present in small-sized and well-
differentiated HCCs but is not present in premalignant nodules (adenomatous 
hyperplasia).(135) 
 
1.10.4 PIVKA-II and treatment with ablation  
Approximately a fifth of all patients who develop HCC are suitable candidates for 
liver resection, though cancer recurrence can still occur following resection.(136) 
The demand for organ donors continues to rise with increasing number of 
patients requiring a liver transplant. Therefore, non-surgical treatments to cure 
small HCCs are increasingly being used where appropriate.(137, 138) 
Controversy remains in the prognostic value of PIVKA-II in HCC patients treated 
with ablation.  
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A meta-analysis published in 2018 showed that high PIVKA-II levels were 
significantly associated with a poorer OS (Hazard ratio, (HR) 1.59, p<0.001) and 
recurrence-free survival (HR 1.76, p<0.001) in patients with HCC treated with 
ablation.(139) Another study showed that in addition to PIVKA-II, AFP-L3 was 
also significantly related to survival, but that PIVKA-II was the sole factor 
associated with local tumour progression. Both serum PIVKA-II and serum AFP 
were significantly related to distant recurrence.(140) A Japanese group showed 
that the cumulative survival rate, recurrence-free survival rates and staying 
within the MC for liver transplantation was significantly lower in patients who had 
a PIVKA-II 100 mAU/mL compared with a PIVKA-II <100 mAU/mL, and 
therefore concluded that PIVKA-II is the optimal prognostic predictor following 
curative ablation treatment.(141) 
 
Again, no studies in the UK have looked at the role of PIVKA-II in patients with 
HCC undergoing ablative treatment, and therefore it is important to assess the 
suitability of this marker in different cohorts of patients and see if current known 
results and findings can be extrapolated to patients in different countries 
diagnosed with early HCC undergoing treatment with ablation. 
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1.11 Aetiology, genetics and biology of neuroendocrine tumours 
NETs originate from cells containing neuroendocrine properties (known as 
enterochromaffin or Kulchitsky cells) and are slow growing cancers.(142, 143) 
Certain proteins are expressed by these cells, including neuron-specific enolase 
and synaptophysin, classically seen in neural cells. They are stimulated by the 
autonomic nervous system and produce amines and peptide hormones such as 
serotonin (5-HT), substance P, vasoactive intestinal peptide (VIP) and 
somatostatin.(143, 144) Historically, NETs were classified according to their 
embryological origin: foregut (includes NETs originating in the bronchi, stomach, 
pancreas, gallbladder and duodenum), midgut (originating in jejunum, ileum, 
appendix and right side of colon) and hindgut (left side of colon and 
rectum).(145) 
 
NETs usually arise sporadically, but a small group of patients will have an 
inheritable condition leading to the development of a NET.(142)  They may be 
associated with familial endocrine cancer syndromes including multiple 
endocrine neoplasia (MEN)1, MEN2, Von Hippel Lindau (VHL) and 
neurofibrotosis type 1.(146-148) The incidence of MEN1 varies between 
different Gastroenteropancreatic (GEP) NETs from nearly 0% in gastrointestinal 
(GI) NETs, to 5% in insulinomas and up to 25-30% in gastrinomas.(149) 
Mutations in the succinate-ubiquinone oxidoreductase subunit D (SDHD) gene 
has been identified in some patients with midgut NETs, which is commonly 
associated with paraganglionomas and phaeochromocytomas.(150) It is 
therefore imperative to take a detailed family history and examination to identify 
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patients who may have an underlying genetic association so genetic screening 
can then be performed in the patient as well as genetic testing in relatives. 
 
Early discoveries in the biology of NETs involve somatostatin (SST) and this 
peptide’s G-protein-coupled membrane somatostatin receptors (SSTR) subtypes 
1-5.(151-153) SST regulates endocrine function with largely inhibitory effects by 
inhibiting secretion of most GI hormones and growth hormone, reducing motility 
in the GI tract and gallbladder contraction and a reduced GI tract blood flow.(151, 
154, 155) SSTR subtypes 2 and 5 are mainly found in NETs, with SSTR2 being 
the predominant subtype seen.(156, 157) 
 
There have been some studies looking at the molecular biology of NETs. One 
study looked at sporadic pancreatic NETs and found the most common mutated 
genes were MEN-1 (44%), DAXX/ATRX (43%) and genes in the mTOR pathway 
(14%). A study of small intestine NETs did not find any significant somatic 
mutations, suggesting this group of NETs are mutationally inactive. However, 
several recurrent somatic copy number alterations were identified in cancer-
related pathways including PI3K/Akt/mTOR signalling, TGF- (via alteration in the 
SMAD gene) and the SRC proto-oncogene.(158) Another study involving small 
intestine NETs identified repeated somatic mutations and deletions in CDKN1B, 
which is a cyclin-dependent kinase inhibitor gene, encoding p27.(159) A different 
study performed whole-genome sequencing of pancreatic NETs and found that 
there was a deficiency in G:C > T:A base excision repair. This was due to 
inactivation of MUTYH gene which encodes a DNA glycosylase. Sporadic 
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pancreatic NETs were seen to contain more germline mutations than anticipated 
in addition to mutations in the DNA repair genes MUTYH, BRCA2 and CHEK2. 
The combination of these mutations, with the mutations seen in MEN1 and VHL, 
were seen in 17% of patients. The study found that somatic mutations (including 
both gene fusions and point mutations) occurred in genes involved in four 
pathways: DNA damage repair, chromatin remodelling, mTOR signalling 
activation and telomere maintenance. The group also showed a subgroup of 
pancreatic NETs associated with hypoxia-inducible factor signalling and 
hypoxia.(160)  
 
1.12 Epidemiology of neuroendocrine tumours 
The incidence of NETs in the UK is rising. Public Health England recorded a 
total of 8,726 neuroendocrine neoplasms (NENs), of which 3,978 were low 
grade NETs, between 2013 and 2014 , yielding an overall incidence rate of 8 
per 100,000 persons. Approximately 75% of lower GI NENs are NETs compared 
to upper GI and lung neoplasms (48% and 36% respectively), Figure 5. There is 
an almost equal distribution of disease between males and females and little 
variation in ethnicity. (161) Public Health England showed that the one-year NET 
survival for patients with either grade 1 (G1) or grade 2 (G2) disease is better 
even in the advanced stage groups (at least 80% in the most advanced stage) 
compared to neuroendocrine carcinomas (NECs) and other subtypes which 
have a poorer one-year survival with survival determined by the stage of 
disease (as low as 20%), Figure 6.(161) The GI tract and pancreas are the 
commonest sites of NET origin, with the lung being the next commonest site. 
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Rarer sites of NET origin include the ovaries, breast, renal tract, head and neck, 
and skin.(162) The primary site of origin is unknown in around 8.7% of 
cases.(161) 
Early diagnosis of NETs allows possible curative treatment by surgical 
resection.(163) More than 50% of NETs are unresectable at the time of 
diagnosis, given the presence of non-specific symptoms and delay in diagnosis 
when the tumour is then diagnosed at an advanced stage.(164) 
 
 
 
 
Figure 5: Morphological and topological distribution of neuroendocrine 
neoplasms diagnosed between 2013 and 2014 in England. (Taken from 
Public Health England, (161)). 
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Figure 6: One year net survival for the different neuroendocrine neoplasm groups diagnosed in England between 2013 
and 2014. (Taken from Public Health England, (161)).
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1.13 Classification of neuroendocrine tumours 
In 2007, the European Neuroendocrine Tumour Society (ENETS) introduced the 
classification of NENs into well-differentiated NETs and poorly-differentiated 
NECs based on two indexes, with the classification positively correlating with 
prognosis.(165) Diagnosis of NETs takes into account both characteristic 
histologic features as well as particular immunoprofiles.(166)   
 
NETs arising in the GI tract follow the World Health Organisation (WHO) 2010 
classification and are graded from G1-3, based on their cellular proliferation rate 
(i.e. Ki-67 index) and the mitotic count.(144, 167) G1 and G2 are well-
differentiated NETs and G3 represents the poorly-differentiated NECs. In 2017, 
a revised WHO classification for pancreatic NENs recognised that the G3 
tumours display heterogeneity in their morphology, and includes both well-
differentiated G3 NETs and poorly-differentiated G3 NECs.(168) Treatments do 
differ significantly between the G3 NETs and G3 NECs, and it is therefore 
important to distinguish between the two subtypes. 
 
Pulmonary NETs have a separate classification terminology to the non-
pulmonary NETs. They are classified as typical carcinoid, atypical carcinoid, 
small-cell lung carcinoma and large-cell neuroendocrine carcinoma.(169) The 
typical and atypical pulmonary carcinoids are well differentiated NETs and 
include low and intermediate grade malignant tumours respectively. The small-
cell lung carcinoma and large-cell neuroendocrine carcinoma correspond to the 
poorly-differentiated NECs.(170)   
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Table 3 summarises the classification system for the pulmonary and GEP 
NENs. 
Classificatio
n 
Grade Differentiatio
n 
Pulmonary 
NENs 
Mitotic 
index 
Ki-67 
index 
WHO 2010      
 Low grade, 
G1 NET 
Well 
differentiated 
Typical 
carcinoid 
<2/10 
HPF 
2% 
 Intermediat
e grade, G2 
NET 
Well 
differentiated 
Atypical 
carcinoid 
<2-
20/10 
HPF 
3-
20% 
 High grade, 
G3 NEC 
Poorly 
differentiated 
Small cell lung 
carcinoma; 
Large cell 
neuroendocrin
e carcinoma 
>20/10 
HPF 
>20% 
*WHO 2017      
 Low grade, 
G1 NET 
Well 
differentiated 
 <2/10 
HPF 
2% 
 Intermediat
e grade, G2 
NET 
Well 
differentiated 
 <2-
20/10 
HPF 
3-
20% 
 High grade, 
G3 NET 
Well 
differentiated 
 >20/10 
HPF 
>20% 
 High grade, 
G3 NEC 
Poorly 
differentiated 
 >20/10 
HPF 
>20% 
 
Table 3: Classification of pulmonary and gastroenteropancreatic NENs. 
*World Health Organisation 2017 classification: Pancreatic NENs. HPF: High 
power fields, NENs, neuroendocrine neoplasms. G, grade. NET, 
neuroendocrine tumour. 
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1.14 Clinical features of neuroendocrine tumours 
A large proportion of NETs are diagnosed incidentally, for example gastric NETs 
and rectal NETs diagnosed on endoscopy and GI NETs including appendiceal 
NETs diagnosed on histology of the resected specimen. Given the increasing 
number of investigations being performed, in particular the 2 week wait for upper 
and lower GI endoscopies, the number of referrals to our centre continues to rise. 
 
NETs can be asymptomatic or non-functioning, or functional resulting in hormone 
secretion (commonly bradykinin and 5-HT) which can cause syndromic 
symptoms.(171)  
 
NETs are associated with various hypersecretory syndromes through hormones 
secreted, determined by the cell of origin.(172) The clinical features and 
functioning syndromes of GEP NETs will be discussed below. 
 
Carcinoid syndrome 
Small intestine NETs account for 75-90% of all carcinoid syndrome (CS) 
cases.(173) All NETs commonly metastasise to the liver. In addition, small bowel 
NETs usually involve the mesenteric lymph nodes. Classical CS results from 
direct release of hormones, in particular 5-HT, into the systemic circulation. 
Hormones released by GI NETs are usually inactivated by liver enzymes thereby 
preventing their release into the systemic circulation. Therefore, patients with GI 
NETs usually only develop CS if they have significant liver metastases.(174, 175) 
Presence of metastases at certain anatomical sites, such as the retroperitoneum, 
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bone, distant nodal disease, as well as lung and ovary primaries, also allows direct 
access to the systemic circulation.(176) This can therefore lead to CS in the 
absence of liver involvement. CS is associated with carcinoid heart disease.(142, 
143) It has been reported that CS occurs in around 10-15% of patients with midgut 
NETs.(177) 
 
Serotonin was initially identified in 1954 and was seen to be associated with 
flushing, diarrhoea and right-sided heart failure in patients with small intestine 
NETs and secretion of this hormone was believed to be a possible cause of this 
syndrome.(178, 179) The typical symptoms of facial flushing, diarrhoea, 
abdominal pain, weight loss and bronchospasm associated with CS is made 
clinically indicating increased levels of circulating serotonin.  
 
Treatment with a somatostatin analogue (SSA) injection is the commonest 
medical therapy in treating carcinoid symptoms and achieving disease 
control.(180) The first synthetic SSA, Octreotide, was produced in the 1980s.(154) 
Two long acting synthetic analogues of somatostatin that we use frequently in 
clinical practice include Sandostatin LAR and Lanreotide Autogel. Studies first 
looking at the role of SSAs in NETs found a significant reduction in carcinoid 
symptoms due to reduction in the secretion of serotonin.(181)  
Randomised controlled trials then followed assessing the effectiveness of SSAs 
in these tumours. The PROMID trial showed a significant increase in median 
progression free-survival (PFS) from 6 months to 14.3 months in patients with 
metastatic midgut NETs treated with Octreotide LAR compared to placebo and 
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36% of the group had CS at baseline.(182) The CLARINET trial showed that 
Lanreotide Autogel significantly prolonged PFS in patients with either G1 or G2 
(Ki-67 <10%) metastatic enteropancreatic NETs (not reached versus 18 months 
in the placebo group). At 24 months, the estimated rate of PFS was 65.1% in the 
treated group compared to 33% in the placebo group.(183) The PROMID trial was 
predominately composed of patients with G1 NETs with generally lower hepatic 
tumour burden compared to the CLARINET trial.(183) Telotristat ethyl, an inhibitor 
of tryptophan hydroxylase (an enzyme involved in the synthesis on serotonin), 
has shown promising results in the management of patients with CS refractory to 
SSAs, showing significant reduction in daily bowel movements.(184) 
 
Other treatments offered include peptide receptor radionuclide therapy (PRRT) 
and Everolimus. PRRT uses radiolabelled somatostatin analogues that binds to 
the SSTR on the tumour cell membrane resulting in internalisation of the 
radiopeptide/SSTR complex and delivery of the radioactivity straight into the 
intracellular area of the tumour cell.(185, 186) Everolimus is an oral mTOR 
inhibitor.(187) The mTOR pathway is a key regulator of cellular proliferation, 
growth, protein synthesis, autophagy and metabolism. Everolimus therefore 
blocks the activity of the mTOR pathway.(188, 189) The NETTER-1 trial revealed 
an improved PFS in patients with metastatic midgut NETs. 65.2% of patients 
treated with PRRT (177Lu-Dotatate) plus normal dose Sandostatin LAR were 
without disease progression compared to 10.8% in the control group where 
doubled dose Sandostatin LAR was given.(186) The RADIANT-2 trial showed that 
Everolimus plus octreotide LAR improved PFS compared to placebo plus 
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octreotide LAR in patients with advanced NETs associated with CS (16.4 months 
versus 11.3 months respectively).(187) The RADIANT-4 trial recruited patients 
with advanced, non-functioning NETs of lung or GI origin and showed that the 
median PFS was 11 months in the Everolimus treated group versus 3.9 months 
in the placebo group. Everolimus was associated with a 52% reduction in the 
estimated risk of progression or death.(188) 
 
Gastric and duodenal NETs 
There are three types of gastric NETs: types 1,2 and 3. Type 1 is the commonest, 
representing 70-80% of all gastric NETs and is associated with atrophic gastritis 
and chronic hypergastrinaemia. Type 2 occurs due to raised gastrin from a 
gastrinoma and is associated with Zollinger-Ellison Syndrome (ZES) and MEN1. 
Type 1 is usually asymptomatic, and both type 1 and 2 are commonly diagnosed 
early following symptoms of reflux, diarrhoea and abdominal discomfort. Type 3 
does not present with symptoms until metastases have occurred. Metastases are 
present in 50-100%, 10-30% and 2-5% of type 3, 2 and 1 respectively.(190, 191) 
Duodenal NETs are mostly sporadic but may also be associated with MEN1. They 
are usually non-functioning but are a frequent cause of ZES.(192) 
 
Pancreatic NETs 
NETs arising in the pancreas secrete various hormones. Table 4 summarises the 
hormones and clinical features associated with the different types of functioning 
pancreatic NETs. 
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Type of pancreatic NET Hormone secreted Clinical features 
Insulinoma Insulin Hypoglycaemic 
symptoms: 
• Confusion 
• LOC 
• Sweating 
• Dizziness 
• Improvement with 
eating 
Gastrinoma Gastrin Severe peptic ulcer 
disease: ZES 
Diarrhoea 
Glucagonoma Glucagon Diabetes mellitus 
Typical skin lesion: 
necrolytic migratory 
erythema 
Weight loss 
Glossitis 
Vasoactive intestinal 
peptide-secreting tumour 
(VIPoma) 
Vasoactive intestinal 
peptide 
Verner-Morrison 
syndrome: 
Severe diarrhoea, 
hypokalaemia and 
metabolic acidosis 
Somatostatinoma Somatostatin Cholelithiasis 
Diabetes mellitus 
Diarrhoea 
Steatorrhoea 
 
Table 4: Types of functioning pancreatic NETs with hormones secreted and 
associated clinical features. (Adapted from Ramage JK et al and Zandee WT 
et al, (142, 171)). LOC, loss of consciousness. ZES, Zollinger-Ellison syndrome.  
 
Despite the relatively slow progression of NETs, they can cause significant GI and 
cardiac pathology related to fibrosis due to desmoplastic reactions. Intestinal 
fibrosis can lead to strictures that can cause further complications including 
chronic abdominal pain, small bowel bacterial overgrowth and bowel obstruction. 
Carcinoid heart disease (CHD) is characterised by fibrous thickening of the 
endocardial surface and cardiac valvulopathy, that can result in heart failure.(175, 
193-195) GI complications can occur due to the tumour itself or secondary to 
treatments given for NETs including SSAs and as a consequence of surgery.(195) 
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These complications can be very troublesome for patients, and are associated 
with a significant morbidity and mortality, therefore impairing the patient’s quality 
of life. At present, there are no effective therapies to prevent these 
complications, and patients often require major surgery and intense input from 
the dieticians and nutrition team including the requirement for parenteral 
nutrition.  It is still poorly understood why some patients develop severe fibrotic 
complications and what factors drives this process.  Therefore, by gaining a 
better understanding in the molecules involved in the fibrosis associated with 
NETs, therapies to target these molecules can be identified with the aim of 
curing or preventing these complications. 
 
1.15 Fibrosis in neuroendocrine tumours 
Local desmoplasia or distal fibrotic reactions can be associated with NETs. The 
commonly encountered fibrotic reactions that can occur are mesenteric fibrosis 
in small bowel NETs and CHD. Mesenteric fibrosis can occur in up to 50% of 
cases and is usually diagnosed radiologically. Complications that can be 
associated with mesenteric fibrosis include the development of intestinal 
ischaemia (in around 10% of cases) and bowel obstruction. Mesenteric 
vasculature involvement can lead to the onset of ascites, and extensive 
infiltration can make surgical resection very challenging or not possible. The 
presence of mesenteric fibrosis is associated with significant morbidity and 
mortality.(196-198)  
CHD occurs due to fibrosis of the cardiac valves, and usually affects the right-
sided heart valves. This fibrotic complication can progress to the development of 
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heart failure and is a major cause of mortality and morbidity in NETs.(196, 199) 
CHD is discussed in more detail later on in this chapter. 
 
1.16 Diagnosis of neuroendocrine tumours 
NETs are usually diagnosed incidentally on imaging or endoscopies performed, 
or on histology. The histological diagnosis and classification of NETs has been 
discussed above. Various transcription factors on histological staining may help 
point towards a primary site of origin when patients present with metastatic 
disease, although individual factors are not 100% sensitive or specific.(200) For 
example, thyroid transcription factor-1 is a good marker to indicate a pulmonary 
site of origin, and CDX2 indicates a small bowel primary site. Pancreatic NETs 
may be positive for Isl1 and PAX8, but these two stains may also label rectal 
NETs.(201)  
Certain biochemical markers and/or radiological features can all aid in making 
the diagnosis of a NET alongside a detailed history. 
 
Biochemical assessment 
Current biomarkers used in NETs are primarily for monitoring the progress of 
cancer, response to treatment and help determine the overall prognosis. 
However, at present there are no markers used in clinical practice to identify the 
onset of fibrosis occurring in NETs. Common biomarkers used currently in NETs 
include chromogranin A (CgA), chromogranin B (CgB), 24 hour urinary 5-
hydroxyindoleacetic acid (5-HIAA), N-terminal pro b-type natriuretic peptide (NT-
proBNP) and pancreatic polypeptide (PP). 
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Biochemical assessments commonly used in clinical practice to help in 
diagnosing MEN1 include measuring the calcium level, parathyroid hormone and 
prolactin level in addition to taking a thorough family history. 
 
CgA is a secretory protein found in the neuroendocrine secretory granules and is 
the sole pan marker for all types of NETs, with high levels correlating with tumour 
bulk.(142, 202, 203) CgA can be secreted in both functioning and non-functioning 
NETs.(204) One study of a mixed cohort of 128 patients showed that elevated 
levels of CgA were seen in 30% and 67% of patients with limited or metastatic 
disease respectively.(205) The level of CgA can be raised in other conditions such 
as renal impairment and protein pump inhibitor (PPI) use, yielding a sensitivity of 
60-90% with a specificity of less than 50%.(206) Markedly raised CgA levels are 
very rarely seen in non-NET cases, but this may be seen in patients on gastric 
acid secretory blockers, in particular PPIs, or in the presence of 
hypergastrinaemia.(207) CgB is also a member of the granin family and may be 
elevated even when CgA is within normal range.(142, 208) The endocrine 
pancreas usually secretes PP, and is also found in high concentrations in GEP 
NETs: 50-80% of pancreatic NETs and >30% of GI NETs. This can therefore be 
a useful marker in certain cases, particularly when CgA and CgB are within their 
reference ranges.(142)  
5-HIAA is a breakdown product of serotonin which can be measured in a 24 hour 
collection of urine. This has been the most useful marker in NET diagnosis and 
follow-up of patients with CS.(209) In the setting of CS, the overall sensitivity and 
specificity of the 24 hour urinary 5-HIAA is 70% and 90% respectively.(210, 211) 
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Midgut NETs are most likely to be associated with the presence of CS and an 
elevated 5-HIAA, thereby resulting in the high specificity of this marker. Foregut 
and hindgut NETs secrete less serotonin than midgut NETs.(210) In patients with 
midgut NETs without CS, the sensitivity of the 24 hour urinary 5-HIAA is lower. 
Levels of this test may also be dependent on tumour load, and therefore may be 
normal in patients with non-metastatic disease. Urinary 5-HIAA may even be 
normal in those with CS, particularly in patients who do not have diarrhoea, 
although this is unusual.(209, 212) The 24 hour urinary collection to measure 5-
HIAA does however require a strict adherence to specific dietary restrictions.(142, 
202) Some medications may also result in both increased 5-HIAA levels (such as 
acetaminophen and diazepam) as well as false negative results (including aspirin 
and levodopa).(213) Some centres are validating the role of plasma 5-HIAA 
measurement which may take over the 24 hour urinary 5-HIAA in the near future, 
and a study has shown that plasma 5-HIAA is proportional to urinary 5-HIAA and 
yielded identical correlation as urinary 5-HIAA with other biomarkers.(214)  
 
NT-proBNP is a useful marker to suggest the presence of left ventricular 
dysfunction.(215) NT-proBNP is used to screen for CHD, and has been shown to 
have both diagnostic and prognostic significance.(216) However, other factors 
including renal, pulmonary and central nervous system diseases, may also 
influence the NT-proBNP level.(217) Elevated levels of NT-proBNP prompt an 
echocardiogram to be performed and referral to cardiology if necessary. A study 
has shown that NT-proBNP is an excellent biomarker for CHD with a sensitivity of 
0.92 and specificity of 0.91 with a cut-off level of 260 pg/mL. Additionally, to 
 75 
diagnose one case of CHD, the number of patients screened reduced from 5.1 to 
1.4.(218) 
 
Radiological assessment 
The radiological assessment of NETs can be categorised as ‘anatomic imaging’ 
and ‘functional imaging’. Anatomic imaging modalities, including CT, US and MRI, 
provide important information on the staging and extent of disease. Functional 
imaging, including somatostatin receptor scintigraphy (SRS), positron emission 
tomography (PET)/CT imaging, and tracers that mark NET metabolism, give 
information related to the biological behaviour of the tumour in addition to medical 
treatments that can be appropriately initiated.(142, 219). Usually, a number of 
imaging modalities are required to reliably detect and diagnose lesions, in 
particular the smaller lesions, adequately stage the disease and finally to assess 
treatment response.  
 
Anatomic imaging 
The main anatomic imaging used in NETs, including the surveillance scans, is 
CT. On biphasic and triphasic contrast enhanced CT imaging (CECT), avid early 
enhancement of lesions, especially with pancreatic NETs, can be seen. An 
isodense lesion with calcification on unenhanced scans can be seen in 
approximately 20% of pancreatic NETs, which is different to pancreatic 
adenocarcinomas that display no calcification.(219) CECT is the gold standard in 
detecting pulmonary NETs, although more than 40% of this group can be 
identified on chest x-ray alone. Pulmonary NETs are highly vascular tumours and 
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show enhancement following intravenous contrast enhancement.(170) Small 
bowel NETs are frequently associated with mesenteric nodules and fibrosis 
resulting from desmoplastic reactions leading to stranding, tethering and fat 
changes on CT. Signs of bowel ischaemia can also be seen radiologically, 
occurring as a result of venous congestion due to encasement by nodal 
metastases. The presence of liver metastases can be seen on the hepatic arterial 
phase of a CT scan, although MRI imaging is superior to CT for identifying liver 
metastases as well as assessing response to liver-targeted treatment.(219) MRI 
has a high sensitivity (94%) in diagnosing pancreatic lesions, but there is a lower 
sensitivity in extra-pancreatic lesions.(220, 221) The benefit of MRI imaging over 
CT imaging, in particular with the surveillance scans, is the reduced risk of ionising 
radiation exposure. 
 
Functional imaging 
As explained earlier, NETs highly express SSTRs, in particular the SSTR2 and 
SSTR5 subtypes. An improvement in the sensitivity and specificity of SSTRs is 
seen with the use of anatomic imaging: single-photon emission computed 
tomography (SPECT) or with SPECT-CT imaging. The abundance of SSTRs on 
the cell surface of NET cells make them an ideal target for both imaging as well 
as treatment.(222)  
 
There are two main types of SRS imaging used in NETs. The first one is octreotide 
imaging which uses the SSTR specific ligand 111In-DPTA-D-Phe-1-octreotide that 
binds primarily to SSTR subtypes 2 and 5.(223) The octreotide scan image is 
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combined with the SPECT/CT images and therefore improves the anatomic 
localisation and overall diagnostic accuracy of this imaging modality.(224-226) 
This improvement in combining the anatomic imaging to the planar images 
acquired by octreotide imaging has been shown to alter the management in 14% 
of patients.(227) The sensitivity of octreotide imaging is limited by tumour 
size.(228) Octreotide scans are useful at detecting liver metastases and 
extrahepatic sites of metastases and are better at detecting liver metastases 
compared to primary tumour detection.(229, 230) Given that octreotide scan is a 
type of functional imaging and requires the presence of SSTR expression to be 
positive, it can identify lesions that have been missed on anatomic imaging such 
as CT or MRI scans performed alone.(225) One study showed that octreotide 
scanning detected new lesions in 28% of patients.(229) Studies concentrating on 
the identification of NET metastases have shown that octreotide imaging picked 
up new lesions in 50% of patients that were missed by CT. However, MRI was 
found to be superior to octreotide scans in detecting hepatic metastases.(228, 
231) The octreotide images are usually obtained 24 hours following ligand 
administration, but may also be acquired at 4 hour and 48 hours post ligand 
injection.(232)  
 
The more recent and improved diagnostic accuracy of SSR imaging is the 
application of DOTA PET/CT which uses the positron-emitting radionuclide 
gallium-68 (68Ga) to label various somatostatin analogues, including 68Ga-
DOTATOC (DOTA Octreotide), 68Ga-DOTANOC (DOTA-Nal-Octreotide) and 
68Ga-DOTATATE (DOTA Octreotate). All of these ligands bind with high affinity 
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to SSTR2 and SSTR5, and 68Ga-DOTANOC also binds to SSTR3.(142) One 
study showed the sensitivity and specificity of 68Ga-DOTATOC to be 96% and 
92% respectively for the identification of unknown primary, initial disease staging 
and follow up post-treatment and was superior to SRS SPECT or CT imaging. 
Bone metastases and other sites of metastatic disease were also detected by 
68Ga-DOTATOC.(233) The improved anatomic resolution of this modality is 
achieved by the combination of PET and CT imaging.(234, 235) 68Ga-DOTANOC 
PET/CT imaging has been stated to change either tumour staging or management 
in 55.5% of cases assessed.(236) 68Ga-DOTATATE has been found to be 
superior with a higher sensitivity and specificity compared to 111In-octreotide 
scintigraphy.(219)  DOTA PET/CT images are obtained just once, 60 minutes 
following radiotracer administration.(235) The major disadvantage of 68Ga-
peptide PET/CT imaging is the limited availability in the UK. 
 
Radioiodinated metaiodobenzylguanidine (123I-MIBG) has a norepinephrine 
analogue and is used to image catecholamine-secreting tumours such as 
phaeochromocytomas and paragangliomas.(237) 123I-MIBG as a high sensitivity 
of 90% with a positive predictive value of 100% in those with functional 
phaeochromocytomas or paragangliomas.(238, 239) However, there is limited 
uptake of 123I-MIBG in GEP NETs, with a positive scan being seen in 49.1% of GI 
NETs versus 91.2% seen with octreotide scan use.(240) PRRT has largely 
replaced 123I-MIBG, and 123I-MIBG is mainly used in locating the catecholamine-
secreting NETs. 
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18-fluoro-deoxy-glucose (18FDG) PET/CT imaging use in NETs is limited given 
that the vast majority of NETs are metabolically inactive and do not take up the 
tracer much, particularly in GEP NETs.(241) High grade NETs are more likely to 
show 18FDG uptake and therefore a positive scan can indicate a more aggressive 
tumour.(242) This scan is used in pulmonary NETs as part of a standard workup 
following detection of a bronchial lesion. In well-differentiated bronchial NETs, 
however, it is usually negative, but if positive again can suggest a poorer 
prognosis with a less favourable phenotype.(162) 
 
1.17 Carcinoid heart disease 
Management of patients with metastatic NETs has developed over recent years, 
with an improvement in quality of life and survival seen.(213, 243) However, 
CHD does remain the major cause of morbidity and mortality in patients with CS. 
Previously, CHD was seen to be present in 50% of patients with CS, but recent 
studies now report that CHD can affect around 20% of patients with carcinoid 
syndrome.(244-247) This fall in CHD prevalence could be a result of the wider 
use of SSA therapy in patients.(243) Progressive heart failure secondary to 
cardiac valvulopathy is the usual cause of death in patients with CHD.(248) The 
tricuspid and pulmonary valves are commonly involved.(213) In >50% of 
patients, progression of valve disease and clinical deterioration can occur 
rapidly.(249) The survival rate for patients with CHD seen in a three year 
mortality data was 31%, whereas patients with NETs without cardiac 
involvement have around twice this survival rate.(245) CHD is diagnosed 
approximately 17 months following the diagnosis of CS.(250) An improvement in 
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the prognosis of CHD has been seen more recently likely owing to advances in 
cardiac investigations, and medical and surgical management.(251) A 
retrospective analysis of 200 patients showed that in patients with CS and CHD 
the median survival has greatly improved from 1.5 years in the 1980s to 4.4 
years in the late 1990s, as a result of increased valve replacement 
procedures.(250)  
 
The exact pathogenesis in CHD is not fully understood and involves a complex 
process. Before covering the pathophysiology, I will outline the main anatomical 
components of cardiac valves. 
 
1.18 Valve interstitial cells 
Valve interstitial cells (VICs) are the most abundant cells found in the heart valve 
that maintain the valve’s structural integrity, and are found dispersed throughout 
the three valve layers: the fibrosa, spongiosa and ventricular/atrial layers. In both 
normal and diseased states, VICs play an important role.(252, 253) The three 
layers have different compositions: the fibrosa layer is rich in collagen, the 
spongiosa layer is rich in proteoglycans and the ventricular/atrial layer is dense in 
elastin.(254) The valve structure is covered by valve endothelial cells, Figure 
7.(255) Studies have shown that an accumulation of VICs associated with 
inflammatory cells, neovascularisation, increased matrix production and 
eventually fibrosis and calcification, occurs in response to valvular injury.(253) In 
diseased valves, VICs become activated to regulate repair and valve 
remodelling.(256)  
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Figure 7: Schematic diagram illustrating the valve layers. Some components 
of this diagram were obtained from Servier (118). 
 
There are five different phenotypes in the VIC group: embryonic progenitor 
endothelial / mesenchymal cells, quiescent VICs (qVICs), activated VICs (aVICs), 
progenitor VICs (pVICs) and osteoblastic VICs (obVICs).(253)  
 
The embryonic progenitor endothelial / mesenchymal cells undergo endothelial to 
mesenchymal transformation (EMT). Individual endothelial cells then migrate into 
the endocardial cushion resulting in the transformation of endothelial cells into 
mesenchymal cells, and matrix remodelling occurs in the cushion to develop  into 
mature heart valves.(253, 257, 258) It is thought that the EMT process also occurs 
after post-natal development in adult valves following injury and valve disease. 
The endothelial cells on the cushion surface contain properties of the valve 
progenitor cells and may result in VICs formation which then participate in valve 
repair.(259)  
 
The qVICs are located in the heart valve leaflet, and maintain the valve structure 
and function, and generally keep the valve avascular by inhibiting angiogenesis. 
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In response to valve injury, qVICs become activated and also give rise to aVICs 
to enable valve repair and remodelling to take place.(253)  
 
The pVICs are valvular stem cells derived from various origins, and are found in 
the bone marrow, circulation, and heart valve leaflet.  They consist of two cell 
types: endothelial progenitor cell (EPC) and dendritic cell (DC).(253) EPC is 
identified by the stem cell markers CD133 and CD34, are highly proliferative and 
are able to form new blood vessels.(253, 260) DC is identified by the intracellular 
calcium binding protein, S100.(253) In response to injury, pVICs including the 
circulating cells, bone marrow derived cells and the resident valvular progenitor 
cells are another source of aVICs.(253)  
 
The aVICs responding to valve injury and disease take on characteristics of 
myofibroblasts but are not smooth muscles as they have incomplete basement 
membranes.(253, 261) These cells are located in the heart valve leaflet. The 
aVICs are positive for alpha-smooth muscle actin (-SMA) and lead to increased 
ECM production and degradation, MMP expression and tissue inhibitors of MMP 
expression, as well as increased proliferation and migration. These are all 
important factors in the repair process. These VICs also increase the secretion of 
cytokines, particularly TGF-.(253) The majority of aVICs are then discarded by 
apoptosis after remodelling has occurred.(262) When this process is 
dysregulated, aVICs survive resulting in abnormal extracellular matrix production 
and remodelling, pathological fibrosis, angiogenesis and neovascularisation and 
calcification, eventually leading to valve disease.(253, 262)  
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The obVICs are also located in the heart valve leaflet too and may be derived 
from pVICs. They actively participate in the calcification process, and also cause 
chondrogenesis and osteogenesis in the heart valve.(253) 
 
1.19 Pathophysiology of CHD 
NETs secrete a range of vasoactive substances, including 5-HT, prostaglandins, 
bradykinin, histamine, and substances containing fibroblast proliferative 
properties (such as substance P) or TGF-, that are thought to be involved in 
the pathogenesis.(176) 5-HT receptors play a major role in the development of 
CHD which are present in the heart, with subtype 5-HT2B receptor found most on 
the valves.(263) Activation of these receptors results in mitogenesis of 
fibroblasts and smooth muscles cells, cytokine recruitment, and up-regulation of 
TGF-. Another factor involved in the pathogenesis of this disease is deficiency 
of the 5-HT transporter which is involved in uptake of 5-HT and inactivation in 
the lungs.(213, 264) This complex process results in the deposition of 
endocardial plaques, plaques in the chordae, papillary muscles and heart 
chambers, and occasionally within vasculature intima, including the pulmonary 
arteries and aorta.(176) These plaque deposits are comprised of myofibroblasts, 
smooth muscle cells, extracellular matrix components including collagen, elastin 
and myxoid matrix, and an endocardial cell layer.(176, 213, 265)  These plaques 
classically involve the right side of the heart (around 90% of cases), likely due to 
pulmonary inactivation of the vasoactive substances, resulting in right heart 
failure.(245) In left valvular pathology, occurring in 5-10% of cases, a bronchial 
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NET, extensive liver metastases or a patent foramen ovale should be 
suspected.(245, 266)  
 
Screening biomarkers currently used 
Currently in clinical practice, the most useful marker that is measured is NT-
proBNP, which has been shown to have both diagnostic and prognostic 
influences in CHD.(216) CgA and urinary 5-HIAA are also used in clinical 
assessment. 
 
Bhattacharyya et al showed that NT-proBNP was significantly higher in patients 
with CHD (median 1,149 pg/mL) compared to those without CHD (median 101 
pg/mL). A cut-off NT-proBNP level of 260 pg/mL is used as a screening tool in 
CHD, and this showed a sensitivity of 92% and specificity of 91%.(218) The 
paired combination of NT-proBNP with CgA has been studied by Korse et al, 
and levels were independently associated with the presence of CHD and 
mortality. Five-year survival was shown to be 81% in patients with a normal 
CgA, 44% in patients with a raised CgA but normal urinary 5-HIAA, and 16% 
when both markers were elevated.(216)  
 
CgA has been shown to be a sensitive marker in CHD, with a sensitivity of 
around 100% but a low specificity of 30% to predict severe CHD. CgA is 
therefore not used as a screening marker in CHD.(213)   
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Both plasma and urinary 5-HIAA levels have been seen to be significantly higher 
in patients with CHD compared to those without this complication.(267, 268) A 
retrospective study showed that a higher peak level of 5-HIAA significantly 
predicted progressive CHD and was also raised in patients who had severe 
symptoms requiring valve surgery.(269) Bhattacharyya et al showed that 24 
hour urinary 5-HIAA 300 mol/24 hours and 3 episodes of facial flushing a 
day are predictors for the development or progression of CHD.(270)  
 
Valve surgery is the only definitive treatment for these patients with severe right-
sided heart failure, if the patient is a suitable candidate. It has been noted that 
operating at an early stage or at a time close to the onset of symptoms is 
preferable, to reduce the risk of worsening right heart failure and reduce the risk 
of surgery.(245) However, some patients may be asymptomatic and therefore a 
delay in diagnosis can occur when treatment options are then limited. The 
benefit of diagnosing fibrosis at an early stage by use of sensitive and specific 
markers can be seen in this group of patients, so cardiac surgery can be offered 
early to reduce the risk of worsening right ventricular failure occurring, and 
therefore improve symptoms and overall survival.  
 
1.20 Vascular adhesion protein-1 
VAP-1 is a 170-kilodalton (kDa) homodimeric transmembrane 
sialoglycoprotein.(271) It has a short (4 amino acid) N-terminal cytoplasmic tail, a 
single transmembrane segment and a large extracellular domain.(272) VAP-1 is 
heavily glycosylated and the adhesive function of VAP-1 is dependent on the 
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terminal sialic acid groups of the glycans.(273) A VAP-1 monomer consists of 
potentially 6 N-linked glycosylation sites and 3 O-linked glycosylation sites, 
Figure 8. VAP-1 consists of two monomers and each monomer contains one 
copper atom.(274) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Structure of vascular adhesion protein-1. The positions of the 
potential glycosylation sites are for illustration purposes only. N1-6, N-linked 
glycosylation sites. O1-3, O-linked glycosylation sites. C, C-terminus. N, N-
terminus. The dotted line represents the outline of the two monomers. 
 
VAP-1 has two main functions: firstly, it is an endothelial cell adhesion molecule 
that regulates lymphocyte binding to the endothelium under certain 
conditions.(275, 276) Secondly, VAP-1 is a copper-dependent semicarbazide-
sensitive amine oxidase (SSAO) known as amine oxidase copper-containing 
3.(277) The enzymatic activity of VAP-1 catalyses the oxidative de-amination of 
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both endogenous and exogenous primary amines leading to the production of 
ammonia, aldehyde and hydrogen peroxide (H2O2).(277) These resulting 
products then activate nuclear factor kappa light chain enhancer of activated B 
cells (NFB) pathway leading to chemokine secretion and upregulation of 
leucocyte adhesion.(278, 279) The active site of SSAOs contains an important 
topoquinone (TPQ) co-factor, modified from a tyrosine residue in a copper 
dependent reaction. Following reduction of the primary amine, the formation of a 
transient Schiff base occurs via the TPQ with the generation of aldehyde. The 
reduced TPQ is then hydrolysed with oxygen leading to the release of H2O2 and 
ammonia.(280) This reaction plays an essential role in the rolling and 
transmigration steps during leucocyte extravasation.(281, 282) The exact 
lymphocyte ligand is currently unknown. It has been proposed that Siglec 9 and 
10 may be the lymphocyte ligands for VAP-1, with Siglec 10 serving as a direct 
substrate to VAP-1 and therefore is dependent on the enzymatic function of 
VAP-1. Siglec 9, however, binds additionally to another site present in the 
enzymatic groove.(283, 284) Maula et al showed that the 6 N-linked 
glycosylation sites located on the extracellular ‘cap’ of VAP-1 contributes to the 
adhesive and enzymatic functions of this molecule.(285) VAP-1 has also been 
found to be expressed highly on endothelial cells, adipocytes, smooth muscle 
cells, pericytes, follicular DCs and hepatic stromal cells.(277, 280, 286) VAP-1 is 
expressed on hepatic endothelium both in normal conditions and in an 
inflammatory environment.(277, 278, 287) VAP-1 has also been shown to play a 
vital role in promoting the onset of liver fibrosis in models of chronic liver 
injury.(277, 288) Weston et al showed several mechanisms by which VAP-1 
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promotes fibrosis in liver disease. Firstly, they showed that VAP-1 is expressed 
by stromal cells and drives amine-oxidase-dependent leucocyte migration. VAP-
1 was shown to link inflammation and fibrosis following liver injury and response 
to exposure of carbon tetrachloride (CCl4). In the absence of VAP-1 or having an 
antibody to VAP-1, there was evidence of reduced fibrosis and a fast recovery 
following liver insult to CCl4. There was a substantial reduction in the absolute 
numbers of both lymphoid and myeloid cells recruitment when VAP-1 was 
absent in the mice models. The group also showed that rendering the catalytic 
site of VAP-1 inactive and using an antibody to VAP-1 led to a reduction in 
lymphocyte transmigration and expression of fibrotic genes. VAP-1 was also 
found to regulate the transcription of profibrotic factors, including collagen I and 
lysyl oxidase-like protein 2 (an amine oxidase that has been shown to be 
associated with fibrosis development) and increased expression of platelet-
derived growth factor receptor beta which is characteristic of activated hepatic 
stellate cells, therefore promoting the fibrotic response in CLD.(277)  
 
VAP-1 also exists in a soluble form (sVAP-1) and represents nearly all of the 
circulating amine oxidase activity in humans.(276, 289, 290) Levels of sVAP-1 
have been found to be significantly raised in chronic liver inflammatory 
conditions, but not in rheumatoid arthritis nor in inflammatory bowel 
disease.(276, 277, 288) A recent study conducted by our Birmingham group 
involving a cohort of patients with primary sclerosing cholangitis (PSC) has 
shown that elevated sVAP-1 levels are associated with a poorer transplant-free 
survival and an increased risk of liver-related death.(291) VAP-1 is released 
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from adipose tissue and from the hepatic vasculature and levels of VAP-1 
measured in the portal and hepatic veins imply that the liver is a major source of 
sVAP-1.(277) The exact mechanism for the release of VAP-1 by adipocytes is 
currently unknown, but it has been shown that VAP-1 release induced by TNF-
alpha may be dependent on MMP activity, and inhibiting MMP resulted in a 
large reduction of VAP-1 release.(289) In patients with non-insulin and insulin-
dependent diabetes, obesity, congestive heart failure and atherosclerosis, 
raised sVAP-1 levels have also been found.(292-295)  
Hsia et al showed the association of VAP-1 with myofibroblast expression in 
cancerous tissue.(296) Our Birmingham group have shown that levels of sVAP-
1 are reduced in colorectal cancer patients. The molecular basis for the reduced 
detection of sVAP-1 levels in colorectal cancer is not yet known, but the cancer 
may activate a mechanism that prevents the recruitment of anti-tumour immune 
cells and the cancer may also have systemic effects in reducing expression of 
VAP-1.(297)  
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1.21 Preliminary data of vascular adhesion protein-1 in neuroendocrine 
tumours 
Preliminary data (unpublished data) from our laboratory suggested that VAP-1 
may also contribute to the fibrotic complications in patients with NETs with our 
data showing increased expression of VAP-1 and fibroblast associated proteins 
in NETs. The data has also shown high VAP-1 expression in carcinoid heart 
disease valves compared to valves with no evidence of carcinoid heart disease. 
Significantly elevated sVAP-1 levels have been found in patients with NETs 
(median 562.5, interquartile range (IQR) 438.8 – 697.3 ng/mL; mean 586.0 ± 
standard deviation (SD)166.2ng/mL) compared to the control group (median 
256.0, IQR 212.0 – 308.0 ng/mL; mean ±SD 265.0±79.3 ng/mL), (p<0.0001), 
and even higher sVAP-1 levels in in those with CHD (median 691.0, IQR 684 – 
854 ng/mL; mean ±SD 744.4±136.6 ng/mL) compared to patients with NETs 
and no CHD (median 511, IQR 411.3 – 583.8 ng/mL; mean ±SD 514.7±128.6 
ng/mL) (p<0.01). However, the numbers included in this preliminary data were 
small, both for the serum and the staining analysis, and therefore no 
conclusions could be firmly drawn. The preliminary data was very interesting 
and therefore further work was undertaken to explore the role of VAP-1 in 
NETs. 
 
We therefore believe that VAP-1 may be a therapeutic target for fibrosis in NET 
patients. This will be the first study assessing the role of VAP-1 in NETs and 
also in CHD. Understanding the role of VAP-1 in driving tissue fibrosis in NETs 
could allow patient stratification for therapy, potentially lead to novel therapies 
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which reduce morbidity and mortality in patients with NETs, and significantly 
improve their quality of life.  
 
1.22 Hypotheses of my research studies presented in this thesis 
The need for accurate biomarkers to diagnose cancer can be appreciated. This 
will improve the overall median survival of HCC patients by the ability to offer 
curative treatments at an appropriate stage when there is early stage disease and 
patients are physically fit enough to undergo treatment. At present there are no 
such biomarkers that clinicians in the UK can use in their clinical practice. 
Particularly in Asia, PIVKA-II has been shown to be a promising marker to aid in 
the diagnosis of early HCC in at-risk groups, and is incorporated into the Japanese 
HCC surveillance guidelines for high-risk patients. With patient cohorts differing 
between the UK and Asia, assessment of PIVKA-II is required to see if this marker 
can be utilised worldwide. 
 
My hypothesis for the role of PIVKA-II in early HCC includes: 
a) PIVKA-II is a potential biomarker in the diagnosis of early HCC. The 
combination of PIVKA-II and AFP markers will yield a greater predictive 
accuracy in diagnosing early HCC. As PIVKA-II is thought to be 
expressed by hepatocytes, I hypothesise that serum levels of PIVKA-II 
will be normal in non-HCC cancers. 
b) PIVKA-II serum levels correspond to disease activity following ablation 
treatment and can therefore be used as a post treatment surveillance 
marker. Therefore, I hypothesise that following treatment and imaging 
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showing no evidence of cancer, PIVKA-II levels will fall, and levels will 
rise with disease recurrence. 
c) Pre-transplant PIVKA-II serum levels can be utilised for the prediction of 
poor prognostic outcomes, with higher levels being associated with the 
presence of MVI and moderately / poorly differentiated HCC. 
 
Serious complications associated with certain cancers can manifest at various 
stages of disease and can present at an advanced stage when treatment options 
are limited. NETs are associated with desmoplasia, with cardiac involvement and 
CHD being the most serious complication related to this disease. The current 
marker used in practice to help in the diagnosis of CHD is NT-proBNP. However, 
this marker may be within normal values despite the presence of CHD and 
therefore levels do not always correlate with disease status and so a delay in 
diagnosis can result. For valve surgery to be considered in patients with CHD, this 
complication needs to be diagnosed at an early stage, so there can be close 
monitoring under a specialist and a timely referral for surgery. Additionally, a 
proportion of patients are not fit enough for valve surgery, and there are no other 
treatments that can be offered to treat this disease. Therefore, the evaluation of 
VAP-1 in NETs could be a significant finding, with this marker being used in both 
diagnosis as well as a target for future treatment. 
 
My hypothesis for assessing the value of VAP-1 in NETs includes: 
a) Serum VAP-1 levels will be increased in patients with NETs compared to 
healthy controls, with levels highest in fibrotic complications associated 
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with NETs (i.e. CHD) compared to the absence of these complications in 
NETs. Serum VAP-1 levels will fall following treatment. 
b) VAP-1 tissue expression will be increased in tissue from midgut NETs 
and in CHD valves. 
  
Figure 9 shows summary flow charts of the patient groups recruited into 
each study. 
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Figure 9: Summary flow charts of recruitment into each study.  
Figure 9a represents the patient groups recruited in VAP-1 in NETs study. Figure 9b represents the patient groups 
recruited into PIVKA-II in HCC study. VAP-1, vascular adhesion protein-1. CHD, carcinoid heart disease. sVAP-1, soluble 
VAP-1. 
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2.1 The role of prothrombin induced by vitamin K absence-II in early 
hepatocellular carcinoma 
 
2.1.1 Recruitment and sample collection 
 
Ethical approval 
Ethical approval was acquired from the National Research Ethics Service 
(NRES), Research Ethics Committee reference 06/Q2707/182. Written informed 
consent was obtained from all study participants. 
 
Study participants for serum analysis 
Consecutive patients with a diagnosis of early HCC included in the study were 
recruited prospectively between January 2016 and April 2018. Early HCC was 
defined by the MC: the presence of either a single lesion 5cm in size, or three 
lesions with a maximum diameter 3cm in size. Diagnosis of early HCC was 
made following either radiology investigations showing characteristic hallmarks 
or a liver biopsy. 
 
Additionally, two reference cohorts were recruited over the same time period. 
The first cohort included patients with liver cirrhosis, as identified on radiological 
imaging. Patients with CLD (no features of cirrhosis radiologically or 
biochemically, or CLD diagnosed on biopsy) formed the second cohort.  
Additionally to the baseline serum samples taken, longitudinal measurements of 
PIVKA-II and AFP were taken at approximately three monthly intervals in 
patients with early HCC who underwent ablation therapy.  
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Patients receiving TACE treatment and Sorafenib were recruited by the 
oncology team, and the baseline serum PIVKA-II and AFP levels taken will be 
included in this study as comparison groups to patients with early HCC. A 
biobank of samples has also been used for non-HCC cancer type groups, and 
was collected by the oncology team. 
 
Sample collection and analyser used 
Blood was taken peripherally from all patients in gold-top tubes (containing 
serum separator clot activator), and centrifuged for 10 minutes. Serum was 
extracted, and aliquots stored at -80oC until analysis.  
Tosoh Bioscience provided an immunoassay analyser which is validated for the 
measurements of PIVKA-II and AFP, and supplied all the reagents required to 
perform the analysis for the entire study. The Tosoh analyser AIA-900 is a two-
step immunoenzymometric assay. The PIVKA-II analyte present in the test 
serum is bound to anti-PIVKA-II mouse monoclonal antibody (Ab), MU3, 
immobilised on the beads in the PIVKA cups. The beads are then washed to 
remove unbound materials, and are then incubated with the conjugate 
(enzyme-labelled anti-prothrombin rabbit polyclonal Ab). The beads are washed 
again to remove unbound conjugate and then incubated with a fluorogenic 
substrate (4-MUP). The enzyme labelled Ab changes the enzyme substrate that 
causes colouration to occur. PIVKA-II is calculated by measuring the 
absorbance of the coloured solution and comparing it with the reference 
calibrator. The amount of enzyme labelled Ab that binds to the beads is directly 
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proportional to the PIVKA-II concentration in test sample. Figure 10 summarises 
these reactions.  
 
Figure 10: Summary of the TOSOH Analyser AIA-900 reactions. Ab, 
antibody. 
 
Inclusion and exclusion criteria 
To be included in this cross-sectional study, patients had to meet: i) the MC for 
early diagnosis of HCC; ii) radiological features to diagnose cirrhosis and iii) 
requirements to diagnose CLD. 
 
Patients were excluded from this study if they were on anticoagulation, were 
pregnant or had co-existing malignancy. 
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Tissue sections for immunohistochemical staining 
Immunohistochemical (IHC) staining of liver tissue, including HCC tissue, was 
also undertaken using Crystal Chem, Anti-PIVKA-II monoclonal antibody, clone 
number PIM 55 (stock concentration 11.3 milligrams /millilitres (mg/mL)). Various 
dilutions were used with a maximum dilution of 1/8000 (concentration used 0.0014 
mg/mL) and both low pH and high pH antigen retrieval solutions were used. 
Casein concentrations were also increased up to 10X solution and addition of 
animal serum block was also performed. An ImmPRESS Excel Amplified 
peroxidase polymer staining kit was also used to enhance specificity for PIVKA-
II.  
 
Immunohistochemical staining method 
Paraffin-embedded slides were firstly de-waxed by rinsing firstly three times 
with Xylene, three times with alcohol and twice with water. Each rinse was left in 
the pots for three minutes. 10mL of high or low pH antigen unmasking solution 
(Vector) was added to 1 litre of distilled water in a microwave pot. The low pH 
antigen solution is citrate-based with pH 6.0, and the high pH antigen solution is 
Tris-based with pH 9.0. This was then microwaved at high power for 10 
minutes. After the slides had finished the final wash in water, they were loaded 
in a rack and microwaved at high power for 30 minutes and left to stand for 10 
minutes. The slides were run in tap water to room temperature and placed in a 
smaller pot of water to cool. Following this, the slides were mounted in a cover 
slip and placed in a sequencer tray. The wells were filled with Tris buffered 
saline with 0.1% tween (TBST) and left for 5 minutes to allow the TBST to drain 
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through. 100 microlitres (l) of hydrogen peroxidase blocking solution (Dako 
REAL) was then added to each well (or 2 drops of BLOXALL when the Excel 
amplified was used) and left for 10 – 20 minutes depending on the tissue type 
stained. After this time, the wells were re-filled with TBST to wash off the 
hydrogen peroxidase solution and left for 5 minutes. 100l of 10X casein 
solution (various casein concentrations used for the PIVKA-II study) was then 
added to each well and left for 10 – 20 minutes depending on the tissue type 
stained. If animal serum blocking solution was used, this was left for 20 
minutes. Following this, the primary antibody (Ab) was added to each well. The 
tray was covered and left to incubate for 1 hour at room temperature. The slides 
were then washed with TBST for 5 minutes. Following this, a polymer-based 
secondary antibody (Immpress Kit) was added and incubated for 30 minutes. 
When the Excel amplified kit was used, 2 drops of R.T.U. goat anti-mouse 
amplifier Ab was added after the wash for 15 minutes followed by a further 
wash with TBST for 5 minutes. With the Excel amplified kit, a horse anti-goat 
polymer-based secondary antibody was added and incubated for 30 minutes. 
Following the second incubation, two washes with TBST were done, each for 5 
minutes. The wells were filled up again with TBST and the cover slip with the 
slide was pulled out and placed on a metal rack. A couple of drops of 3,3'-
diaminobenzidine (DAB) was added to each slide and left for 5 minutes. Water 
was then poured over the slides and the excess water was drained off. 
Following this, 5-6 drops of filtered Mayer’s haematoxylin was added and left for 
30-40 seconds, and washed off by pouring water. The slides were then placed 
in warm water and the dehydration process then commenced. This involved 
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rinsing the slides three times in alcohol and then in Xylene three times. Cover 
glass slides were then placed on a piece of tissue paper and DPX mountant 
was put in the middle of each cover glass slide. The slides were taken out of the 
holder and placed on the DPX cover glass slide. 
 
Visualisation of staining 
The chromogenic stained tissue section images were taken using the Zeiss 
Axio Scan.Z1 slide scanner. Image analysis was performed using Zen Imaging 
Software.  
 
2.1.2 Statistical analysis 
Statistical analysis of data was performed using SPSS Statistics version 23 
(IBM Corp. Armonk, NY). The distributions of continuous variables were 
assessed prior to analysis using graphical methods. Normally distributed factors 
were reported as means ± standard deviations (SDs), with medians and 
interquartile ranges (IQRs) used for non-normal factors. Categorical variables 
were stated as absolute values with percentages. 
 
Comparisons between the three patient groups were then performed, using 
one-way analysis of variance (ANOVA) for normally distributed variables, 
Kruskal-Wallis tests for non-normal variables, and Fisher’s exact tests for 
categorical variables. For the markers of interest, where the overall effect was 
significant by Kruskal-Wallis test, pairwise post-hoc comparisons were 
performed using Dunn’s test. Comparisons of continuous variables between two 
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groups (e.g. HCC vs non-HCC) were performed using Mann-Whitney U tests. 
PIVKA-II and AFP levels were then compared across the different HCC stage 
groups using Jonckheere-Terpstra tests, to account for the fact that the HCC 
stages were ordinal. Relationships between PIVKA-II and a range of laboratory 
markers were assessed using Spearman’s rank (rho) correlation coefficients. 
The abilities of PIVKA-II and AFP to differentiate between early HCC and both 
CLD and cirrhosis, and between early HCC and cirrhosis, were then assessed 
using receiver operating characteristic (ROC) curves. In order to further assess 
the relationship between PIVKA-II and the distribution of disease, patients were 
then divided into five groups, based on the quintiles of PIVKA-II, and the 
distribution of disease compared across each group.  
 
A multivariable binary logistic regression model was then produced to assess 
whether PIVKA-II and AFP were significant independent predictors of early 
HCC. Hosmer-Lemeshow goodness of fit tests were produced for each variable 
separately, with log2-transformations applied where poor fit was detected. 
Predicted values were then produced from the model, and the predictive 
accuracy of the combination of PIVKA-II and AFP compared to that of the 
individual factors using ROC curves. 
 
Median PIVKA-II/AFP levels were compared across various explant findings 
including the presence of vascular invasion, HCC differentiation and number of 
lesions. Mann-Whitney tests was used for comparison across two groups and 
Jonckheere-Terpstra tests for comparisons across ordinal factors. For 
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comparisons between non-HCC cancer types, Fisher’s exact and Kruskal-Wallis 
tests were used for categorical and continuous variables, respectively. 
 
Patients that had missing data for a variable were excluded from any analyses 
including that variable. For PIVKA-II/AFP values that were below the lower limit 
of detection for the assay, a value of 1 was assumed. Throughout the analysis, 
a critical p-value of p<0.05 was used as a cut-off for statistical significance. 
 
2.2 Assessing the role of vascular adhesion protein-1 in neuroendocrine 
tumours 
 
2.2.1 Recruitment and sample collection 
 
Ethical approval 
Ethical approval for the Human Biomaterials Resource Centre (HBRC), University 
of Birmingham, generic tissue banking is NRES Committee North West – 
Haydock 15/NW/0079. Under this approval, the HBRC project approvals are 
HBRC 15 – 235 and HBRC 13 – 152. Written informed consent was obtained from 
all study participants. 
 
Study participants for serum VAP-1 analysis 
Consecutive patients with midgut NETs or CHD were recruited prospectively 
between October 2014 – August 2018. The pancreatic NET group were 
recruited prospectively between September 2016 – June 2018. Patients were 
recruited during NET clinic review. Baseline and subsequent longitudinal serum 
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samples of VAP-1 were taken within twelve months of the baseline sample in 
midgut NET patients having SSA treatment or undergoing surgery. Healthy 
volunteer samples were also used as a control group and were supplied by the 
University of Birmingham HBRC. 
 
Blood samples were collected in red-top tubes (containing serum clot activator), 
spun, and serum extracted and stored in the University of Birmingham HBRC 
until analysis.  
 
Tissue sections for immunohistochemical and immunofluorescence 
staining 
The University of Birmingham HBRC have also provided us with surgically 
resected paraffin embedded tissue (4 micrometres sections) for 
immunohistochemical and immunofluorescence studies. This includes the CHD 
valves, midgut NET tissue, control valves and cardiac myxoma tissue. The 
control valves included both aortic and mitral degenerative disease.  
 
Immunohistochemical staining method 
The sections were stained as described previously but the Excel amplified kit 
was not used. 
 
Haematoxylin and Eosin staining method 
The midgut NET and CHD valve tissue were also stained with haematoxylin and 
eosin. This involved placing the paraffin-embedded slides in xylene three times 
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(2 minutes each time), three times in alcohol (2 minutes each time), twice in 
water (2 minutes each time), once in haematoxylin harris (PFM medical) for 4 
minutes, once in water for 2 minutes, once in acid alcohol for 30 seconds, once 
in water for 2 minutes, once in Scott’s Tap Water Substitute for 30 seconds, 
once in water for 2 minutes, once in Eosin for 1 minute, twice in water (2 
minutes each time), three times in alcohol (2 minutes each time) and three 
times in xylene (2 minutes each time). The slides were then taken out of the 
holder and placed on the DPX cover glass slide and mounted using DPX. 
 
Immunofluorescence staining method 
The paraffin-embedded sections were initially stained following the same 
protocol as the immunohistochemical staining described earlier. After the slides 
had completed the de-waxing protocol, they were added to 1 litre of distilled 
water that contained 10mL of high or low pH antigen unmasking solution and 
microwaved at high power for 30 minutes and left to stand for 10 minutes. The 
slides were then run in tap water to room temperature and placed in a smaller 
pot of water to cool. Following this, the slides were mounted in a cover slip and 
placed in a sequencer tray. The wells were filled with phosphate-buffered saline 
with 0.1% tween (PBST) and left for 5 minutes to allow the PBST to drain 
through. 100l of casein X2 solution and goat serum was then added to each 
well and left for 30 minutes. Following this, the primary antibody (Ab) was added 
to each well. The tray was covered and left to incubate for 1 hour. The slides 
were then washed with PBST for 5 minutes and a secondary fluorescent 
antibody (Thermofisher antibodies 1/500 dilution or VectoFluor Duet Double 
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Labeling Kit) was added and incubated for 30 minutes. Following the second 
incubation, two washes with PBST were done, each for 5 minutes. The slides 
were then removed from the sequencer tray and a frame was drawn around the 
tissue using an ImmEdge hydrophobic barrier pen. Thermofisher Hoerscht 
33342 (dilution used 1/1000) was then applied and left on for 10 minutes. A 
further wash with PBST was performed for 5 minutes. Vector TrueVIEW 
Autofluorescence Quenching Kit (150l of Vector TrueVIEW Reagent for each 
tissue section) was then applied for 5 minutes followed by a wash with PBST for 
another 5 minutes.  Cover glass slides were then placed on a piece of tissue 
and mounting media in the Vector TrueVIEW Autofluorescnce Quenching kit 
was put in the middle of each cover glass slide. The slides were placed on the 
mountant cover glass slide. 
Table 5 summarises the primary antibodies used for both staining methods in 
midgut NETs and cardiac tissue. 
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 Suppli
er 
Clone 
numb
er 
Suppli
er 
code  
Antige
n 
Retriev
al 
(All are 
Vector 
Labs) 
Stock 
concentrati
on 
Used 
concentrati
on for 
midgut 
NET tissue 
Diluti
on for 
midgu
t NET 
tissue 
Used 
concentrati
on for 
cardiac 
tissue 
Diluti
on for 
cardia
c 
tissue 
Chromoge
nic 
Staining 
         
VAP-1 R&D 39311
2 
 Tris-
based 
500 ug/mL 1.67 ug/mL 1/300 2.5 ug/mL 1/200 
IMC IgG2b Dako  X 0944 Tris-
based 
100 mg/L 1.67 ug/mL 1/60 2.5 ug/mL 1/40 
Collagen I Abcam  ab347
10 
Tris-
based 
1 mg/mL 5 ug/mL 1/200 5 ug/mL 1/200 
IMC Rabbit 
IgG 
(Collagen I) 
Dako  X 0903 
pAb 
Tris-
based 
1 mg/mL 5 ug/mL 1/200 5 ug/mL 1/200 
Alpha-SMA Sigma-
Aldrich 
1A4  Tris-
based 
2.3 mg/mL 0.5 ug/mL 1/5000 - - 
IMC IgG2a Dako  X 0943 Tris-
based 
100 mg/L 0.5 ug/mL 1/200 - - 
CD45 Abcam  Ab105
58 
pAb 
Citrate 
- based 
1 mg/mL 2 ug/mL 1/500 2 ug/mL 1/500 
IMC Rabbit 
IgG (CD45) 
Dako  X 0903 
pAb 
Citrate 
- based 
1 mg/mL 2 ug/mL 1/500 2 ug/mL 1/500 
S100 Dako  IR504 
pAb 
Tris-
based 
Pre-dilute - - Pre-dilute Pre-
dilute 
CD34 Dako QBEn
d 10 
IR632 
 
Tris-
based 
Pre-dilute - - Pre-dilute Pre-
dilute 
CD31 Dako JC70A  Tris-
based 
205 mg/L - - 2.05 ug/mL 1/100 
IMC IgG1 
(CD31) 
Dako  X 0931 Tris-
based 
100 mg/L - - 2.05 ug/mL 1/50 
Collagen III Abcam  ab777
8 
pAb 
Tris-
based 
1 mg/mL - - 5 ug/mL 1/200 
IMC Rabbit 
IgG 
(Collagen 
III) 
Dako  X 0903 
pAb 
Tris-
based 
1 mg/mL - - 5 ug/mL 1/200 
Fluorescen
t Staining 
         
VAP-1 R&D 39311
2 
 Tris-
based 
500 ug/mL 2.5 ug/mL 1/200 2.5 ug/mL 1/200 
IMC IgG2b Dako  X 0944 Tris-
based 
100 mg/L 2.5 ug/mL 1/40 2.5 ug/mL 1/40 
Collagen I Abcam  ab347
10 
Tris-
based 
1 mg/mL 5 ug/mL 1/200 5 ug/mL 1/200 
IMC Rabbit 
IgG 
(Collagen I) 
Dako  X 0903 
pAb 
Tris-
based 
1 mg/mL 5 ug/mL 1/200 5 ug/mL 1/200 
Alpha-SMA Sigma- 
Aldrich 
1A4  Tris-
based 
2.3 mg/mL 10 ug/mL 1/230 10 ug/mL 1/230 
IMC IgG2a Dako  X 0943 Tris-
based 
100 mg/mL 10 ug/mL 1/10 10 ug/mL 1/10 
Table 5: Summary of primary antibodies used for staining in midgut 
NET and cardiac tissue. IMC, isotype matched control. pAb, polyclonal 
antibody. 
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Visualisation of staining 
The chromogenic stained tissue section images were taken using the Zeiss 
Axio Scan.Z1 slide scanner. The fluorescent stained tissue section images were 
taken using the Zeiss LSM 780 confocal microscope. Image analysis was 
performed using Zen Imaging Software.  
 
Enzyme-linked immunosorbent assay (ELISA) 
Serum aliquots were stored at -80oC until analysis. Measurement of soluble VAP-
1 in patient serum was performed using the Human VAP-1 Quantikine ELISA kits 
(R&D, DVAP10). The human VAP-1 microplates were already coated with a 
monoclonal Ab specific for human VAP-1. To each well 100l of assay diluent 
was added. The samples were prepared using a 70 or 80-fold dilution with the 
calibrator diluent. The human VAP-1 standard concentrations used were 
50ng/mL, 25ng/mL, 12.5ng/mL, 6.25ng/mL, 3.13ng/mL, 1.56ng/mL, 0.781ng/mL 
and 0ng/mL. Both the standard concentrations and the samples were run in 
duplicates. Into each well, 50l of human VAP-1 standard or sample were 
pipetted. The microplates were then covered with an adhesive strip and incubated 
for 2 hours at room temperature on a horizontal microplate shaker set at 500rpm. 
After the 2 hours incubation, each well was aspirated and washed with 400l wash 
buffer for a total of four washes. After each wash, the plate was inverted and 
blotted against paper towels. Following the washes, 200l of human VAP-1 
conjugate (conjugated to horseradish peroxidase) was added to each well and 
the plate was covered with an adhesive strip and incubated for a further 2 hours 
on the microplate shaker. A total of four washes was again performed after the 2 
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hour incubation. 200l of substrate solution was then added to each well and the 
plate was covered with an adhesive strip and incubated at room temperature for 
30 minutes on the benchtop protected from light. 50l of stop solution was then 
added after 30 minutes to each well. The colour in the wells changed from blue to 
yellow. The optical density of each well was determined within 30 minutes of 
adding the stop solution using a microplate reader set at 450nm and 540nm. The 
readings at 540nm were subtracted from the readings at 450nm to correct for 
optical imperfections in the plate. The standard curve used was the second order 
polynomial curve. The concentration of VAP-1 was then calculated and multiplied 
by the dilution factor of 70 or 80. 
 
Inclusion and exclusion criteria 
To be included in this study, patients had to have a diagnosis of midgut NET, CHD 
or pancreatic NET.  
 
In the serum VAP-1 analysis, for the midgut NET patients who had a primary small 
bowel resection, there was evidence of recurrent disease when the sample was 
taken. No surgical resection was performed in the pancreatic NET group. 
 
Patients were excluded from the serum VAP-1 analysis if they had active co-
existing malignancy.  
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2.2.2 Image analysis 
Once the tissue sections were uploaded using the slide scanner, the quantification 
of both VAP-1 and Collagen I were performed using Ilastik (version 1.3.0) and Fiji 
Image J (version 2.0.0-rc-66/1.52b). Using Ilastik, a group of sections from the 
midgut NET, control valves and the CHD cohorts were trained in order to 
recognise the antibody staining. A live update was performed to ensure the 
antibody staining was correctly identified. Once the training was complete, all the 
sections from each cohort were then inputted into Ilastik generating images that 
used the training performed to correctly identify the antibody staining in each 
section. Following this, an automated macro was inputted into Fiji Image J with 
the antibody staining set in the programme of the macro as ‘2’. The images 
generated by Ilastik were then analysed on Fiji Image J and the percentage area 
of antibody expression was calculated.  
 
A highly experienced pathologist reviewed all the CHD and control valve stained 
sections to identify the exact location of the positive staining and also suggested 
additional stains to use to help further accurately identify the positive stained cells 
appearance, location within the valves using elastin and haematoxylin van gieson 
staining (EHVG), and assess the association of VAP-1 staining with other markers 
including S100 and CD34. 
 
2.2.3 Statistical analysis 
Statistical analysis of data was performed using SPSS Statistics version 23 
(IBM Corp. Armonk, NY) and GraphPad software (Prism 7) version 7.0b.  
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A quantitative analysis was performed using the Mann-Whitney U test to assess 
the % area of VAP-1 expression in both the CHD and control valves. 
Continuous variables are reported as medians and IQRs, with comparisons 
between non-paired samples performed using Mann-Whitney U tests and the 
paired samples performed using Wilcoxon’s test. Age is reported as mean ±SD 
with p-Values from independent samples t-tests. Categorical data is reported as 
N (%) with p-Values from Fisher’s exact tests. Comparisons between more than 
two patient groups were performed using Kruskal-Wallis tests, with pairwise 
post-hoc comparisons performed using Dunn’s test where significant 
differences were detected. Relationships between sVAP-1 and a range of 
clinical markers or findings were assessed using Spearman’s correlation 
coefficients. Changes in carcinoid syndrome symptoms were compared using 
McNemar’s test.  
 
Throughout the analysis, a critical p-value of p<0.05 was used as a cut-off for 
statistical significance. 
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3.1 Introduction and aims 
3.1.1 Introduction 
HCC distribution varies according to geographic location. In areas such as 
Eastern Asia and sub-Saharan Africa, the burden of HCC is highest due to a high 
prevalence of endemic HBV infection. In comparison with the global burden of 
disease, the UK has a low incidence of HCC.(298) However, the incidence of HCC 
is now rising in the UK.(4) The development of HCC in cirrhosis is not always 
associated with end-stage liver disease, and in fact does usually occur in the 
presence of adequate liver functional reserve.(299) Overall risk for developing 
HCC in patients with cirrhosis is dependent on various factors, including liver 
disease aetiology (highest in patients with HCV infection), location and ethnicity 
(highest in Asians) and cirrhosis stage (highest in those with hepatic 
decompensation).(300, 301) However, at present in a large number of cases, 
diagnosis is made in the advanced stages of disease, so curative treatment 
options are often limited.(302)  
 
There is a demanding requirement for screening tests that can be used in the 
surveillance of HCC in at-risk patient groups to increase the number of cases 
diagnosed with early HCC so curative treatment options can be implemented and 
improve the overall life expectancy for patients. US imaging has limitations for use 
as a screening tool in HCC. The overall sensitivity of this radiological investigation 
is around 65-80%, and is lower in the early stages of disease where there are 
non-specific features seen and characteristics have not been well defined in the 
setting of cirrhosis and HCC surveillance.(303-306) Additionally, it is subjective 
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and increasing incidence of obesity in the West can also limit the sensitivity of US 
imaging.(53) Traditionally, AFP has been the marker used in HCC surveillance, 
but the EASL-EORTC guidelines suggest that AFP should no longer be monitored 
given the suboptimal sensitivity and specificity associated with this marker.(17)  
 
PIVKA-II has emerged in Japanese guidelines as part of HCC surveillance in 
patients at high risk, and numerous studies in Asia have been performed looking 
at the value of this marker in HCC. Studies performed to date have shown variable 
efficacy of PIVKA-II as a single biomarker in diagnosing HCC. PIVKA-II does 
appear to be an attractive biomarker in European patient cohorts given that it has 
been shown to be elevated in early stage disease and in NASH associated HCC, 
whereas AFP is found to be high in viral hepatitis and advanced disease.(121) 
Studies (including those in the UK) involving the application of the GALAD model, 
which incorporates three serological markers (AFP, AFP-L3 and PIVKA-II), have 
shown that this improves the detection and diagnosis of HCC, including the 
detection of early HCC.(50, 306) PIVKA-II therefore does appear to have a role in 
the Western population. 
 
The majority of studies already conducted evaluating the role of PIVKA-II in HCC 
have been largely performed in Asia, where liver disease aetiology differs from 
the UK, and viral hepatitis is the commonest disease aetiology in comparison to 
the UK, where alcoholic liver disease (ALD) and non-alcoholic fatty liver disease 
(NAFLD) are usually the causes of liver disease. PIVKA-II has been shown to 
perform better for viral aetiologies of cirrhosis and HCC compared to non-viral 
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aetiology.(307) Therefore it is important to assess this marker in the UK 
population to see if it could potentially be used as a screening test to provide early 
diagnosis of HCC early so that treatment can be offered and overall survival 
improved. 
 
 
3.1.2 Aims 
 
The overall aim of this study is to assess whether PIVKA-II could be a potential 
diagnostic biomarker in a cohort of UK patients with early HCC. 
 
The aims of this study include: 
a) Evaluating the role of PIVKA-II in diagnosing early HCC, compared to the 
traditional marker AFP, and as a combination of both biomarkers. 
b) Assessing if levels of PIVKA-II are raised in non-HCC patients (including 
pancreatic cancer, cholangiocarcinoma and gallbladder cancer). 
c) Assessing PIVKA-II levels in patients undergoing local ablative therapy 
and the ability of PIVKA-II to differentiate therapeutic responders from non-
responders.  If PIVKA-II accurately differentiates treatment responders 
from non-responders then it could potentially be used as a selection tool 
for patients suitable for early phase clinical trials i.e.  immunotherapy.    
d) Assessing if levels of PIVKA-II increase with disease progression of 
HCC. 
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3.2 Results 
 
Immunohistochemistry analysis 
HCC tissue was stained with an anti-PIVKA-II monoclonal Ab. Despite using 
increasing Ab dilutions (up to 1/8000 dilution), high casein solution concentrations 
(10X solution), addition of animal serum block and both low and high pH antigen 
retrieval solutions, background staining was present with positive PIVKA-II 
expression in normal liver, non-lesional liver tissue and HCC. No specific areas of 
PIVKA-II staining in HCC tissue was seen and granular staining was also present. 
Lower dilutions and use of the amplified kit increased the background staining, 
and positive staining was also evident in the fibrous septa as well as in the tumour 
and non-tumour parenchymal areas. Figure 11.  
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Figure 11: Immunohistochemistry staining of PIVKA-II in normal liver and HCC sections. Scale bars 100 m. Figure 
11A represents normal liver tissue with positive PIVKA-II staining using a 1/4000 Ab dilution. Presence of background 
positive staining can be seen in Figure 11A with also darker areas present in the cytoplasm of the hepatocytes. Figure 11B 
represents HCC stained using a 1/800 Ab dilution and an amplified kit. A lot of background staining is present as well as 
positive lymphocyte and fibroblast staining seen in the fibrous septa. Figure 11C represents HCC tissue stained using a 
1/8000 Ab dilution and a low pH antigen retrieval solution. In this image the presence of very non-specific positive staining 
can be seen. Figure 11D represents the non-lesional liver to the HCC tissue in Figure 11C and more positive staining is 
present here with the presence of granular staining as well as a checkerboard appearance. Figure 11E shows HCC tissue 
stained using a 1/8000 Ab dilution, high pH antigen retrieval solution and casein 10X solution. In this figure positive 
cytoplasmic and nuclear staining is present as well positive granular areas. This is similar to the staining seen in Figure 
11F which represents the non-lesional liver area to the HCC tissue in Figure 11E, which additionally shows positive staining 
in the fibrous septa.  
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PIVKA-II and AFP with HCC stage 
In total, 141 patients with HCC have been included. Early HCC was found in 70 
patients, 20 patients were within the MC and underwent TACE treatment 
(termed TACE-early), 16 patients had TACE treatment and fell in the 
intermediate stage, BCLC stage B (termed TACE-intermediate), and 35 patients 
were within the advanced stage, BCLC stage C and received Sorafenib. Levels 
of PIVKA-II showed a significant increase with tumour stage (p<0.001) with 
medians of 173.9 mAU/mL (IQR: 47.2 – 515.7), 145.4 mAU/mL (IQR: 48.7 – 
1224.0), 917.6 mAU/mL (IQR: 179.3 – 3802.1) and 6430.2 mAU/mL (IQR: 
320.0 – 29306.4), respectively. Levels of AFP were also found to increase 
significantly with tumour stage (p=0.012), Figure 12.  
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Figure 12: Medians of PIVKA-II and AFP with tumour stage. Medians of PIVKA-II (Figure 12A) and AFP (Figure 12B) 
across the four HCC groups (early HCC; n=70, TACE-early; n=20, TACE-intermediate; n=16, advanced HCC, n=35). A 
logarithmic10 scale has been used for the PIVKA-II and AFP values. Jonckheere-Terpstra test performed and showed a 
significant difference across the groups (p<0.001 for PIVKA-II and p=0.012 for AFP). TACE, transarterial chemoembolisation. 
 
 
 
 
  A B 
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Comparisons between non-HCC cancer types 
Three cancer groups were included for analysis (Table 6): pancreatic cancer 
(N=49), cholangiocarcinoma (N=18) and gallbladder cancer (N=4). PIVKA-II 
levels were found to differ significantly between the groups (p=0.034), being 
highest in cholangiocarcinoma 76.3 mAU/mL (IQR: 32.8 – 121.7), followed by 
pancreatic and gallbladder cancer, at 69.2 mAU/mL (IQR: 39.0 – 106.0) and 27.5 
mAU/mL (IQR: 20.5 – 34.4) respectively. Post-hoc pairwise analysis found the 
difference in PIVKA-II between gallbladder and pancreatic cancer groups to be 
significant (p=0.028). No significant differences in AFP levels were detected 
between the groups, with medians ranging from 3.7 – 5.3 ng/mL (p=0.504). 
Metastases were present in half of the pancreatic cancer group, and rates were 
not found to differ significantly across the three groups (p=0.661) In addition, there 
were no significant differences between the three groups in the rates of  lymph 
node (LN) involvement (p=0.111) or vascular invasion (p=0.535).  
Combining these three non-HCC groups as one and comparing it with the early 
HCC group, a significant difference in the median PIVKA-II and AFP level was 
found (p=0.004 and p<0.001 respectively). 
 
Table 6: Characteristics of three non-HCC cancer groups. Data are 
reported as N (%), with p-values from Fisher’s exact tests, or as median 
(IQR), with p-values from Kruskal-Wallis tests, as applicable. Bold p-Values 
are significant at p<0.05. LN, lymph node. N, number. 
Group N 
Metastases 
present 
LN 
involved 
Vascular 
invasion PIVKA-II AFP 
Type of Cancer  p=0.661 p=0.111 p=0.535 p=0.034 p=0.504 
Pancreatic 49 25 (51%) 12 (24%) 23 (47%) 69.2 (39.0 
– 106.0) 
3.7 (2.4 – 
5.9) 
Cholangiocarcinoma  18 8 (44%) 5 (28%) 6 (33%) 76.3 (32.8 
– 121.7) 
3.7 (2.5 – 
7.2) 
Gallbladder 4 1 (25%) 3 (75%) 1 (25%) 27.5 (20.5 
– 34.4) 
5.3 (3.5 – 
7.3) 
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Post-hoc test for PIVKA-II: Gallbladder cancer vs. Pancreatic cancer: 
p=0.028. Other two pairwise comparisons non-significant.  
 
Patient characteristics 
The total pool of patients in this study was 238: 70 with early HCC, 122 with 
cirrhosis and 46 with CLD. The cirrhosis and CLD groups served as reference 
groups for analysis. The majority of the CLD patients had an aetiology of 
NAFLD (67%), compared to <30% of the other groups. ALD was the most 
common aetiology in the cirrhosis group (51%), with only 4% of CLD patients 
having ALD. In the early HCC group, 33% had ALD, 23% NAFLD, and the 
remainder had other aetiologies.  
Comparisons of baseline characteristics between the three disease groups are 
reported in Table 7. Of the continuous variables considered, only albumin and 
sodium were found to be normally distributed, hence values for the remainder 
were reported as medians and IQRs throughout. The three disease groups 
were found to have similar gender distributions (p=0.100), but significantly 
different ethnicity distributions (p<0.001), with higher proportions of non-
Caucasian patients in the CLD group (24%) than in those with cirrhosis (4%) or 
early HCC (11%). Creatinine levels were not found to differ significantly 
between the three disease groups (p=0.352). However, significant differences in 
ALT, albumin, bilirubin, haemoglobin, platelets and INR (all p<0.001) as well as 
sodium (p=0.031) were detected. On post-hoc analysis of these factors, only 
ALT was found to differ significantly between the early HCC and cirrhosis 
groups, with medians of 33 vs. 24 units/litre (U/L) (p=0.002).   
 
 123 
 
N CLD 
(N= 46) 
Cirrhosis 
(N= 122) 
Early HCC 
(N= 70) 
p-Value 
Demographics      
Age at Sample (Years) 238 50.9 ± 13.8 58.1 ± 10.2 61.8 ± 9.1 <0.001 
Male 238 31 (67%) 76 (62%) 54 (77%) 0.100 
Ethnicity 167 
   
<0.001 
Caucasian  26/34 (76%) 94/98 (96%) 31/35 (89%)  
Non-Caucasian  8/34 (24%) 4/98 (4%) 4/35 (11%)  
Laboratory tests      
ALT (U/L) 237 40 (26 – 61) 24 (19 – 34) 33 (23 – 49) <0.001 
Albumin (g/L) 237 49 ± 3 42 ± 6 42 ± 5 <0.001 
Bilirubin (umol/L) 237 9 (6 – 13) 17 (10 – 37) 17 (11 – 24) <0.001 
Sodium (mmol/L) 237 141 ± 2 140 ± 3 140 ± 3 0.031 
Creatinine (umol/L) 237 74 (65 – 93) 76 (63 – 88) 70 (64 – 85) 0.352 
Haemoglobin (g/L) 238 147 ± 17 135 ± 22 141 ± 16 <0.001 
Platelets (109/L) 238 224 (199 – 273) 115 (76 – 178) 102 (72 – 129) <0.001 
Prothrombin time (INR) 235 1.0 (1.0 – 1.1) 1.2 (1.1 – 1.4) 1.2 (1.1 – 1.2) <0.001 
Tumour markers      
AFP (ng/mL) 238 2.7 (1.9 – 4.1) 4.7 (3.0 – 6.9) 12.1 (5.9 – 80.8) <0.001 
PIVKA-II (mAU/mL) 238 28.7 (21.2 – 40.0) 51.1 (26.6 – 149.5) 173.9 (47.4 – 477.8) <0.001 
 
Table 7: Summary of patient demographics, laboratory tests and tumour markers across the three groups. The groups 
are early HCC (N=70), cirrhosis (N=122) and CLD (N=46). Micromole/litre (umol/L). Data are reported as N (%), with p-values 
from Fisher’s exact tests; mean±SD, with p-Values from one-way ANOVA or median (IQR), with p-Values from Kruskal-Wallis 
tests, as applicable. Bold p-values are significant at p<0.05.  
Dunn’s Tests for tumour markers: 
AFP: CLD vs cirrhosis (p=0.002), CLD vs early HCC (p<0.001) and cirrhosis vs early HCC (p<0.001) 
PIVKA-II: CLD vs cirrhosis (p<0.001), CLD vs early HCC (p<0.001) and cirrhosis vs early HCC (p=0.001) 
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Performance of PIVKA-II and AFP as a diagnostic marker for early HCC 
AFP and PIVKA-II values were found to follow skewed distributions, and so were 
analysed using a non-parametric approach. Both AFP and PIVKA-II were found 
to differ significantly across the three patient groups (both p<0.001, Table 7), with 
the median values showing progressive increases through the CLD, cirrhosis and 
early HCC cohorts. Post-hoc analyses found significant differences between 
every pair of patient groups for both AFP and PIVKA-II.  
 
The discriminative abilities of the two markers were then assessed using a ROC 
curve analysis (Figure 13). Both AFP and PIVKA-II were found to be 
significantly predictive of early HCC vs. CLD or cirrhosis (both p<0.001). The 
predictive accuracy of AFP was found to be superior to that of PIVKA-II, with 
AUROCs of 0.845 (95% CI: 0.790 – 0.901) and 0.713 (95% CI: 0.641 – 0.784) 
respectively. A similar trend was also observed in using AFP and PIVKA-II for 
the prediction of HCC compared to cirrhosis, with AUROCs of 0.821 (95% CI: 
0.758 – 0.884) and 0.663 (95% CI: 0.583 – 0.742) respectively.  
 
A multivariable analysis was then produced, in order to consider the combined 
effect of the two biomarkers for the prediction of early HCC vs cirrhosis. A 
Hosmer-Lemeshow test showed reasonable model fit for AFP, but indicated 
significant poor fit for PIVKA-II. As such, the PIVKA-II values were log2-
transformed, which improved the goodness of fit to acceptable levels. 
The multivariable model found both biomarkers to be significant independent 
predictors of early HCC, with odds ratio of 1.15 (95% CI: 1.08 – 1.23, p<0.001) 
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for a unit increase in AFP, and 1.16 (95% CI: 1.01 – 1.34, p=0.039) for a two-
fold increase in PIVKA-II. The predicted values were then generated from the 
model for each patient in the study, to give a combined value for the two 
biomarkers. The resulting values had an AUROC of 0.833 (95% CI: 0.773 – 
0.894, p<0.001), indicating that the predictive accuracy of the combination of 
AFP and PIVKA-II was only a marginal improvement over that previously 
observed for AFP alone (AUROC=0.821, 95% CI: 0.758 – 0.884), Table 8. 
 
 
 
Figure 13: ROC curves for the diagnosis of early HCC vs. CLD/cirrhosis and 
vs. cirrhosis only. AUROC, area under the receiver operating characteristic 
curve. 
 
 
 
 
 
 
 
(A) HCC vs CLD/cirrhosis (B) HCC vs cirrhosis 
AFP AUROC 0.845 (95% CI: 0.790 – 0.901) 
PIVKA-II AUROC 0.713 (95% CI: 0.641 – 0.784) 
AFP AUROC 0.821 (95% CI: 0.758 – 0.884) 
PIVKA-II AUROC 0.663 (95% CI: 0.583 – 0.742) 
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 A) HCC vs. CLD/Cirrhosis B) HCC vs. Cirrhosis 
Factor AUROC (95% CI) p-
Value 
AUROC (95% CI) p-
Value 
PIVKA-II 0.713 (0.641 – 0.784) <0.001 0.663 (0.583 – 0.742) <0.001 
AFP 0.845 (0.790 – 0.901) <0.001 0.821 (0.758 – 0.884) <0.001 
AFP and 
PIVKA-
II* 
0.865 (0.815 – 0.915) <0.001 0.833 (0.773 – 0.894) <0.001 
 
Table 8: Comparisons of ROC curves using individual markers and 
combining both markers. Bold p-Values are significant at p<0.05.*A 
combination of the two markers, based on the predicted values from a 
multivariable binary logistic regression model. 
 
 
Cut-off levels of AFP and PIVKA-II 
For the differentiation of early HCC from cirrhosis, the cut-off value for PIVKA-II 
with the greatest value of the Youden’s J statistic was 155 mAU/mL, which 
returned a sensitivity of 53% and specificity of 76%. For AFP, a cut-off level of 
8.5 ng/mL returned a sensitivity of 61% and specificity of 87%. When these two 
cut-offs were combined, of those with negative values for both AFP and PIVKA-
II, 14% (13/95) had early HCC, compared to 82% (23/28) of patients with 
positive values for both markers. For 133 patients who had a negative AFP 
(8.5 ng/mL), 95 also had a negative PIVKA-II (155 mAU/mL), with 38 having 
a positive PIVKA-II. The rates of early HCC in these groups were 14% and 37% 
respectively, giving a sensitivity of 52% and specificity of 77%.  
 
Distribution of disease groups by PIVKA-II 
The relationship between PIVKA-II ranges and disease group (i.e. CLD, 
cirrhosis and early HCC) were then assessed in further detail. Patients were 
first divided into five groups based on PIVKA-II values, each made up of 
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approximately 20% of the cohort. The distribution of disease within each of 
these PIVKA-II groups was then calculated, and reported in Table 9 and Figure 
14.  
The rate of early HCC was found to increase progressively across the groups, 
from 11% of those with PIVKA-II  24 mAU/mL, to 54% in those with PIVKA-II 
>293 mAU/mL, greater than a four-fold increase. No patients were seen to have 
CLD with the group with the highest PIVKA-II value (>293 mAU/mL). 
PIVKA-II 
(mAU/mL) CLD Cirrhosis Early HCC 
≤24 15 (33%) 25 (56%) 5 (11%) 
25 - 38 18 (36%) 23 (46%) 9 (18%) 
39 - 72 11 (23%) 26 (54%) 11 (23%) 
73 - 293 2 (4%) 26 (55%) 19 (40%) 
>293 0 (0%) 22 (46%) 26 (54%) 
Table 9: Distribution of disease based on PIVKA-II ranges. When the 
highest PIVKA-II level is applied, no patients are diagnosed with CLD. In the 
early HCC, the rates of diagnosis progressively increased across the PIVKA-
II ranges, with a greater than four-fold increase from the lowest PIVKA-II 
level to the highest PIVKA-II level.  
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Figure 14: Graphical representation of the distribution of disease based 
on PIVKA-II ranges. PIVKA-II categories are based on the quintiles of the 
distribution.  
 
Correlation between laboratory values with AFP and PIVKA-II 
The associations between PIVKA-II and AFP with various laboratory variables 
were then assessed using Spearman’s rho correlation coefficients. PIVKA-II 
showed a significant positive correlation with AFP. Significant positive correlations 
were found between PIVKA-II and bilirubin, INR and MELD score, with significant 
negative correlations with albumin, sodium and platelets identified. However, AFP 
showed significant correlations with fewer variables: significant negative 
correlations were found with albumin, sodium and platelets and no significant 
positive correlations were seen, Table 10. 
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PIVKA-II AFP 
Rho p-Value Rho p-Value 
AFP 0.353 <0.001 - - 
ALT -0.050 0.444 0.104 0.111 
Albumin -0.323 <0.001 -0.193 0.003 
Bilirubin 0.256 <0.001 0.053 0.419 
Sodium -0.128 0.050 -0.132 0.042 
Creatinine -0.054 0.410 -0.038 0.559 
Haemoglobin -0.154 0.018 -0.043 0.511 
Platelets -0.273 <0.001 -0.224 <0.001 
INR 0.342 <0.001 0.090 0.170 
MELD score 0.289 <0.001 0.029 0.669 
 
Table 10: Correlations between laboratory variables and PIVKA-II/AFP. 
Data are reported as Spearman’s rho correlation coefficients. Bold p-Values 
are significant at p<0.05. ALT, alanine transaminase. INR, international 
normalised ratio. MELD, model of end-stage liver disease. 
 
 
AFP and PIVKA-II with size and number of lesions 
Relationships between tumour-related factors (size and number of lesions) and 
both AFP and PIVKA-II were assessed within the early HCC subgroup (N=70), 
Figure 15 and Figure 16. The size of lesions was split into three groups: < 20 
millimetres (mm) (n=22), 20 – 29 mm (n=29) and  30 mm (n=19). AFP was not 
found to be significantly associated with the size of lesions (p=0.979) with 
median values of 12.4 ng/mL (IQR 6.6 – 114.7), 20.5 ng/mL (IQR 5.7 – 47.1) 
and 10.2 ng/mL (IQR 6.9 – 326.2) respectively. The number of lesions were 
divided into two groups: 1 lesion (n=55) and  2 lesions (n=15). AFP was also 
not significantly associated with the number of lesions (p=0.626), with median 
values of 11.4 ng/mL (IQR 5.9 – 70.7) and 23.9 ng/mL (IQR 5.8 – 124.6) 
respectively. PIVKA-II was not found to be significantly associated with the 
number of lesions (p=0.573), with median values of 191.2 mAU/mL (IQR 47.4 – 
653.3) where there was 1 lesion present and 95.2 mAU/mL (IQR 46.7 – 367.2) 
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with  2 lesions. However, a significant correlation with the size of lesions was 
detected (rho: 0.348, p=0.003), with median PIVKA-II levels of 65.3 mAU/mL 
(IQR: 43.8 – 186.8), 211.2 mAU/mL (64.0 – 472.7) and 373.4 mAU/mL (48.6 – 
3337.9) for lesions of < 20 mm, 20 – 29 mm and  30 mm, respectively. 
 
     A          B 
 
Figure 15: PIVKA-II and AFP correlating with lesion size. Median HCC 
size is 25 mm (IQR 17 – 30). Figure 15A shows a significant positive 
correlation with PIVKA-II and HCC size (Spearman’s rho correlation co-
efficient 0.348, p=0.003), whereas Figure 15B shows no significant 
correlation with AFP and HCC size (Spearman’s rho correlation co-efficient 
0.003, p=0.979). A logarithmic10 scale has been used for both PIVKA-II and 
AFP values.  
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Figure 16: PIVKA-II and AFP correlating with the number of lesions. 
Figure 16A shows a negative correlation with PIVKA-II and number of lesions 
(Spearman’s rho correlation co-efficient -0.069, p=0.573) and Figure 16B 
shows a positive correlation with AFP and number of lesions (Spearman’s 
rho correlation co-efficient 0.059, p=0.626). A logarithmic10 scale has been 
used for both PIVKA-II and AFP values.  
 
 
Changes in AFP and PIVKA-II post-transplant 
In total, 5 patients underwent liver transplantation and had pre- and post-
transplant AFP and PIVKA-II measurements taken with a median of 372 days 
(IQR 259 – 707) apart, Table 11. The median pre- and post-transplant AFP level 
was 5.8 ng/mL (IQR 3.4 – 27.9) and 8.5 ng/mL (IQR 3.7 – 11.5) respectively and 
showed no significant difference, (p=0.438). Although all 5 patients showed a 
reduction in PIVKA-II between the pre- and post-transplant measurements, 
resulting in the median from falling from 124.6 mAU/mL (IQR 95.2 – 472.7) to  
38.2 mAU/mL (IQR 29.0 – 38.7), this change did not reach statistical significance 
(p=0.063), although this may be as a result of insufficient statistical power, due to 
the small sample size.   
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Median (IQR) Changes 
p-
Value 
 
Pre-Transplant 
Post-
Transplant Decrease Increase 
AFP 
(ng/mL) 
5.8 (3.4 – 27.9) 8.5 (3.7 – 
11.5) 
3 2 0.438 
PIVKA 
(mAU/mL) 
124.6 (95.2 – 
472.7) 
38.2 (29.0 – 
38.7) 
5 0 0.063 
 
Table 11: Changes in AFP and PIVKA-II post-transplant. Analysis is 
based on the N=5 transplant patients with pre- and post-transplant 
measurements recorded. The p-Values are from Wilcoxon’s tests, and bold 
values are significant at p<0.05.  
 
 
PIVKA-II and AFP correlating with explant histology 
For early HCC, 16 patients underwent liver transplantation. The disease aetiology 
of liver disease was ALD (n=3), NAFLD (n=4), ALD/NAFLD (n=1), HBV (n=2), 
HCV (n=4), primary biliary cirrhosis (n=1) and PSC  (n=1). No cancer was 
detected on explant histology in 2 patients, hence these were excluded from 
further analysis. 
 
Table 12 shows the associations between tumour related factors and both AFP 
and PIVKA-II measurements. PIVKA-II was seen to be significantly higher in the 
presence of vascular invasion on explant histology (median 380.5 mAU/mL vs. 
50.6 mAU/mL for yes vs. no, p=0.036), whereas no significant difference in AFP 
was detected (p=0.635). Neither PIVKA-II nor AFP showed a significant 
association with the number of lesions (p=0.364 and p=0.240) respectively. 
PIVKA-II was seen to increase significantly with poorer HCC differentiation 
(p=0.026), with a median of 50.6 mAU/mL vs. 2199.1 mAU/mL for well vs. poorly 
differentiated tumours. 
 133 
 
Table 12: AFP and PIVKA-II vs. explant findings in transplanted 
patients. Data are reported as medians (IQR), and p-Values are from Mann-
Whitney tests for comparisons across two groups, or Jonckheere-Terpstra 
tests for three groups. Bold p-Values are significant at p<0.05.  
 
AFP and PIVKA-II measurements in patients undergoing ablation treatment 
A total of 13 patients underwent ablation treatment and had longitudinal 
measurements of AFP and PIVKA-II recorded. Baseline levels were recorded 
with a median of 35 days (range 19 – 112) days prior to ablation being 
performed. Levels were then measured in the post-ablation period until either 
recurrence or the end of follow up. A total of 31 measurements were performed 
during this period, with a median of 2 per patient (range: 1 – 6) over a median of 
202 days of post-ablation follow up (range: 35 – 548). Four patients developed 
 
N PIVKA-II 
(mAU/mL) 
p-
Value 
AFP (ng/mL) p-
Value 
Vascular 
Invasion  
 
 
0.036 
 
0.635 
No 10 50.6 (28.7 – 
205.6) 
 16.0 (5.8 – 
202.8) 
 
Yes 4 380.5 (206.5 – 
7343.5) 
14.2 (3.8 – 
26.0) 
Number of 
Lesions 
 
 
0.364 
 
0.240 
1 9 205.6 (46.4 – 
472.7) 
 8.0 (4.2 – 
19.8) 
 
>1 5 54.8 (28.7 – 
124.6) 
24.1 (23.9 – 
27.9) 
HCC 
Differentiation 
 
 
0.026 
 
0.198 
Well 2 50.6 (46.4 – 
54.8) 
 9.0 (5.8 – 
12.1) 
 
Moderately 8 62.8 (28.0 – 
165.1) 
13.9 (4.3 – 
25.9) 
Poorly 4 2199.1 (256.5 – 
9162.1) 
133.6 (14.2 – 
1001.4) 
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recurrence during the study, at which point follow up ended, and no further 
measurements of AFP or PIVKA-II were undertaken.  
 
Longitudinal trends in both markers are shown graphically in Figure 17a. From 
this, it appeared that those patients who developed recurrence tended to have 
increasing PIVKA-II and AFP levels in the post-ablation period. In addition, 
patients with recurrence also appeared to have higher PIVKA-II levels prior to 
ablation. In order to assess the latter, patients were divided into groups based 
on their PIVKA-II and AFP levels prior to ablation, using the median as a cut-off 
value. Of those with pre-ablation PIVKA-II levels of less than 125 mAU/mL 
(n=6), no patients developed recurrence during the follow-up period. However, 
for those with PIVKA-II of 125 mAU/mL or more (n=7), a total of four developed 
recurrence, giving a Kaplan-Meier estimated recurrence rate of 100% after 17 
months of follow-up (Figure 17b). Despite this, no significant difference was 
detected between the groups (p=0.097), likely as a result of small statistical 
power resulting from the small sample size. A weaker association between pre-
ablation AFP levels and recurrence was detected, with Kaplan-Meier estimated 
rates of 33% vs. 43% at one year for AFP < 9ng/mL (n=6) vs. 9+ ng/mL (n=7). 
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Figure 17a: Spider plots of longitudinal PIVKA-II and AFP levels. The broken line represents the timing of the ablation. 
Patients with red triangles are those where recurrence was diagnosed after the final measurement. The same colour coding 
for individual patients is used on both plots. A logarithmic10 scale has been used for both PIVKA-II and AFP values.  
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Figure 17b: Kaplan-Meier curves of recurrence by pre-ablation PIVKA-II and AFP levels. Pre-ablation levels were 
dichotomised based on the median levels. P-Values are from log-rank tests. 
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3.3 Discussion 
Previous studies have shown positive PIVKA-II staining in the cytoplasm of 
HCC cells.(119, 135) An alternative anti-PIVKA-II Ab has been previously 
used in other studies which have described positive PIVKA-II staining (EIDIA 
Co. / Eisai Co., MU-3) (119, 132, 308, 309). Unfortunately on contacting the 
company the Ab was taken over by a different company (Sekisui) and was 
no longer available for research use and therefore I used the Ab from Crystal 
Chem. The IHC staining in this study did not show specific cytoplasmic 
staining in HCC cells and background staining was also present. Various 
factors were changed to improve the PIVKA-II staining in HCC tissue 
including increasing Ab dilution and increasing blocking steps and 
concentration of casein block, but this did not influence the PIVKA-II specific 
staining in HCC. Therefore, further staining analysis was not undertaken in 
this study. 
 
This study aimed to assess the value of PIVKA-II in diagnosing early HCC 
and comparing this marker to the traditional marker used, AFP. Additionally, 
the efficacy of PIVKA-II as a treatment response marker following ablation 
therapy was explored. The results have shown that AFP is superior to 
PIVKA-II in diagnosing early HCC vs. cirrhosis. Both markers were found to 
be significant independent predictors of early HCC on multivariable analysis; 
however, the predictive accuracy of the combination of AFP with PIVKA-II 
was only marginally superior to that of AFP alone.  Studies previously 
combining both markers have shown better performance than using 
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individual markers.(119-121, 126) Studies performed to date assessing the 
efficacy of PIVKA-II in diagnosing HCC have mainly been conducted in Asia, 
with fewer studies done in Europe. Studies performed in the western 
population have shown that PIVKA-II is a better marker in diagnosing early 
HCC, and the combination of both markers does improve the overall 
diagnostic accuracy.(119, 121) The main difference between this study and 
previous studies, including the study by Poté et al, is the cause of liver 
disease. The majority of other studies assessing the role of PIVKA-II have 
included patients with viral hepatitis, whereas the cause of liver disease in 
patients included in our study was predominantly either ALD or NAFLD. A 
possible explanation why PIVKA-II was not found to be a superior marker to 
AFP in diagnosing early HCC vs. cirrhosis, is that half of the cirrhosis cohort 
had underlying ALD, and it has been shown previously that serum PIVKA-II 
levels are higher in ALD than in patients with viral hepatitis.(310-312) A 
previous study using two different monoclonal antibodies to measure 
PIVKA-II (19B7 and MU-3), showed the presence of two separate PIVKA-II 
variants. The ratio of 19B7:MU-3 was significantly higher in ALD than in viral 
related liver disease or HCC, therefore suggesting the presence of a 
different PIVKA-II variant in ALD, and a different production pathway of 
PIVKA-II in ALD.(312) Another possible reason for serum PIVKA-II levels to 
be higher in patients with ALD, could be as a result of vitamin K deficiency, 
which has been shown to occur in patients with ALD.(313) The addition of 
vitamin K was found to inhibit PIVKA-II production in a dose-dependent 
manner, although there was no correlation seen between serum vitamin K 
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and PIVKA-II levels.(311) PIVKA-II has got a similar sensitivity to GP73 but 
poorer specificity in diagnosing early HCC (37), a poorer sensitivity but better 
specificity compared to OPN, and a poorer sensitivity compared to GP73 in 
diagnosing early HCC.(28, 39) In order to evaluate which marker(s) 
diagnose early HCC with the optimal sensitivity and specificity, comparisons 
between these markers with PIVKA-II, and also the combination of markers, 
by performing a multi-centre analysis is required, to validate and assess the 
sensitivity and specificity of the various markers.  
Across the various HCC stages, the median PIVKA-II measurement was 
found to progressively increase with tumour stage (p<0.001), suggesting the 
possible role of PIVKA-II in determining stage of disease. From this cohort 
of patients, the cut-off for PIVKA-II in diagnosing early HCC was higher at 
155 mAU/mL than cut-offs previously reported, yielding a sensitivity and 
specificity of 53% and 76% respectively. When the cut-off levels for both 
markers were used, the rate of early HCC was nearly six times more (82%) 
compared to both markers below the cut-off values (14%). In the subgroup 
of patients with a negative AFP (level below the cut-off value), PIVKA-II 
provided additional recognition of early HCC with a sensitivity of 52% and 
specificity of 77%. PIVKA-II levels found in the non-HCC cancer types were 
lower than the cut-off for diagnosing early HCC with the median PIVKA-II 
level greatest in the cholangiocarcinoma group. The median value of PIVKA-
II was found to increase across the three groups (CLD, cirrhosis and early 
HCC). Interestingly, after PIVKA-II ranges were applied, no patients within 
the CLD group with the highest cut-off PIVKA-II value would be predicted to 
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have early HCC, and higher PIVKA-II values would increase the number of 
patients diagnosed with early HCC. The correlation of AFP and PIVKA-II 
with various laboratory variables found that PIVKA-II showed a significant 
correlation with variables that AFP did not, including bilirubin, INR and MELD 
score. Hence, this suggests that PIVKA-II is superior to AFP in assessing 
liver function which is an important factor when deciding on treatment.  
Interestingly, the results showed that PIVKA-II has a significant positive 
correlation with tumour size, which surprisingly was not also seen with 
AFP (p=0.003 vs. p=0.979 respectively). This again is in keeping that 
PIVKA-II may be a superior marker in the advanced stages of HCC given 
that it has a better performance in larger tumours. Previous studies have 
also shown the role of PIVKA-II with BCLC stage and tumour size.(123, 
124) The presence of MVI is a known prognostic indicator in patients with 
HCC who have undergone surgical resection and liver transplantation.(63, 
314-316). In addition to MVI, tumour differentiation is another important 
prognostic factor in this group of patients.(317, 318) This study’s results 
have shown that in the presence of MVI on explant histology, pre-
transplant PIVKA-II serum levels were significantly higher (p=0.034), but 
this was not seen with AFP (p=0.825). PIVKA-II levels pre-transplant were 
found to be significantly higher in moderately- or poorly-differentiated HCC 
(p=0.026), and again this was not seen with AFP (p=0.198). Therefore, 
these results show that serum PIVKA-II levels are associated with the 
development of MVI suggesting that tumours secreting higher levels of 
PIVKA-II are of a more aggressive phenotype, which has previously been 
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shown and it has been reported that PIVKA-II levels are also associated 
with the rate of tumour growth.(319) A study has previously shown that 
PIVKA-II levels are an independent predictor for increased Ki-67 
expression, thereby providing evidence for a positive correlation between 
PIVKA-II levels and cellular proliferation rates.(122)  
 
In the longitudinal data analysis following ablation treatment in early HCC, 
those who developed recurrence tended to have higher AFP and PIVKA-II 
levels that increased over time. The median values in the pre-ablation 
period for PIVKA-II was 125 mAU/mL, and 9 ng/mL for AFP. Using these 
cut-off levels, the Kaplan-Meier estimated recurrence rates were 100% vs. 
0% in those with pre-ablation PIVKA-II of 125 vs. <125 mAU/mL after 17 
months. The likely reason for this not reaching statistical significance 
between these two groups is the small number of patients in the 
longitudinal data analysis (p=0.097). However, the association between 
recurrence and the pre-ablation AFP level was weaker. The Kaplan-Meier 
estimated recurrence rates were 33% vs. 57% with AFP <9 ng/mL and 9 
ng/mL respectively.  
 
3.4 Conclusion 
In conclusion, this study shows that AFP is superior to PIVKA-II in 
diagnosing early HCC with only a marginal benefit when combining the 
two markers. This challenges the current guidelines that recommend HCC 
surveillance should not include AFP measurement. A likely reason for the 
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improved performance of AFP that is now seen, is the introduction of new 
anti-viral treatments that largely eliminates the previously false positive 
high AFP levels seen in active viral hepatitis. Pre-transplant PIVKA-II 
levels were significantly associated with the presence of MVI and in 
moderately- or poorly-differentiated HCC. PIVKA-II could therefore be a 
prognostic marker in HCC and may support patient stratification for 
therapy. Despite a small number in the longitudinal data analysis, PIVKA-II 
shows a promising role in the surveillance of recurrent HCC post-ablation. 
Incorporation of AFP-L3 with AFP and PIVKA-II measurements is an 
appealing area to study in various HCC centres in the UK to assess 
whether the combination of these three markers can further improve the 
diagnostic accuracy of early HCC.   
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CHAPTER 4: 
SOLUBLE VAP-1 IN 
NEUROENDOCRINE TUMOURS 
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4.1 Introduction and aims 
4.1.1 Introduction 
NETs are known to be associated with desmoplasia and the development of 
fibrosis. Desmoplastic reactions that occur with midgut NETs can lead to 
serious complications including intestinal strictures and bowel obstruction. 
There are no biomarkers currently used in NET patients that allow the 
identification of possible fibrosis. Currently, when GI complications occur, there 
is no effective treatment other than surgery. For surgery to be performed, 
patients need to be at a certain level of physical fitness and additionally side 
effects post-surgery can also become problematic for the patient. Therefore 
surgery may not be suitable for some patients. CHD is a serious fibrotic 
complication that can occur with NETs and is associated with an increased 
mortality.(245) Once cardiac valvulopathy occurs, valve surgery is the only 
effective treatment available, which again requires the patient to have a certain 
level of fitness to undergo the operation. Some patients are asymptomatic and 
are not diagnosed until the disease is advanced, which may also limit treatment 
options. Therefore, identifying fibrosis early would allow a prompt diagnosis to 
be made which then enables treatment to be commenced in a timely manner 
with an aim to improve patients’ quality of life and overall survival.  
 
VAP-1 has been shown to play a vital role in promoting the onset of liver fibrosis 
in models of chronic liver injury as well as angiogenesis.(277) Increased levels 
of sVAP-1 have also been found in chronic liver disease.(277) Levels of sVAP-1 
have been found to be lower in colorectal cancer (297) and levels have been 
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shown to be highest in early stage disease and decrease with disease 
progression with lower levels predicting the presence of hepatic or lymph node 
metastasis.(320) Similar findings have also been shown in gastric cancer with 
sVAP-1 levels decreasing with disease progression.(321) In HCC, sVAP-1 
levels have been shown to be significantly higher compared to cirrhosis (322).  
Both an anti-VAP-1 monoclonal antibody and a small molecule inhibitor of VAP-
1 are already being studied in clinical trials (for liver disease and diabetic 
retinopathy), and there is currently a high level of interest in the role of amine 
oxidases such as VAP-1 in stromal biology.(323, 324) 
 
Our preliminary data has shown that VAP-1 may also contribute to the fibrotic 
complications in patients with NETs. Significantly elevated sVAP-1 levels have 
been found in patients with NETs (median 562.5, IQR 438.8 – 697.3 ng/mL) 
compared to the control group (median 256.0, IQR 212.0 – 308.0 ng/mL) 
(p<0.0001), and even higher sVAP-1 levels in in those with CHD (median 691.0, 
IQR 684 – 854 ng/mL) compared to patients with NETs and no CHD (median 
511, IQR 411.3 – 583.8 ng/mL) (p<0.01). However, given the low patient 
numbers in the pilot study, further work was required to explore the role of 
sVAP-1 in NETs given that no overall conclusion could be made from the 
preliminary data due to a small sample cohort.  
 
VAP-1 serum levels could be an effective stratification marker for patients with 
NETs to predict outcomes and where to escalate therapy.  More importantly 
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VAP-1 could be a new therapeutic target for NETs to prevent fibrotic 
complications and improve overall survival. 
 
4.1.2 Aims 
Preliminary data demonstrated increased concentrations of sVAP-1 in the 
peripheral blood of NET patients.  
 
The aims of this section are to: 
a) Extend our cohort of patients in which we are measuring sVAP-1 and 
attempt to correlate the values we obtain with relevant clinical parameters. 
b) Compare sVAP-1 levels in the different NET cohorts and healthy 
volunteers. The NET cohorts included midgut NETs, pancreatic NETs (CHD is 
very rarely seen in pancreatic NETs so sVAP-1 are expected to be low) and 
CHD. 
c) Compare sVAP-1 levels pre- and post-treatment in midgut NETs. 
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4.2 Results 
Soluble VAP-1 across all groups 
In total, 99 patients have been included, consisting of 12 patients in the healthy 
control group, 20 patients with pancreatic NETs, 50 patients with midgut NETs 
and 17 patients with CHD. Circulating sVAP-1 levels differed significantly across 
the four groups (p<0.001), with median levels highest in the CHD group (Figure 
18).  The median sVAP-1 (IQR) for the healthy controls, pancreatic NETs, 
midgut NETs and CHD were 740.4 ng/mL (IQR: 534.5 – 867.1),  979.4 ng/mL 
(IQR: 877.3 – 1620.0), 1005 ng/mL (IQR: 790.1 – 1148) and 1280 ng/mL (IQR: 
961.2 – 1652.0) respectively.  
From our own large NET and CHD centre’s experience, CHD is very rarely seen 
in pancreatic NETs. Therefore a subgroup analysis was undertaken in which the 
pancreatic NET group was excluded, and the difference in sVAP-1 between the 
healthy controls, midgut NET and CHD groups was performed and remained 
significant (p<0.001, Figure 19). These results are in keeping with our pilot data 
which showed that sVAP-1 levels increased across the controls, midgut NET 
and CHD groups, differing from previous studies showing a decrease in sVAP-1 
levels in tumour and in disease progression.(297, 320, 321) 
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Figure 18: Levels of sVAP-1 shown across the healthy controls, 
pancreatic neuroendocrine tumour, midgut neuroendocrine tumour 
and CHD groups. A significant difference across the groups is seen, 
p<0.001. Post-hoc analysis showed a significant difference between the 
HC vs midgut NET group (p=0.032), HC vs pancreatic NET group 
(p=0.004), HC vs CHD group (p<0.001) and midgut NET vs CHD group 
(p=0.038). Post-hoc analysis showed both the pancreatic NET vs CHD 
group and pancreatic vs midgut NET groups had a p-Value of 1.000. HC, 
healthy controls. Panc, pancreatic.  
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Figure 19: Levels of sVAP-1 shown across the healthy control, 
midgut neuroendocrine tumour and CHD groups. A significant 
difference, p<0.001, is observed. Post-hoc analysis demonstrated a 
significant difference between the HC vs midgut NET group (p=0.015), HC 
vs CHD group (p<0.001) and the midgut NET vs CHD groups (p=0.014).  
 
Soluble VAP-1 levels and clinical variables 
Various clinical variables were studied to assess their correlation with sVAP-1 
levels. These included blood pressure, body mass index (BMI), HbA1c, gender, 
hypertension, cerebrovascular disease, ischaemic heart disease, 
hypercholesterolaemia (and being on a statin) and smoking. A previous study 
has shown significant correlations in women between sVAP-1 and BMI and 
triglycerides, and in men between sVAP-1 and diabetes, glucose and metabolic 
syndrome.(325) Out of the continuous variables correlated with sVAP-1, BMI 
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was found to be significantly negatively correlated with sVAP-1 (p=0.011), whilst 
a significant positive correlation with HbA1c was detected (p=0.008), Table 13. 
 
 Correlation with sVAP-1  
 rho p-Value 
Systolic BP (mmhg) 0.006 0.955 
Diastolic BP (mmhg) -0.060 0.582 
BMI (kg/m2) -0.273 0.011 
HbA1c (mmol/mol) 0.292 0.008 
 
Table 13: Correlations between sVAP-1 and BP, BMI and HbA1c in 
the pancreatic neuroendocrine tumour, midgut neuroendocrine 
tumour and CHD groups. Data are reported as Spearman’s rho 
correlation coefficients. Bold p-values are significant at p<0.05. BP, blood 
pressure. BMI, body mass index. 
 
In patients where ethnicity was known (N=36), the majority were Caucasian 
(97%). None of the categorical variables analysed were found to be significantly 
associated with sVAP-1 levels. Table 14.  
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 Median (IQR) 
sVAP-1 (ng/mL) 
 
p-Value 
Gender  0.403 
Male (N=51) 1016.1 (810.2 – 1308.4)  
Female (N=36) 1042.5 (874.4 – 1310.0)  
Hypertension  0.660 
Yes (N=27) 1066.9 (780.1 – 1320.5)  
No (N= 60) 1019.8 (867.9 – 1267.1)  
Diabetes  0.084 
Yes (N=15) 1189.2 (906.6 – 1631.2)  
No (N=72) 988.1 (818.0 – 1244.3)  
Cerebrovascular 
disease 
 0.675 
Yes (N=6) 1010.5 (720.3 – 1461.7)  
No (N=81) 1023.6 (833.0 – 1280.4)  
Ischaemic heart disease  0.743 
Yes (N=5) 1087.0 (920.3 – 1143.8)  
No (N=82) 1019.8 (831.1 – 1308.4)  
Hypercholesterolaemia  0.333 
Yes (N=7) 833.0 (728.1 – 1189.2)  
No (N=80) 1028.1 (861.1 – 1314.4)  
On Statin  0.141 
Yes (N=20) 1125.7 (905.1 – 1501.9)  
No (N=67) 982.6 (813.9 – 1280.4)  
Smoker  0.227 
Yes (N=11) 931.2 (867.5 – 1339.7)  
No (N=34) 1019.4 (790.7 – 1320.5)  
Ex-smoker (N=12) 1147.4 (1034.2 – 
1564.8) 
 
 
Table 14: Summary of categorical variables associated with sVAP-1 
levels. Median and IQR of sVAP-1 shown, with p-Values derived from 
either Mann-Whitney U tests or Kruskal Whitney tests, as applicable.  
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Survival analysis 
A survival analysis was performed in the pancreatic NET, midgut NET and CHD 
groups. Patients were split into three groups, based on the sVAP-1 tertiles. A 
trend towards higher mortality in higher sVAP-1 was observed, although this 
was not significant (p=0.153). Figure 20. These findings are similar to a study 
undertaken by our Birmingham group which showed that in patients with 
primary sclerosing cholangitis, higher sVAP-1 levels was significantly 
associated with the risk of liver transplantation or death (HR 2.02, 1.17 – 3.51, 
p=0.012).(291) 
 
 
Figure 20: Kaplan Meier curve analysis based on sVAP-1 tertiles 
(<880, 880 – 1149 and 1150+ ng/mL).  
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Baseline characteristics of groups 
Table 15 illustrates the baseline characteristics seen of patients in the midgut 
NET and CHD groups. The pancreatic NETs have been analysed separately as 
they are rarely associated with the development of CHD. A significant difference 
was noted in the NT-proBNP level (p<0.001), with higher levels seen in the 
CHD group than midgut NET, with medians of and 571 ng/L (IQR: 203 – 1691) 
and 89 ng/L (IQR: 51 – 279) respectively. This significant difference is expected 
given that NT-proBNP is released by the atria and ventricles in the heart in 
response to wall stretch (265), and our results are also in keeping with previous 
findings that showed significantly higher NT-proBNP levels in patients with CHD 
compared with no CHD.(218) As expected, the presence of liver metastases 
was found to be significantly higher in the CHD group, (p=0.028), whilst CHD 
patients had a significantly lower rate of carcinoid symptoms than midgut NETs 
(p=0.045). An explanation for the lower rate of carcinoid symptoms seen in 
CHD compared with the midgut NET group is that prior to sample collection, 
82% of patients in the CHD group were already on an SSA, compared to 6% of 
the midgut NET group (p<0.001), therefore illustrating that their symptoms were 
controlled by SSA treatment. The effect of surgical resection on sVAP-1 levels 
was also analysed to assess whether resection and removal of the tumour 
resulted in a reduction in sVAP-1 levels. Surgical resection was performed prior 
to sample collection in 28% of patients in the midgut NET group and 12% of 
patients in the CHD group (p=0.322). There was no significant difference 
between the two groups regarding tumour grade (p=0.300) or CgA (p=0.148). In 
the midgut NET group, the median sVAP-1 level in patients who had undergone 
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surgery pre-sample collection was 1024.3 ng/mL (IQR: 788.1 – 1128.9) and 
925.8 ng/mL (800.5 – 1155.8) in those who had not undergone surgery pre-
sample collection (p=0.856).  
 
Patients from the midgut NET and CHD groups were then combined in order to 
analyse the NET patients as one group and increase the total cohort size, and 
associations between sVAP-1 levels and a range of factors were assessed. 
Levels of sVAP-1 were not found to differ significantly between those who had 
evidence of liver metastases and those who did not have evidence of liver 
metastases, p=0.745, with median levels of 1044.9 ng/mL (IQR: 813.9 – 
1171.3) and 1052.4 ng/mL (IQR: 833.0 – 1262.6) respectively. In addition, no 
significant association between sVAP-1 and tumour grade was detected, with 
medians of 1052.4 ng/mL (IQR: 854.7 – 1171.3) seen in grade 1 and 1084 
ng/mL (IQR: 993.7 – 1320.5) in grade 2, p=0.383.  
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 N Midgut CHD p-Value 
Demographics   
Age at sample 
(Years) 
67 65.8 ± 11.5 68.2 ± 9.6 0.444 
Male 67 32 (64%) 9 (53%) 0.565 
Tumour features     
Grade 
G1 
G2 
48 
31 
17 
 
25 (69%) 
11 (31%) 
 
6 (50%) 
6 (50%) 
0.300 
CgA (pmol/L) 62 206 (70 – 
1062) 
578 (160 – 
3124) 
0.148 
24 hour urinary 5-
HIAA (umol/24 hrs) 
50 94.2 (29.9 – 
174.9) 
193.2 (90.05 
– 788.1) 
0.068 
NT-proBNP (ng/L) 64 89 (51 – 279) 571 (203 – 
1691) 
<0.001 
Liver metastases 67 33 (66%) 16 (94%) 0.028 
Carcinoid 
symptoms 
67 35 (70%) 7 (41%) 0.045 
Facial flushing 
Diarrhoea 
Abdominal pain 
Weight loss 
Wheeze 
 22 (44%) 
20 (40%) 
17 (34%) 
16 (32%) 
- 
6 (35%) 
5 (29%) 
1 (6%) 
1 (6%) 
- 
 
0.581 
0.565 
0.028 
0.050 
- 
Treatment pre- 
sample 
    
Had surgery for 
primary NET 
67 14 (28%) 2 (12%) 0.322 
On SSA 67 3 (6%) 14 (82%) <0.001 
Type of SSA 
Sandostatin 
Lanreotide 
17 
11 
6 
 
- 
3 (100%) 
 
 
11 (79%) 
3 (21%) 
0.029 
 
Table 15: Summary of patient demographics, tumour features and 
treatment pre-sample across the midgut neuroendocrine tumour and 
CHD groups. The groups are midgut NET (N=50) and CHD (N=17). Data 
are reported as N (%), with p-values from Fisher’s exact tests; mean±SD, 
with p-Values from independent samples t-tests, or median (IQR), with p-
Values from Mann-Whitney U tests, as applicable. Bold p-values are 
significant at p<0.05. CgA, chromogranin A, 5-HIAA, 5-hydroxyindoleacetic 
acid. SSA, somatostatin analogue. 
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Correlation between sVAP-1 and tumour features  
The associations between sVAP-1 with various tumour features, including CgA, 
24 hour urinary 5-HIAA and NT-proBNP, were assessed in the combined 
midgut NET and CHD groups using Spearman’s rho correlation coefficients. 
CgA and 24 hour urinary 5-HIAA are two biochemical tumour markers used in 
clinical practice in NETs, with the urinary 5-HIAA reflecting the hormone-
secretion activity of the tumour and CgA reflecting tumour bulk. NT-proBNP is 
the biochemical marker used in CHD surveillance in NET patients. Positive 
correlations were seen between sVAP-1 and CgA, 24 hour urinary 5-HIAA and 
NT-proBNP, although none reached statistical significance. In the CHD group 
alone, positive correlations were found again between the three tumour features 
and sVAP-1, again not reaching statistical significance. Tables 16a and 16b. 
Statistical significance is likely not seen between sVAP-1 and the biochemical 
markers assessed given that the current markers used in clinical practice are 
not associated with the presence of fibrosis in NETs. 
 N sVAP-1 (ng/mL) p-Value 
CgA  62 0.149 0.247 
24 hour urinary 5-HIAA 50 0.265 0.063 
NT-proBNP  64 0.218 0.084 
 
Table 16a: Correlations between sVAP-1 and CgA, 24 hour urinary 5-
HIAA and NT-proBNP in both the midgut neuroendocrine tumour and 
CHD groups. Data are reported as Spearman’s rho correlation co-
efficients.  
 
 N sVAP-1 (ng/mL) p-Value 
CgA  16 0.406 0.119 
24 hour urinary 5-HIAA  13 0.516 0.071 
NT-proBNP  14 0.147 0.615 
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Table 16b: Correlations between sVAP-1 and CgA, 24 hour urinary 5-
HIAA and NT-proBNP in the CHD group. Data are reported as 
Spearman’s rho correlation co-efficients.  
 
 
Longitudinal analysis of sVAP-1 
A longitudinal analysis was performed to assess whether sVAP-1 could be a 
treatment response marker. Samples were taken in the midgut NET group prior 
to (termed first sample) and following treatment (termed second sample) with 
either surgery, SSA or both.  
Due to time limitations in this project, a total of 23 patients were included in the 
analysis. At the time of first sample, 61% were male and the median age was 
62 years (IQR: 53 – 70). Pre-first sample, 9 (39%) patients had undergone 
primary surgical resection and 1 (4%) patient was treated with SSA. Treatment 
was started after a median of 27 days (IQR: 0-70) following the first sample 
being taken, and 18 (78%) patients were started on SSA, 3 (13%) patients 
underwent surgery and 2 (9%) were followed up after having both treatments. 
The second sample was taken a median of 203 days (IQR: 56 – 260) following 
treatment, by which time 21 (91%) patients were on SSA. Table 17. 
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Factor Statistic 
Age at First Sample (Years) 62 (53 - 70) 
Gender (Male) 14 (61%) 
Grade 
 
1 14 (74%) 
2 5 (26%) 
Liver Metastases 16 (70%) 
Surgery Pre-First Sample 9 (39%) 
SSA Pre-First Sample 1 (4%) 
Days First to Second Sample 231 (92 - 330) 
First Sample to Treatment 27 (0 - 70) 
Treatment to Second Sample 203 (56 - 260) 
Treatment During Follow-up 
 
SSA 18 (78%) 
Surgery 3 (13%) 
Surgery + SSA 2 (9%) 
On SSA by second sample 21 (91%) 
Type of SSA 
 
Lanreotide 6 (29%) 
Sandostatin 15 (71%) 
Table 17: Summary of patient demographics in the longitudinal 
analysis in the midgut neuroendocrine tumour group. Data are 
reported as median (IQR), or as N (%), as applicable.  
 
Levels of sVAP-1 were recorded at both sample timepoints for all patients 
included in this analysis. There was no significant change observed following 
treatment with medians of 1016 ng/mL (IQR: 812 – 1140) versus 1023 ng/mL 
(IQR: 927 – 1197) at the first and second sample taken respectively (p=0.501). 
Figure 21. The changes in CgA, NT-proBNP and 24 hour urinary 5-HIAA were 
also assessed, but data were not recorded for all 23 patients, with the sample 
size ranging from N=8 – 15. There were no significant changes seen between 
the first and second samples for any of the three markers (p=0.092, p=0.497 
and p=0.383, for CgA, NT-proBNP and 24 hour urinary 5-HIAA respectively). 
Table 18. 
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Analyses were then performed to assess whether sVAP-1 levels differed based 
on whether or not patients had undergone surgery prior to the first sample 
(Table 19). This found no significant differences between the surgical and no 
surgical groups with respect to the first and second samples, or in the degree of 
change after treatment, with neither group having significant changes in sVAP-1 
levels after surgery. A similar analysis was performed for those 20 patients who 
had imaging performed after the first sample was taken, to assess whether 
disease progression correlated with sVAP-1 levels (Table 20). None of these 
comparisons between the stable (N=15) and progressing (N=5) disease groups 
were found to be statistically significant. 
 
Figure 21: Changes in sVAP-1 levels between the first and second 
samples in the midgut neuroendocrine tumour group. Prior to 
treatment, the median sVAP-1 was 1016 ng/mL (IQR: 788 – 1152). This 
was not found to change significantly by the second sample following 
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treatment (p=0.501), with N=13 patients having an increase in VAP-1, and 
N=10 a reduction, resulting in a median of 1023 ng/mL (IQR: 921 – 1255). 
Each colour represents an individual patient.  
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    Median IQR N Patients with:   
Marker N Sample 1 Sample 2 Reduction Increase p-Value 
sVAP-1 23 1016 (821 - 1140) 1023 (927 - 1197) 10 13 0.501 
5-HIAA* 8 107 (32 - 620) 37 (20 - 239) 6 2 0.383 
CgA 12 170 (67 - 1403) 57 (41 - 259) 10 2 0.092 
NT-proBNP 15 68 (51 - 131) 110 (43 - 165) 7 8 0.497 
 
Table 18: Changes in sVAP-1, 24 hour urinary 5-HIAA, CgA and NT-proBNP between the first and second 
samples in the longitudinal analysis in the midgut neuroendocrine tumour group. Only patients with samples at 
both timepoints are included in the analysis. p-Values are from Wilcoxon’s test. * represent 24 hour urinary 5-HIAA 
collection.  
 
 Surgery Pre-First Sample p-Value 
(Yes vs. No)** sVAP-1 (ng/mL) No (N=14) Yes (N=9) 
First Sample 916 (728, 1171) 1033 (983, 1129) 0.557 
Second Sample 990 (876, 1255) 1097 (948, 1120) 0.890 
Change -15 (-67, 230) 81 (-69, 133) 0.829 
p-Value (First vs. Second)* 0.903 0.496 - 
 
Table 19: Subgroup analyses for sVAP-1 by surgery in the longitudinal analysis in the midgut neuroendocrine 
tumour group. Data are reported as median (IQR). *Wilcoxon’s tests comparing the first and second sample values 
within each subgroup. **Mann-Whitney tests, comparing values between those that did and did not undergo surgery 
before the first sample.  
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 Disease on Imaging after First Sample p-Value (Stable vs. 
Progression)** sVAP-1 (ng/mL) Stable (N=15) Progression (N=5) 
First Sample 1067 (788, 1152) 880 (855, 1033) 0.672 
Second Sample 952 (876, 1139) 1255 (958, 1284) 0.163 
Change -44 (-203, 133) 230 (104, 251) 0.349 
p-Value (First vs. Second)* 0.978 0.625 - 
Table 20: Subgroup analyses for sVAP-1 by imaging findings after the first sample in the longitudinal analysis in 
the midgut neuroendocrine tumour group. Data are reported as median (IQR). *Wilcoxon’s tests comparing the first 
and second sample values within each subgroup. **Mann-Whitney tests, comparing values between those with stable 
versus progressive disease.  
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Carcinoid syndrome symptoms in longitudinal analysis 
Changes in carcinoid syndrome symptoms were also assessed between the 
two samples taken. At the time of the first sample, 70% of patients displayed at 
least one carcinoid symptom, reducing significantly to 35% at the second 
sample (p=0.021, Table 21). All five individual symptoms were found to occur at 
a lower rate at the second sample, with the exception of wheeze, which had a 
rate of 0% at both times. However, a significant change was only noted in the 
rate of weight loss, falling from 22% to 0% (p<0.001). 
Symptoms First Sample Second Sample p-Value 
Carcinoid Syndrome 16 (70%) 8 (35%) 0.021 
Flushing 11 (48%) 6 (26%) 0.125 
Diarrhoea 10 (43%) 3 (13%) 0.065 
Abdominal Pain 9 (39%) 4 (17%) 0.180 
Wheeze 0 (0%) 0 (0%) - 
Weight Loss 5 (22%) 0 (0%) <0.001 
 
Table 21: Changes in carcinoid syndrome symptoms between the 
first and second samples in the midgut neuroendocrine tumour 
longitudinal analysis. Data are reported as N (%), with p-values from 
McNemar’s test. Bold p-values are significant at p<0.05. 
 
 
 
Pancreatic NET analysis 
 
Table 22 summarises the baseline characteristics in the pancreatic NET group. 
The mean age was 61.2 years and half the group were male. The median 
tumour size was 25.5mm (IQR: 18.8 – 47.8). Liver metastases was present in 7 
(35%) patients and 5 (25%) patients experienced carcinoid symptoms. Three 
patients (15%) were on SSA pre-sample, all of whom were on Lanreotide 
Autogel. 
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 N Pancreatic NET 
Demographics 
Age at sample (Years) 20 61.4 ± 12.2 
Male 20 10 (50%) 
Tumour features   
Grade 
G1 
G2 
18 
 
 
 
8 (44%) 
10 (56%) 
CgA (pmol/L) 20 43 (25 – 110) 
24 hour urinary 5-HIAA 
(umol/24 hrs) 
3 19.3 (7.0 – 33.5) 
NT-proBNP (ng/L) 18 89 (42 – 135) 
Liver metastases 20 7 (35%) 
Size (mm) 18 25.5 (18.8 – 47.8) 
Carcinoid symptoms 20 5 (25%) 
Facial flushing 
Diarrhoea 
Abdominal pain 
Weight loss 
Wheeze 
 1 (5%) 
1 (5%) 
4 (20%) 
1 (5%) 
- 
Treatment pre-sample   
On SSA 20 3 (15%) 
 
Table 22: Summary of patient demographics, tumour features and 
treatment pre-sample in the pancreatic neuroendocrine tumour 
group. Data are reported as N (%), mean±SD, or median (IQR), as 
applicable.  
 
Correlations between sVAP-1 levels and various factors were then assessed, 
none of which were found to be statistically significant, Table 23. 
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 N sVAP-1 (ng/mL) p-Value 
CgA 20 -0.083 0.729 
24 hour urinary 5-HIAA 3 0.500 0.667 
NT-proBNP 18 0.157 0.533 
Grade 18 -0.108 0.670 
Size 18 -0.119 0.639 
Liver metastases 20 0.027 0.909 
 
Table 23: Correlations between sVAP-1 and CgA, 24 hour urinary 5-
HIAA, NT-proBNP, tumour grade, tumour size and liver metastases in 
the pancreatic neuroendocrine tumour group. Data are reported as 
Spearman’s rho correlation co-efficients.  
 
Comparisons of markers across the midgut NET, pancreatic NET and CHD 
groups 
Comparisons of CgA, NT-proBNP and 24 hour urinary 5-HIAA were performed 
across the pancreatic NET, midgut NET and CHD groups, using Kruskal-Wallis 
tests. A significant difference was seen across the three groups for all markers 
(CgA, p<0.001; NT-proBNP, p<0.001 and 24 hour urinary 5-HIAA, p=0.013). 
Post-hoc analyses using Dunn’s multiple comparisons tests showed that a 
significant difference was present between the pancreatic NET and midgut NET 
groups (p=0.002), and the pancreatic NET and CHD groups (p<0.001) for CgA; 
the pancreatic NET and CHD groups (p<0.001), and the midgut NET and CHD 
groups (p<0.001) for NT-proBNP; and the pancreatic NET and CHD groups 
(p=0.013) for 24 hour urinary 5-HIAA. Table 24.  
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 Pancreatic Midgut CHD p-
Value 
CgA 
(pmol/L) 
43 (25 – 110) 206 (70 – 
1062) 
578 (160 – 
3124) 
<0.001 
NT-
proBNP 
(ng/L) 
89 (42 – 135) 89 (51 – 279) 571 (203 – 
1691) 
<0.001 
24 hour 
urinary 
5-HIAA 
(umol/24 
hrs) 
19.3 (7.0 – 
33.5) 
94.2 (29.9 – 
174.9) 
193.2 (90.5 – 
788.1) 
0.013 
 
Table 24: Comparisons of CgA, NT-proBNP and 24 hour urinary 5-
HIAA across the pancreatic neuroendocrine tumour, midgut 
neuroendocrine tumour and CHD groups. Data reported as median 
(IQR), with p-Values from Kruskal Wallis tests. Bold p-values are 
significant at p<0.05. Dunn’s Tests for tumour markers: CgA: pancreatic 
vs midgut, p=0.002, pancreatic vs CHD,  p<0.001; NT-proBNP: pancreatic 
vs CHD (p<0.001), midgut vs CHD (p<0.001); 24 hour urinary 5-HIAA: 
pancreatic vs CHD, p=0.013.  
 
 
Therefore, the sVAP-1 results in this chapter have shown that levels increase 
across the healthy controls, pancreatic NETs, midgut NETs and CHD groups 
with levels highest in CHD. Interestingly, there was no significant difference 
seen between sVAP-1 levels in pancreatic NETs vs. midgut NETs or CHD. No 
significant difference in sVAP-1 levels between the first and second samples in 
the midgut NET group was seen, similar to the results assessing changes in the 
current biochemical markers used in clinical practice (CgA, NT-proBNP and 24 
hour urinary 5-HIAA) between the two samples. 
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4.3 Discussion 
Despite NETs being slow-growing tumours, significant gastrointestinal and 
cardiac complications can occur related to intestinal, peritoneal and cardiac 
valve fibrosis, particularly in midgut NETs, which are the commonest site for 
tumour formation.  Such complications are associated with significant morbidity 
and mortality, and at present there are no effective diagnostic markers or 
treatments targeted at diagnosing the fibrosis. Previous work has demonstrated 
that circulating sVAP-1 levels is higher in the presence of liver fibrosis with 
levels correlating with the degree of fibrosis present, as well as higher sVAP-1 
levels are associated with a poorer liver transplant-free survival.(277, 291) 
Levels of sVAP-1 have been shown to be lower in colorectal cancer (297) and 
decrease with tumour progression in both colorectal and gastric cancer (320, 
321), whereas sVAP-1 levels were found to be high in HCC.(322) By gaining a 
better understanding of sVAP-1 being associated with the development of 
scarring and fibrosis in NETs, patients could be stratified based on abundance 
of sVAP-1, in addition to offering the potential target for new treatments to cure 
or prevent fibrosis. A non-invasive method in screening for fibrosis in NETs is 
therefore paramount, so a diagnosis can be made and treatment instituted in a 
timely fashion.  
 
The sVAP-1 analysis has shown results in keeping with the preliminary work 
previously carried out. A significant difference in sVAP-1 levels was observed 
across the healthy controls, midgut NETs, pancreatic NETs and CHD groups, 
with the highest levels seen in the CHD cohort. This reflects the degree of 
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fibrosis present in CHD resulting in right-sided valvular disease and heart 
failure. A Kaplan Meier curve for survival analysis across the midgut NET, 
pancreatic NET and CHD groups showed a trend that higher sVAP-1 levels are 
associated with poorer survival, although this was not statistically significant. 
This may not have reached statistical significance as the sample size was small 
and a longer duration of disease is required given that NETs are known to be 
generally slow-growing tumours. Previous work in Birmingham have shown that 
higher circulating VAP-1 levels are associated with a poorer liver transplant-free 
survival.(291) The source of sVAP-1 is not known in NETs, but one possible 
source could be from fibroblasts present in the fibrotic stroma and fibrotic area 
of the CHD valve.  
 
After excluding the pancreatic NET group, comparisons across the three 
remaining groups (healthy controls, midgut NETs and CHD) found sVAP-1 
levels were significantly different across the groups, again with levels seen 
highest in CHD. Post-hoc analysis demonstrated that the pairs exhibiting the 
significant change in sVAP-1 levels were healthy controls vs. midgut NETs 
(p=0.015), healthy controls vs. CHD (p<0.001) and midgut NETs vs CHD 
(p=0.014). In the midgut NET group, 70% of patients experienced carcinoid 
symptoms compared to 41% of CHD patients, p=0.045. Patients with CHD are 
likely to have liver metastases and develop carcinoid symptoms; however in 
these patient groups, over 80% of patients in the CHD cohort were already on a 
SSA injection at the time of sample collection compared to 6% of midgut NET 
patients, and therefore had controlled carcinoid symptoms.  
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The longitudinal analysis of sVAP-1 first and second samples showed variation 
in the changes seen between both samples, with 10 patients showing a 
reduction in the sVAP-1 levels and 13 patients having an increase in sVAP-1 
levels following treatment, p=0.501. The markers currently used in clinical 
practice, CgA, NT-proBNP and 24 hour urinary 5-HIAA, also did not have a 
significant change in their measurements following treatment (p=0.092, p=0.497 
and p=0.383 respectively). Serial measurements were not taken following 
treatment and the follow up sVAP-1 samples were taken at various timepoints 
(median of 203 days post-treatment, IQR: 56 – 260) for individual patients. 
Additionally, the half-life of circulating sVAP-1 is currently unknown, and 
therefore the optimal timepoint on when to measure the sVAP-1 level following 
treatment also remains unknown. In addition to the circulating form, future work 
could also assess the amine oxidase enzyme activity of VAP-1 in the different 
cohorts of patients. Having primary surgical resection prior to the first sample 
being taken did not influence the sVAP-1 levels, nor was there any significant 
change observed in sVAP-1 levels between the first and second samples. 
Similarly, no significant change was seen in sVAP-1 levels between patients 
who had stable disease or evidence of progression on imaging (p=0.349). A 
significant reduction in carcinoid symptoms was found following treatment 
(p=0.021). Therefore, the improvement seen in carcinoid symptoms did not 
correlate with the change in sVAP-1 levels between the first and second 
samples. Given that the half-life of VAP-1 is not known, future work should 
include analysing further sequential serum samples taken at more follow-up 
dates following treatment commencement including surgical resection in order 
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to assess any change seen in sVAP-1 more accurately. The current biomarkers 
used in clinical practice in NETs and CHD reflect the tumour bulk, functional 
status / hormone secretion and the presence of possible CHD. However, 
compared to VAP-1, none of these biomarkers indicate the presence of fibrosis 
which plays an important role in the complications, morbidity and mortality seen 
in NETs and CHD. 
The pancreatic NET sVAP-1 levels were found to be significantly higher than 
the healthy controls (p=0.004), but were not significantly different to either the 
midgut NET or the CHD groups (p=1.000 for both comparisons). Comparing the 
median CgA, NT-proBNP and 24 hour urinary 5-HIAA across the pancreatic 
NETs, midgut NETs and CHD groups, the pancreatic NET group had the lowest 
values for CgA and 24 hour urinary 5-HIAA (p<0.001 and p=0.013, 
respectively). Therefore, sVAP-1 levels may be indicative of the degree of 
fibrosis present in pancreatic NETs, which is not the case with the current 
markers used in clinical practice. Further work to analyse this group further 
would require more patients to be included and then performing further 
statistical analysis using ROC curves or multivariate analysis to draw the 
comparisons between the various biochemical markers. This may be cost-
effective as despite having high sVAP-1 levels in pancreatic NETs, the current 
tumour markers used in clinical practice are significantly lower in this group 
compared with the midgut NET and CHD groups. Therefore, fibrosis occurring 
in pancreatic NETs may be associated with complications, and treatment 
targeting VAP-1 may be beneficial in this group of patients as well.  
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4.4 Conclusion 
In conclusion, the sVAP-1 levels seen in the groups analysed have shown that 
the levels are highest in the CHD group and levels are significantly higher in the 
pancreatic NET, midgut NET and CHD groups vs the healthy controls. 
Interestingly, the sVAP-1 levels seen in pancreatic NETs are higher than initially 
expected, suggesting an element of fibrosis occurring in the tumour stroma in 
pancreatic NETs, although the release of soluble VAP-1 from fibroblasts has yet 
to be demonstrated in this context. The levels of sVAP-1 were raised in both the 
pancreatic and midgut NETs, yet fibrotic complications mainly occur in midgut 
NETs. Most pancreatic NETs are characterised mainly by a hypervascular 
appearance with a less prominent fibrotic stroma.(326) However, previous 
studies have also shown a group of serotonin-expressing pancreatic NETs that 
are associated with a fibrous stroma.(327, 328) This group of tumours was 
found to differ from serotonin-positive ileal NETs in their histological pattern and 
had less positive staining for CDX2, possibly suggesting that pancreatic NETs 
are derived from a separate cell lineage compared to the enterochromaffin cell 
type seen in midgut NETs.(327, 328) This could also explain why sVAP-1 levels 
are increased in pancreatic NETs in this study as a fibrous stroma could be 
present in the pancreatic NETs. The 24 hour urinary 5-HIAA was normal in this 
study in the pancreatic NET group, but only 3 out of 20 patients had a result for 
this marker. The fibrotic pancreatic NETs are likely to have more benign 
biological characteristics compared to other fibrotic NETs (327), and this could 
explain why fibrotic complications, including CHD, is not commonly seen in 
pancreatic NETs. A positive significant correlation was found between HbA1c 
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and sVAP-1 levels. This is in keeping with previous work which have shown 
elevated sVAP-1 levels in hyperglycaemia and positive correlations with sVAP-
1.(292, 295, 329) Survival analysis showed that higher sVAP-1 levels are 
associated with a poorer survival, although this was not statistically significant, 
likely due to the small sample size in this analysis. The longitudinal analysis did 
not show any significant changes in the sVAP-1 level between the first and 
second samples, which is likely to be multifactorial: serial measurements were 
not taken, and therefore the trend in sVAP-1 is not known after a particular 
timepoint following treatment; sample size is small and the circulating sVAP-1 
half-life is currently not known. The changes in sVAP-1 did not correlate with the 
significant reduction in carcinoid symptoms seen following treatment, therefore 
suggesting the symptoms are hormone-related and not associated with the 
amount of fibrosis present. 
 
Therefore, the overall findings show that the circulating form of sVAP-1 could be 
a possible biomarker used in screening for fibrosis in the NET patient cohorts 
and could be used as a stratification tool in patients as well. Further work is 
required to increase both patient numbers and samples for individual patients in 
the longitudinal analysis, as sVAP-1 may also have a role both as a prognostic 
marker as well as a treatment response marker.  
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ANALYSIS OF MIDGUT 
NEUROENDOCRINE TUMOUR 
STROMA 
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5.1 Introduction and aims 
5.1.1 Introduction 
NETs are a slow-growing cancer and are associated with desmoplastic reactions, 
both local and distant to the tumour. Complications of fibrosis include the 
development of CHD and intestinal and peritoneal fibrosis.(196) Midgut NETs are 
associated with mesenteric fibrosis leading to intestinal oedema, ischaemia and 
obstruction causing significant morbidity in this group of patients.(330) Up to 50% 
of patients with a midgut NETs develop mesenteric fibrosis.(331) Mesenteric 
fibrosis is caused by an extensive desmoplastic reaction surrounding a 
mesenteric mass.(330) Surgery at present is the only treatment option that can 
be offered to patients with the fibrotic complication.(332) However, following post-
surgical resection further complications can occur, these including malabsorption, 
short bowel syndrome and bile acid malabsorption.(194) In addition to resulting in 
significant morbidity, mesenteric fibrosis is also a poor prognostic factor relating 
to overall survival.(196, 198) There has been literature published describing 
possible factors of fibrosis development with treatments targeting these 
mediators. 
 
Understanding of the tumour microenvironment is crucial given that this may 
influence tumour growth, tumour cell survival and facilitate metastases, therefore 
causing tumour progression.(333) It has been shown that the midgut NET stroma 
differs to other cancers with a predominant desmoplastic reaction occurring with 
limited leucocyte involvement.(330, 334) In addition to the tumour cells, fibroblasts 
are a major cellular component of tumour stroma. In cancer, these fibroblasts 
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(cancer-associated fibroblasts, CAFs) have a different phenotype and express -
SMA.(330) Unlike quiescent fibroblasts, CAFs have the potential to proliferate and 
form ECM and growth factors.(335) Midgut NETs express high levels of -SMA 
in the fibroblast population present in the tumour stroma.(336) Kidd et al showed 
that cells from tumour stroma had the stellate appearance of CAFs and following 
stimulation with TGF1, led to upregulation of growth factor transcription, which 
highlights the possible role of CAFs in regulating fibrotic signalling in tumour 
stroma.(337) Leucocyte infiltration has been shown to be limited in NETs, with 
macrophages being the dominant leucocyte found, staining positive for TGF and 
platelet-derived growth factor, therefore acting as another mediator stimulating 
fibrosis.(334, 338) ECM remodelling and a change in the composition of the ECM 
has been found in both cancer and fibrotic conditions and inappropriate fibroblast 
activation seen in fibrotic conditions leads to increased collagen production.(339) 
Type I collagen and fibronectin are the main components found in tumour ECM 
(340) and only a limited understanding on the exact ECM composition in midgut 
NETs is currently known. It may be that the ECM composition may influence 
tumour function in midgut NETs by causing the tumour cells to release 
biochemical, including serotonin, and biomechanical signals, including adenosine 
triphosphate.(341) Kidd et al showed the collagen III expression surrounding 
CAFs in small bowel fibrosis.(337) The ECM also contain various proteoglycans, 
and transcription levels in these proteoglycans show changes in NETs during 
tumour progression, although their role in fibrosis development in midgut NETs 
remains unclear.(342)  
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Fibrotic complications of midgut NETs are therefore associated with significant 
morbidity and mortality, and at present, there are no effective diagnostic markers 
or treatments targeted at diagnosing the fibrosis. The application of non-invasive 
biomarkers could result in beneficial clinical implications. VAP-1 may have a 
significant role in NETs, given that the enzyme activity of VAP-1 is dependent on 
having amines as the substrate, and therefore either the amines secreted by the 
tumour, or breakdown products from monoamine oxidases or other amine 
oxidases, can stimulate certain cell populations to produce VAP-1. Therefore, 
VAP-1 could be a potential biomarker in diagnosing fibrosis, which could also be 
a treatment target in the future.  
 
5.1.2 Aims 
The overall aim is to understand the contribution of VAP-1 to the fibrosis that 
develops near and distal to the tumour which can lead to the onset of 
desmoplastic reactions.  
 
The aim of this section is to:  
a)  Study the expression of VAP-1 in primary tumours from midgut 
NET primary and metastases. 
b) Define the cell-specific expression of VAP-1 in the tumour 
microenvironment. 
c) Correlate VAP-1 expression in the midgut NETs with the 
immune microenvironment. 
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5.2 Results 
Tissue sections used 
In total, 10 cases of midgut NETs with LN metastases were stained with various 
primary antibodies, in addition to 4 primary midgut NETs. Figures 22 and 23 
represent tissue sections stained with VAP-1 and collagen I, and the haematoxylin 
and eosin stained sections, respectively. Figure 22 shows the presence of 
positive brown staining (representing VAP-1 and collagen I) in the peri-tumoural 
stroma surrounding the clusters of tumour cells. Collagen I was used as it is a 
known ECM marker. The positive staining of both markers is in a very similar 
distribution and can also be seen to be present lining adipocytes. Compared to 
collagen I, some VAP-1 positive staining can also be seen within the tumour cells. 
Figure 23 shows the presence of clusters of NET cells and extracellular matrix 
with immune cell aggregates amongst the tumour cell areas. 
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Figure 22: Representative images of paired whole midgut 
neuroendocrine tumour cases for VAP-1 staining and Collagen I 
staining. VAP-1 staining is shown in images a and c; collagen I staining is 
shown in images b and d; n=2. Objective 20X. Scale bars 2000 m. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Representative images of paired whole midgut neuroendocrine 
tumour cases for VAP-1 staining (a and c) and Collagen I staining (b and d). 
Objective 20X. Scale bars 2000 µm. 
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Figure 23: Representative images of whole midgut neuroendocrine 
tumour case and cropped areas stained with haematoxylin and eosin. 
Whole midgut case is shown in image a, and cropped areas are shown in 
images b and c, n=1. Scale bar image a 2000 m. Scale bars images b 
and c 200 m. Haematoxylin and Eosin stain. Clusters of neuroendocrine 
tumour cells are seen in images b and c and extracellular matrix can be 
seen in image b. Immune cell aggregates can be seen in image c amongst 
the tumour cell areas (black arrows).
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Threshold images 
The VAP-1 and collagen I staining were analysed using Ilastik and Fiji Image J 
in order to establish the quantification of the % area of epitope expression. The 
threshold images represent the positive brown Ab staining on the images taken 
by Zen software and is seen as red on the images below. Figure 24. 
 
Figure 24: Representative images of cropped tumour areas of midgut 
neuroendocrine tumours with LN metastases stained with VAP-1 and 
Collagen I with matched threshold images. Image Ia represents VAP-1 
staining and image Ic represents collagen I staining. Images Ib and Id 
represent the threshold images of Ia and Ic respectively, used for the 
quantification of % area of expression (staining shown as red); 18.9% and 
33.4% respectively; n=1. Granules of VAP-1 (represented by a box in image 
Ia) within the tumour cells can be seen.  
 
 
Percentage area of VAP-1 and Collagen I expression 
Cropped tumour areas were taken to analyse the median (IQR) individual % 
area of VAP-1 and collagen I expression in all 14 midgut NET cases, Figure 25. 
Cropped areas were then taken to correlate median (IQR) VAP-1 expression 
with collagen I expression, Table 25 and Figure 26. A positive correlation was 
found between VAP-1 and collagen I expression, although this was not 
significant (Spearman’s rho correlation co-efficient 0.310, p=0.281). For whole 
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images used, a positive correlation was again seen between VAP-1 and 
collagen I expression (Spearman’s rho correlation co-efficient 0.064, p=0.829), 
Table 26. 
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Table 25: Summary of the median % expression of Collagen I and VAP-1 in midgut NET cases with lymph node 
metastases and primary midgut NETs. * Represents the primary midgut NETs. Median values taken after cropped 
tumour areas of whole image performed, represented by ‘N’.  
 
 
 
 
 
 
 
 
 
 
Median % 
expression 
(IQRs) 
Case 1 
(N=5) 
Case 2 
(N=3) 
Case 3 
(N=5) 
Case 4 
(N=5) 
Case 5 
(N=4) 
Case 6 
(N=4) 
Case 7 
(N=4) 
Case 8 
(N=5) 
Case 9 
(N=5) 
Case 
10 
(N=5) 
Case 
11* 
(N=5) 
Case 
12* 
(N=5) 
Case 
13* 
(N=3) 
Case 
14* 
(N=5) 
Collagen I 
 
 
 
 
VAP-1 
26.1 
(23.7 – 
32.1) 
 
16.6 
(15.3 – 
23.3) 
56.4 
(53.5 – 
79.8) 
 
17.8 
(7.2 – 
26.0) 
48.5 
(28.7 – 
65.2) 
 
31.8 
(15.0 – 
36.0) 
37.5 
(29.9 – 
44.0) 
 
18.0 
(15.1 – 
22.7) 
63.8 
(45.5 – 
80.5) 
 
39.9 
(20.3 – 
48.0) 
43.4 
(20.8 – 
57.7) 
 
48.4 
(31.8 – 
63.2) 
31.6 
(25.2 – 
66.2) 
 
18.4 
(17.0 – 
20.9) 
38.2 
(31.9 – 
40.9) 
 
78.7 
(65.7 – 
88.1) 
52.7 
(43.6 – 
60.1) 
 
46.1 
(10.4 – 
53.0) 
30.1 
(25.2 – 
35.0) 
 
43.2 
(36.4 – 
48.5) 
35.7 
(32.9 – 
42.1) 
 
20.1 
(9.9 – 
24.2) 
40.5 
(36.3 – 
48.3) 
 
18.0 
(11.0 – 
19.7) 
78.5 
(50.9 – 
87.1) 
 
20.3 
(9.0 – 
35.4) 
32.6 
(21.9 – 
53.5) 
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Figure 25: Graphs showing median values of % area of Vascular 
Adhesion Protein-1 and Collagen I expression. Graph a showing the 
median values of % area of VAP-1 expression for each case, shown as 
median values with IQRs of cropped tumour areas. Graph b showing the 
median values of % area of Collagen I expression for each case, shown as 
median values with IQRs of cropped tumour areas. Mets, metastases. 
 
 
Figure 26: Scatter plot showing the median % area of VAP-1 expression 
against the % area of Collagen I expression for each case. Cropped tumour 
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areas of whole image used. Spearman’s rho correlation co-efficient 0.310 
(p=0.281). VAP-1, vascular adhesion protein-1. 
 
 
Table 26: Median values with IQRs of % area expression of whole images 
combined for Collagen I and VAP-1. Spearman’s rho correlation co-efficient 
0.064 (p=0.829).  
 
 
Primary antibodies with isotype matched controls 
Midgut NET tissue were individually stained with VAP-1, collagen I, -SMA 
(fibroblasts marker) and CD45 (marker for leucocyte common antigen) , with 
their matched isotype matched control (IMC) for each primary Ab. VAP-1 
expression can be seen in the peri-tumoral stroma, and a dense fibro-reticular 
network is present in these tumours with positive staining of collagen I and -
SMA in a very similar distribution. There is the presence of CD45 positive 
staining in these tumours as well, reflecting the presence of an immune 
component in the peri-tumoral stroma. Figure 27. 
 
 
 
 
 
 
 
 
 Collagen I VAP-1 Spearman’s Correlation 
Co-efficient 
p-Value 
Median 
 
Percentile 25 
 
Percentile 75 
31.1 
 
26.8 
 
33.0 
18.3 
 
15.9 
 
23.8 
0.064 0.829 
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Figure 27: Representative images of cropped tumour areas of 
midgut neuroendocrine tumours with LN metastases stained with 
VAP-1, Collagen I, -SMA, CD45 and matched IMC. Images Ia and Ib 
represents VAP-1 and IMC respectively; IIa and IIb represents Collagen I 
and IMC respectively; IIIa and IIIb represent -SMA and IMC 
respectively; IVa and IVb represents CD45 and IMC respectively; n=3. 
Scale bars 100 m. SMA, smooth muscle actin. IMC, isotype matched 
control. 
 
VAP-1 positive staining 
In addition to the positive VAP-1 staining seen in the peri-tumoral area in midgut 
NETs, VAP-1 is also present in the villous architecture, lamina propria layer and 
submucosal layer in the small bowel, as well as lining adipocytes. Figure 28. 
These findings are similar to our Birmingham group showing positive VAP-1 
staining with a different primary antibody in the lamina propria and submucosal 
 
 
 
 
 
Figure 21: Representative images of cropped tumour areas of midgut 
neuroendocrine tumours with LN metastases. Images Ia and Ib represents 
VAP-1 and isotype matched control (IMC) respectively; IIa and IIb represents 
Collagen I and IMC respectively; IIIa and IIIb represent a-SMA and IMC 
respectively; IVa and IVb represents CD45 and IMC respectively. Scale bars 
100 µm. 
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 186 
layers of the colon (297), and to the study by Abella et al that showed positive 
VAP-1 expression using another primary antibody in the culture medium from 
adipocytes.(289)  
 
 
 
 
 
 
Figure 28: Representative images of cropped areas of midgut 
neuroendocrine tumours stained with VAP-1 in villous core and 
lining adipocytes. Image Ia shows VAP-1 staining present in the core of 
the villous architecture, the lamina propria layer and in the submuscosa 
layer. Image Ib shows the presence of abundant VAP-1 lining adipocytes. 
N=2. Scale bar as shown.  
 
VAP-1 and -SMA expression 
The sections stained with both VAP-1 and -SMA were then cropped to identify 
similar tumour areas stained with each marker. The distribution of VAP-1 and -
SMA staining appear to be in the same areas, with increased intensity of VAP-1 
expression seen compared with -SMA, indicating that midgut NETs are 
characterised by a dense stromal network. Figure 29. Given that NETs can 
cause fibrosis as a result of desmoplasia and VAP-1 is known to be associated 
with fibrosis, the findings of positive VAP-1 and -SMA staining occurring in 
same areas was expected. 
VAP-1 present in villous core VAP-1 lining adipocytes
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Figure 29: Representative images of cropped tumour areas of midgut 
neuroendocrine tumours with LN metastases stained with VAP-1 and 
-SMA. Images Ia and IIa represent VAP-1 staining and images Ib and IIb 
represent -SMA staining. Scale bars 100 m. Images Ic and IIc represent 
VAP-1 staining zoomed in at 40% and images Id and IId represent -SMA 
staining zoomed in at 40%. Scale bars 50 m. There appears to be some 
areas where VAP-1 expression is seen more dense than -SMA (red box 
in image IIc highlights this); n=2. Images I and II are separate cases.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Ia 
Id 
Ib 
Ic 
IIa IIb 
IIc IId 
VAP-1
VAP-1 zoomed 
in at 40%
VAP-1
VAP-1 zoomed 
in at 40%
a-SMA
a-SMA zoomed 
in at 40%
a-SMA
a-SMA zoomed 
in at 40%
 188 
Dual fluorescent staining in midgut NETs 
Immunofluorescent staining was performed to allow visualisation of co-
localisation using two markers together. Additionally, immunofluorescence 
enables more quantitative analysis given that an exact quantity of fluorescence 
is known per Ab and has a wider dynamic range.  IHC staining is based on 
enzyme activity which increases variability and does not always represent the 
target concentration. Midgut NET tissue was dual stained with VAP-1 and 
collagen I, and VAP-1 and -SMA. The cases show the presence of tumour 
cells surrounded by a dense stromal and collagen network, similar to the 
chromogenic staining performed. Co-localisation of both markers are seen as 
yellow in both VAP-1/collagen I and VAP-1/-SMA, and individual areas of sole 
markers are also seen in the images below and VAP-1 can be seen lining the 
blood vessels. Figures 30 and 31.  
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Figure 30: Representative images of cropped tumour areas of midgut 
neuroendocrine tumours with LN metastases dual stained with VAP-1 
and -SMA. The blue staining (Hoerscht) illustrates the nuclei. The red 
staining indicates -SMA, IgG2a Alexa Fluor wavelength 594. The green 
staining indicates VAP-1, IgG2b Alexa Fluor wavelength 488. Images Ia-c 
represent the matched IMC; Ia involves all three channels, Ib represents 
the red channel and Ic represents the green channel. Figures IIa-d and 
IIIa-d represent two different cases. Images IIa and IIIa show the presence 
of all three channels, IIb and IIIb show the presence of -SMA and VAP-1, 
IIc and IIIc show the presence of -SMA and IId and IIId show the 
presence of VAP-1; n=2. Scale bars 20 m. Objective 20X. Co-localisation 
of the two markers can be seen as yellow in both cases, and the cases 
show the presence of tumour cells surrounded by a dense stromal network 
associated with VAP-1. Individual areas of -SMA and VAP-1 can also be 
seen, with more VAP-1 staining seen lining blood vessels in image II 
(white arrow). Certain areas of VAP-1 expression can also be seen with no 
-SMA expression (represented as a box in image III). 
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Figure 31: Representative images of cropped tumour areas of midgut 
neuroendocrine tumours with LN metastases dual stained with VAP-1 
and Collagen I. The blue staining (Hoerscht) illustrates the nuclei. The red 
staining indicates collagen I, VectaFluor Duet Dylight 594. The green staining 
indicates VAP-1, VectaFluor Duet Dylight 488. Images Ia-c represent the 
matched IMC; Ia involves all three channels, Ib represents the red channel 
and Ic represents the green channel. Figures IIa-d and IIIa-d represent two 
different cases. Images IIa and IIIa show the presence of all three channels, 
IIb and IIIb show the presence of collagen I and VAP-1, IIc and IIIc show the 
presence of collagen I and IId and IIId show the presence of VAP-1; n=2. 
Scale bars 20 m. Objective 20X. Co-localisation of the two markers can be 
seen as yellow in images IIIa-b, and both cases show the presence of tumour 
cells surrounded by a dense collagen network associated with VAP-1. 
Individual areas of collagen I (orange arrow) and VAP-1 (white arrow) can 
also be seen. Certain areas of VAP-1 expression can also be seen with no 
collagen I expression.   
 
 
 
 
 
 
 
 
3c
 
IIIa
 
IIIb
 
IIId
 
IIIc
 
VAP-1 (green) 
and collagen I
(red). Hoerscht
staining 
represents the 
nuclei (blue)
Collagen I (red)
VAP-1 (green) 
and collagen I 
(red)
VAP-1 (green)
 195 
Immune cell recruitment 
The immune microenvironment in midgut NETs has not been widely studied. 
CD45 was used to assess the presence of leucocyte infiltration in midgut NETs. 
An immune cell infiltrate is present surrounding the tumour cell clusters, similar to 
the VAP-1 staining. Figure 32. Previous work has highlighted that VAP-1 drives 
the immune cell infiltrate and this could explain the findings shown here where 
positive CD45 staining is seen in similar areas where VAP-1 resides due to 
leucocyte transmigration.  
 
 
Figure 32: Representative images of cropped tumour areas of 
midgut neuroendocrine tumours with LN metastases stained with 
VAP-1 and CD45. Images Ia and IIa represent VAP-1 staining and 
images Ib and IIb represent CD45 staining; n=2. Scale bars 100 m. The 
images show an immune cell infiltrate surrounding the tumour areas 
similar to the VAP-1 staining. Image IIb shows a highly infiltrated immune 
cell area present in between the clusters of neuroendocrine tumour cells.  
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5.3 Discussion 
Despite NETs generally being slow-growing tumours, they are associated with 
considerable complications as a result of desmoplasia. Midgut NETs are 
associated with mesenteric fibrosis, which in turn can lead to ischaemia and small 
bowel obstruction, which is a significant cause of morbidity in these patients.(330) 
At present, surgery remains the only treatment option when patients develop 
mesenteric fibrotic complications. Further side effects and consequences 
following surgery can also have an impact on patients’ quality of life, including 
short bowel syndrome and malabsorption.(194, 332)  
 
The Birmingham group have identified VAP-1 as a potential marker of fibrosis 
and therefore I investigated the expression of this protein in NETs. VAP-1 
expression was found in the peritumoral stroma and the villous architecture, and 
was also seen to line blood vessels and adipocytes. NET cells abundantly 
express proangiogenic molecules, thereby enhancing the recruitment and 
proliferation of endothelial cell precursors leading to angiogenesis.(343) The 
VAP-1 positive endothelial cells present in the tumour, could also be driving this 
process secondary to the oxidase activity of VAP-1, and the production of 
hydrogen peroxide, which in turn may regulate the process of 
angiogenesis.(344) Granules of VAP-1 within the tumour cells were seen, 
possibly indicating that VAP-1 may also be released by these cells and then 
adhere to the underlying matrix.  
 
A positive correlation was seen between VAP-1 and collagen I, although this 
was not statistically significant, suggesting that the clusters of tumour cells are 
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surrounded by a dense ECM. Alpha-SMA expression was also found in the 
peritumoral area, supporting previous findings of high levels of -SMA 
production in the fibroblast population in tumour stroma.(336) These findings 
are in keeping with previous work undertaken in Birmingham which have shown 
that VAP-1 promotes the expression of profibrotic genes, including, COL1A1, 
and therefore increased production of collagen I (277) and that either absence 
or inhibition of VAP-1 in mouse models protected the liver from steatohepatitis 
and hepatic fibrogenesis with a reduction in SMA and COL1A1 gene 
expression.(345) Dual staining using VAP-1/-SMA and VAP-1/collagen I did 
show some evidence of co-localisation of both markers and the presence of 
tumour cells being surrounded by a dense stromal and collagen network 
associated with VAP-1. Weston et al also showed that VAP-1 is expressed in -
SMA stromal cells in liver cirrhosis.(277) Therefore it is likely that NET 
associated fibroblasts express VAP-1 and that both tumour and stroma may 
contribute to the pool of circulating VAP-1.  
 
This is the first description of VAP-1 in the tumour microenvironment in NETs. 
Interestingly it has been shown that midgut NETs may have evidence of 
chromosomal gain in chromosome 17q (346), and the AOC3 gene is located on 
chromosome 17q.(347) Therefore, given that there is evidence of chromosomal 
gain in midgut NETs, increased production of VAP-1 may take place. Previous 
studies reporting on the NET microenvironment have shown that there is 
predominantly a desmoplastic reaction mainly composed of CAFs expressing -
SMA and limited leucocyte infiltration. Studies have shown that through their 
 198 
secretion of factors including serotonin, TGF- and platelet derived growth 
factor, NET cells can stimulate the activation and proliferation of 
fibroblasts.(343) Previous work has shown that CD8+ lymphocytes, T regulatory 
cells and programmed death ligand 1 expressed on tumour cells / tumour 
infiltrating cells are present in midgut NETs.(348, 349) Impaired cytolytic activity 
of natural killer cells has also observed in gastroenteropancreatic NETs.(350) 
Results in this chapter have shown an immune cell infiltrate surrounding the 
tumour areas similar to the VAP-1 staining. This could represent the VAP-1 
driving the immune cell infiltrate to areas where VAP-1 resides by the rolling, 
adhesion and transmigration steps of leucocyte transmigration. This therefore 
suggests that, in addition to the fibrotic composition of midgut NETs, an 
inflammatory component may also be present in the tumour microenvironment 
of midgut NETs. Additionally, liver myofibroblasts are known to control 
recruitment and positioning of lymphocytes (351), and VAP-1 may play a similar 
role in controlling the entry and retention of these immune cell populations 
through its adhesive function or enzymatic activity. Given the previous findings 
a high population of CAFs present in the tumour stroma, VAP-1 may be 
expressed on activated fibroblasts given the similar distribution of -SMA and 
VAP-1 seen in the staining. On the dual fluorescent staining, individual areas of 
VAP-1, -SMA and collagen I were seen, where there was no co-localisation 
present, possibly suggesting two reasons: firstly, individual cell types are 
producing each marker separately and are also present in the tumour 
microenvironment, and secondly, where there are certain areas of solely VAP-1 
expression, this could be as a result of circulating sVAP-1 adhering to the 
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stromal matrix. There may also be other markers that VAP-1 could be related to 
that have not been assessed in this study. These include markers of CAFs 
including, fibroblast activation protein, desmin and vimentin.(352, 353) 
Additionally, collagen III fibres and connective tissue growth factor have been 
found to be abundantly expressed in small bowel NETs (336, 337, 343) and 
therefore assessing the association between these markers and VAP-1 should 
also be considered in future work. 
 
In this chapter, the presence of VAP-1 has been shown in the tumour stroma of 
midgut NETs, and is associated with a dense fibrotic network, with the presence 
of immune cell infiltration. CHD is a major fibrotic complication of NETs which is 
associated with major morbidity and mortality. Understanding the 
microenvironment present in this fibrotic complication would potentially allow 
targeted treatment to be given. Levels of sVAP-1 have already been shown in 
this thesis to be significantly raised in CHD. The tissue expression of VAP-1 
also needs to be studied in CHD, to assess whether VAP-1 may also have a 
similar expression in CHD valves, given that it is a known fibrotic site occurring 
in NETs. 
 
5.4 Conclusion 
In conclusion, the immunohistochemical and immunofluorescent staining has 
shown the presence of VAP-1 in the peritumoral stroma of midgut NETs. A 
dense fibro-reticular network is present in these tumours, illustrating the fibrotic 
nature of this cancer. An inflammatory component can also be identified in 
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these tumours with the leucocyte recruitment possibly being driven by the 
presence of VAP-1.  
Surgery at present is the only treatment that can be offered to patients who 
develop mesenteric fibrosis as a result of the midgut NET. VAP-1 as a 
treatment target could be an alternative treatment option offered in these 
patients who develop fibrotic complications without the associated risk of post-
surgical adverse effects that can occur. 
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CHAPTER 6: 
IMMUNOHISTOCHEMICAL 
ANALYSIS OF CARCINOID HEART 
DISEASE VALVES 
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6.1 Introduction and aims 
6.1.1 Introduction 
In patients with CS, CHD still remains a major negative prognostic factor with 
valve surgery currently being the only effective treatment. Despite valve 
replacement being the mainstay of treatment in CHD, a high mortality rate is 
present post-operatively.(354) CHD usually affects the right- and left -sided valves 
in 85% and 15% of cases respectively.(355) Transthoracic echocardiography is 
usually able to identify CHD in the advanced stages, yet the identification and 
diagnosis of early stage disease remains a challenge.(356) Current clinical 
practice for surveillance of CHD includes NT-proBNP measurement and an 
echocardiogram if the NT-proBNP is above the normal level, or an 
echocardiogram is directly performed based on examination findings or patients’ 
symptoms. The urinary 5-HIAA is well known to be significantly higher in CHD 
compared with NET patients without this cardiac complication.(357) 
 
The exact pathogenesis involved in CHD is not fully understood. The exposure of 
high levels of serotonin and other vasoactive mediators are thought to be factors 
involved in CHD development.(355) 5-HT receptors play an important role in the 
development of CHD. Following activation of these receptors, mitogenesis of 
fibroblasts and smooth muscle cells takes place, as does up-regulation of TGF-
1.(213) Fibrous-like plaques then get deposited, usually on the right-sided 
valves, leading to heart failure.(243)  
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Another factor that may play a role in the pathogenesis and development of CHD 
is VAP-1, given its association with fibrosis. As well as being a diagnostic marker, 
VAP-1 could also be a treatment target. This would therefore enable earlier 
recognition and diagnosis of CHD being made, and treatment can then be offered 
at an appropriate time, thereby improving overall morbidity and mortality in this 
group of patients.  
 
6.1.2 Aims 
The aim is to understand the contribution of VAP-1 to the fibrosis that develops 
in CHD valves. This will be correlated with the expression of ECM proteins, 
angiogenesis markers and cellular populations (such as fibroblasts):  
 
The aim of this section is to:  
a) Study the expression of VAP-1 in CHD valves and define the cell specific 
expression of VAP-1 and correlate with the immune microenvironment. 
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6.3 Results 
In total 33 CHD valves, 6 control valves and 4 myxoma tissue sections were used. 
The disease aetiology in the control valves used included calcific aortic stenosis, 
acute aortic dissection, aortic and mitral fibrotic valves and aortic medial cystic 
degeneration. These control valves were chosen as the underlying disease either 
only affected the aortic root and not the valve, with no valve fibrosis involved, or 
valve fibrosis was present but not expected to be to the same extent as seen in 
CHD valves. 
Comparisons between the CHD and control valves were initially performed, in 
relation to VAP-1 expression, and haematoxylin and eosin staining in both valve 
types. Following this, a quantitative analysis was performed to assess the VAP-1 
expression in the CHD valves and control valves to determine if a significant 
difference in expression of VAP-1 is present between both valves. The next aim 
was to analyse the distribution of VAP-1 in CHD valves by undertaking a 
comprehensive study of the stroma seen in CHD valves using collagen I and III 
and -SMA. These markers were used as it is known that the carcinoid plaque 
deposits are comprised of myofibroblasts, smooth muscle cells and ECM. 
Additionally, CD31 and CD45 staining were undertaken in both valve types to 
assess the possible presence of neovascularisation and an immune cell 
infiltration, and determine if these processes are related to VAP-1 expression. The 
expression of VAP-1 was also compared in different areas of the carcinoid plaque, 
to assess if expression increases with increasing fibrosis in the plaque. 
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CHD express increased levels of VAP-1 compared to control valves 
Figure 33 represents the haematoxylin- and eosin-stained sections of CHD and 
control valves. A cluster of immune cells are seen in the CHD valve both in the 
underlying valve as well as in the carcinoid plaque found superior to the valve. 
Figure 34 represents whole-image tissue sections stained with VAP-1 and the 
matched IMC in a CHD valve and control valve.  
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Figure 33: Representative images of a carcinoid heart disease case 
with a cropped area, and a control valve case with a cropped area 
stained with haematoxylin and eosin. CHD case shown in image a, 
cropped area in image b, control valve case in image c and cropped 
control valve area in image d. Scale bars as illustrated; n=2. A cluster of 
immune cells can be seen in image b (highlighted by red box) present in 
the underlying valve and also in the plaque area superior to the valve.  
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Figure 34: Representative images of a whole carcinoid heart disease case 
and a control valve case for VAP-1 staining with paired IMC. CHD case is 
shown in image a, control valve case is shown in image c with their paired IMC  
in images b and d respectively. N=2. Objective 20X. Scale bars as illustrated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
c d 
a b 
CHD CHD 
Control Control
VAP-1 
VAP-1 
IMC VAP-1
IMC VAP-1
 208 
The VAP-1 stained CHD and control valves were analysed using Ilastik and Fiji 
Image J in order to establish the quantification of the % area of VAP-1 expression. 
The threshold images below are seen in red and represent the positive brown Ab 
staining on the images taken by Zen software. Figure 35. 
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Figure 35: Representative images of whole CHD and control valves 
stained with VAP-1 with matched threshold images. Images Ib and IIb 
represent VAP-1 staining in CHD valves and images IIIb and IVb represent 
VAP-1 staining in control valves. Images Ia and IIa represent the threshold 
images of Ib and IIb respectively, used for the quantification of % area of VAP-1 
expression (staining shown as red); 3.4% and 5.4% respectively. Images IIIa 
and IVa represent the threshold images of IIIb and IVb respectively, used for the 
quantification of % area of VAP-1 expression (staining shown as red); 0.3% and 
0.1% respectively. N=4.  
 
 
The % area of VAP-1 expression was quantified in both the CHD and control 
valves. Table 27, Table 28, Figure 36. The median % area of VAP-1 expression 
values for CHD and control valves were 1.40% (IQR 0.80 – 2.15) versus 0.15% 
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(IQR 0.10 – 0.23) respectively, and this was found to be significant (p<0.001), 
Figure 37. 
 
% area 
VAP-1 
expression 
Case 1 
(N=4) 
Case 2 
(N=3) 
Case 3 
(N=3) 
Case 4 
(N=2) 
Case 5 
(N=3) 
Case 
6 
(N=6) 
25% 
percentile 
0.1 0.1 0.1 0.1 0.1 0.1 
Median 0.2 0.1 0.3 0.1 0.1 0.2 
75% 
percentile 
0.4 0.2 0.3 0.2 0.1 0.4 
 
Table 27: Summary of the median % area VAP-1 expression in the 
whole images of six control valve cases with the IQRs.  
VAP-1, Vascular Adhesion Protein-1. N, number of values taken for each 
case. 
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Table 28: Summary of the median % area VAP-1 expression in the whole 
images of thirty-three CHD valve cases with the IQRs. VAP-1, Vascular 
Adhesion Protein-1. N= number of values taken for each case. 
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Figure 36. Graphs showing the median values of % area of VAP-1 
expression in control valves and CHD valves. Graph a shows the 
median values of % area of VAP-1 expression for each control valve case, 
shown as median values with IQRs of whole images. Graph b shows the 
median values of % area of VAP-1 expression for each CHD case, shown 
as median values with IQRs of whole images. Please note differences in 
the x-axis scale between the two cohorts. VAP-1, vascular adhesion 
protein-1. CHD, carcinoid heart disease. 
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Figure 37. Graph showing the median with IQR % area of VAP-1 
expression between the CHD and control valve groups. A significant 
difference is seen between the two groups (p<0.001).  
 
The CHD and control valve sections were reviewed by a pathologist with 
extensive experience in identifying valvular diseases and understanding the valve 
anatomy. IHC staining of VAP-1 in CHD valves shows evidence of VAP-1 
expression in the carcinoid plaque as well as in the atrial/ventricular and fibrous 
valve layers, Figure 38. VAP-1 expression is also present lining the vasculature 
both in the carcinoid plaque as well as in the underlying valve, Figure 39.  
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Figure 38: Representative images of a CHD case with VAP-1 staining 
and matched EHVG staining. VAP-1 staining shown in images a and c, 
and matched EHVG staining shown in images b and d. The three valve 
layers are arrowed in image d (1= fibrosa layer, 2= spongiosa layer, 3= 
atrial / ventricular layer). Carcinoid plaque is evident on the 
atrial/ventricular surface and also on the fibrous surface. N=1. Scale bars 
as illustrated. EHVG, Elastin and Haematoxylin Van Gieson. 
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Figure 39: Representative images of CHD cases with VAP-1 staining. 
VAP-1 staining seen in images Ia, Ic, II and III. Image Ib represents the 
matched EHVG staining for image Ia. Image Ic is the cropped area 
highlighted by the red box in image Ia and images II and III represent 
different CHD cases. VAP-1 can be seen lining vasculature both in the 
carcinoid plaque (blue arrow in images Ic, II and III) as well as in the 
underlying valve (orange arrow in images Ic and II); n=3. Scale bars as 
illustrated.  
 
 
The vascular areas seen within the underlying valve in the above figure could be 
a result of hypoxia secondary to valve injury leading to neovascularisation or may 
occur as a granulation repair response driven by VAP-1 present in the carcinoid 
plaque.  
 
VAP-1 expression was seen to vary according to the CHD valve area. There was 
no VAP-1 expression seen in the chords of the CHD valve, with increasing VAP-
1 expression seen in the myxoid area (a myxoid stroma rich in proteoglycans), 
collagen area and elastin area of the valve respectively. Figure 40. This reflects 
that VAP-1 is expressed in different degrees of fibrosis, where fibrosis is most 
mature in the elastin area, and the absence of fibrosis in the chords of the valve. 
The cells staining positive in the myxoid, collagen and elastin areas do display a 
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stellate appearance. In the myxoid and collagen areas, VAP-1 expression is 
confined to the cells, whereas there is positive staining both in the cells as well as 
in the interstitium with increasing maturity in the elastin areas of the plaque. 
 
Figure 40: Representative images of CHD cases with VAP-1 staining 
and matched EHVG staining through the different fibrotic areas of the 
CHD plaque. Images Ia-c represent the chords (n=3) where no VAP-1 
expression is seen. Images IIa-c represent the myxoid area (n=3), images 
IIIa-c the collagen area (n=3) and IVa-c the elastin area (n=3) of the plaque. 
Increasing VAP-1 expression can be seen reflecting maturity of fibrosis within 
the plaque. The chords are outlined in images a-c, with overlying plaque. 
Scale bars 100 m
 165 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36: Representative images of CHD cases with VAP-1 staining. 
Matched EHVG staining for the same cases are shown below the CHD 
cases. Images Ia-c represent the chords where no VAP-1 expression is 
seen. Images IIa-c represent the myxoid area, images IIIa-c the collagen 
area and IVa-c the elastin area of the plaque. Increasing VAP-1 expression 
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Collagen I and collagen III in CHD and control valves 
Increased expression of collagen I and collagen III was seen in both the CHD 
and control valves, but with greater expression in the CHD valves. Collagen I 
was detected in both the cells producing collagen I and also in the surrounding 
stroma, whereas collagen III stained more selectively. The staining of collagen I 
was greater in the CHD valves compared to the control valves, Figures 41 and 
42.  
 
Figure 41: Representative images of a CHD case and control valve 
case stained with Collagen I and IMC. Image Ia represents collagen I 
staining in a CHD case with the IMC shown in image Ib. Image IIa 
represents collagen I staining in a control valve case with the IMC shown 
in image IIb. N=2. Scale bars 200 m.  
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Figure 42: Representative images of matched CHD cases and 
matched control valve cases stained with Collagen I and VAP-1. The 
top two rows are both CHD cases and the bottom two rows are control 
valve cases. Matched cases have been used for collagen I and VAP-1. In 
all cases, collagen I expression can be seen in cells producing collagen I 
but also in the stroma surrounding the cells. Higher intensity of collagen I 
expression can be seen in the CHD cases compared with the control 
valve cases. N=4. Scale bars 200 m.  
 
Collagen III can be seen to stain more selectively compared with collagen I with 
staining present in the cells producing collagen III and not in the surrounding 
stroma, Figures 43 and 44. Collagen III has similar staining to VAP-1 expression 
seen in the CHD cases. Like collagen I, more intense collagen III staining was 
seen in the CHD cases compared with the control valve cases. 
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Figure 43: Representative images of a CHD case and control valve 
case stained with Collagen III and IMC. Image Ia represents collagen 
III staining in a CHD valve with the IMC shown in image Ib. Image IIa 
represents collagen III staining in a control valve case with the IMC 
shown in image IIb. N=2. Scale bars 200 m.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ia Ib 
IIa IIb 
CHD
Collagen III
Collagen III
Control
IMC Collagen III
IMC Collagen III
CHD
Control
 221 
 
Figure 44: Representative images of matched CHD cases and 
matched control valve cases stained with Collagen III and VAP-1. The 
top two rows are both CHD cases and the bottom two rows are control 
valve cases. Matched cases have been used for collagen III and VAP-1. 
Collagen III can be seen to stain more selectively compared with collagen 
I, with staining present in the cells producing collagen III and not in the 
surrounding stroma. Collagen III has similar staining to VAP-1 expression 
seen in the CHD cases. Less intense collagen III expression can be seen 
in the control valve images compared with the CHD cases as well as 
compared with the collagen I expression seen in control valves. N=4. 
Scale bars 200 m.  
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CD45, CD31 and CD34 in CHD and control valves 
CD45 positive staining was present in both the CHD and control valves. There 
did not appear to be increased CD45 staining in the CHD group compared with 
the control valve group. Figures 45 and 46. 
 
Figure 45: Representative images of a CHD case and a control valve 
case stained with CD45 and IMC. Image Ia represents CD45 staining in 
a CHD valve with the IMC shown in image Ib. Image IIa represents CD45 
staining in a control valve case with the IMC shown in image IIb. N=2. 
Scale bars 200 m.  
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Figure 46: Representative images of matched CHD cases and  
matched control valve cases stained with CD45 and VAP-1 . The top 
two rows are both CHD cases and the bottom two rows are control valve 
cases. Matched cases have been used for CD45 and VAP-1. CD45 
staining is present in both CHD valves and control valves. The staining of 
CD45 appears to be in similar areas to the positive VAP-1 staining 
present. N=4. Scale bars 200 m.  
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CD31 positive vessels were noted in the CHD valves, with very low expression in 
the control valves, highlighting a potential role for VAP-1 in the development of 
valvular neovascularisation, Figures 47 and 48. 
 
Figure 47: Representative images of a CHD case and control valve 
case stained with CD31 and IMC. Image Ia represents CD31 staining in a 
CHD valve with the IMC shown in image Ib. Image IIa represents CD31 
staining in a control valve case with the IMC shown in image IIb. N=2. Scale 
bars 200 m.  
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Figure 48: Representative images of matched CHD cases and 
matched control valve cases stained with CD31 and VAP-1. The top 
two rows are both CHD cases and the bottom two rows are control valve 
cases. Matched cases have been used for CD31 and VAP-1. CD31 
expression can be seen in the CHD valves but not in the control valves 
illustrating the neovascularisation present in CHD. N=4. Scale bars 200 
m.  
 
 
CD34 positive staining is present in both valve types. The staining can be seen 
lining vasculature. Given that CD34 is a progenitor cell marker, the positive 
staining seen in the control valves in addition to the non-vascular areas in the 
CHD valves could represent the differentiating cells present. Figure 49. 
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Figure 49: Representative images of matched CHD cases and 
matched control valve cases stained with CD34 and VAP-1. The top 
two rows are both CHD cases and the bottom two rows are control valve 
cases. Matched cases have been used for CD34 and VAP-1. CD34 
staining can be seen in both valve types. CD34 staining can be seen lining 
vasculature (highlighted by red boxes in CHD images). N=4. Scale bars 
200 m.  
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Dual fluorescent staining in CHD valves 
CHD valve tissue was dual stained with VAP-1 and -SMA, Figure 50 and 
VAP-1 and collagen III, Figure 51. The staining shows the presence of a dense 
stromal and collagen network in the CHD valves. Co-localisation of both 
markers is seen as yellow in both VAP-1/collagen III and VAP-1/-SMA, and 
individual areas of each marker are also seen in the images. Compared to the 
chromogenic staining, positive collagen III staining appears to  be present more 
in the surrounding stroma than the cells producing collagen III and there does 
appear to be a greater collagenous deposition than VAP-1 expression. 
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Figure 50: Representative images of CHD cases dual stained with VAP-
1 and -SMA. The blue staining (Hoerscht) illustrates the nuclei. The red 
staining indicates -SMA, IgG2a Alexa Fluor wavelength 594. The green 
staining indicates VAP-1, IgG2b Alexa Fluor wavelength 488. Images Ia-c 
represent the matched IMC; Ia involves all three channels, Ib represents the 
red channel and Ic represents the green channel. Figures IIa-d and IIIa-d 
represent two different cases. Images IIa and IIIa show the presence of all 
three channels, IIb and IIIb show the presence of -SMA and VAP-1, IIc and 
IIIc show the presence of -SMA and IId and IIId show the presence of VAP-
1. N=2. Scale bars 20 m. Co-localisation of the two markers can be seen as 
yellow in image IIIb (white box), and the cases show the presence of valve 
cells surrounded by a dense stromal network associated with VAP-1. 
Individual areas of -SMA and VAP-1 can also be seen. This therefore 
highlights that cells producing both VAP-1 and -SMA are present in these 
valves, but individual cell types produce each marker independently too. 
Certain areas of VAP-1 expression can also be seen with no -SMA 
expression (represented as a white box in image IIb).  
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Figure 51: Representative images of CHD cases dual stained with 
VAP-1 and Collagen III. The blue staining (Hoerscht) illustrates the nuclei. 
The red staining indicates collagen III, VectaFluor Duet Dylight 594. The 
green staining indicates VAP-1, VectaFluor Duet Dylight 488. Images Ia-c 
represent the matched IMC; Ia involves all three channels, Ib represents 
the red channel and Ic represents the green channel. Figures IIa-d and 
IIIa-d represent two different cases. Images IIa and IIIa show the presence 
of all three channels, IIb and IIIb show the presence of collagen III and 
VAP-1, IIc and IIIc show the presence of collagen III and IId and IIId show 
the presence of VAP-1. N=2. Scale bars 20 m. Co-localisation of the two 
markers can be seen as yellow in image IIb (white box), and the cases 
show the presence of valve cells surrounded by a dense collagen network 
associated with VAP-1. Individual areas of collagen III (orange arrow) and 
VAP-1 (white arrow) can also be seen. Certain areas of VAP-1 expression 
can also be seen with no collagen III expression.  
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S100 and VAP-1 in CHD and control valves and myxoma tissue 
After reviewing the tissue sections with our pathologist, the overlap with cardiac 
myxomas was suggested. Cardiac myxomas are a benign tumour of the heart, 
and represent nearly half of all benign cardiac tumours, with an incidence of 
0.03%.(358, 359) Around 75% of these tumours occur in the left atrium and are 
composed of fibrous and gelatinous areas. The myxoma cells are stellate, with 
the myxoma stroma composed of proteoglycans, elastin and collagen.(359) The 
cells producing VAP-1 appeared to display a stellate appearance, Figure 52.  
 
Figure 52: Representative images of CHD valves stained with VAP-1 
with the cells producing VAP-1 have a stellate appearance. N=2. Scale 
bars 100 m.  
 
The presence of stellate cells in CHD in a myxoid background was found to be 
similar to the myxoma cells seen in cardiac myxomas, and therefore myxoma 
tissue was also stained to see if a similar cell type is present in both diseases. 
One of the cell markers known to be positive in cardiac myxomas is S100 (359, 
360), which also has a stellate appearance, Figure 53. S100 is regulated by 
calcium binding and is capable of actively participating in processes involved in 
cellular proliferation, tumour angiogenesis and metastasis and immune 
evasion.(361) 
 
 
 
 
 
CHD
VAP-1
VAP-1 stellate 
appearance
 234 
 
Figure 53: Representative images of myxoma valves with S100 
staining. Images I and II are separate cases. Images Ib and IIb are 
zoomed in areas of images Ia and IIa respectively. Cells producing S100 
have a stellate appearance (black arrow in image Ib). Haemosiderin can 
also be seen which are golden in colour and granular in appearance (red 
box in image Ib). N=2. Scale bars as illustrated. 
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Myxoma tissue were also stained with VAP-1. VAP-1 expression was present in 
the myxoma tissue and some cells producing S100 did appear to be similar to the 
cells producing VAP-1, Figure 54. 
 
Figure 54: Representative images of matched myxoma cases with 
S100 and VAP-1 staining. Images Ia and IIa illustrate S100 staining and 
images Ib and IIb are matched cases of VAP-1 staining. Some myxoma 
cells producing S100 do appear to be similar to the cells producing VAP-1 
(shown in black boxes). VAP-1 expression can be seen in myxoma tumour 
tissue as well. Image IIa shows the presence of myxoma cells around a 
vessel (black arrow). The stellate cell appearance can be clearly seen in 
Images IIa and IIb (red arrows). VAP-1 can again be seen lining the 
vasculature in image IIb (red box). In all images more VAP-1 positive cells 
can be seen compared to S100 positive cells. Scale bars as illustrated.  
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CHD and control valves were both stained with S100. In CHD, the cells 
producing S100 also have a stellate appearance. S100 positive cells are also 
seen in the control valves. Figure 55. 
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Figure 55: Representative images of CHD and control valve cases 
with S100 and VAP-1 staining. Images I and II are CHD cases and 
images III and IV are control valve cases. Images Ia, IIa, IIIa and IVa 
illustrate S100 staining and images Ib, IIb, IIIb and IVb show paired VAP-
1 staining. Image IIc is a zoomed in area of S100 staining which shows 
the cells producing S100 in CHD also display a stellate appearance. 
S100 positive cells are also present in the control valves. N=4. Scale 
bars as illustrated.  
 
 
Therefore, in summary this chapter shows a significantly increased VAP-1 
tissue expression in CHD valves compared with control valves. A dense stromal 
and collagen network is present in the valves with co-localisation of VAP-
1/collagen III and VAP-1//-SMA seen in some areas. There is increased VAP-
1 expression seen with older ECM in the carcinoid plaque and 
neovascularisation can be seen in the CHD valves but not in the control valves, 
possibly highlighting the angiogenesis role of VAP-1 in CHD. 
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6.4 Discussion 
CHD is a serious complication associated with NETs and can lead to significant 
morbidity and mortality. Some patients may be asymptomatic and therefore 
making the diagnosis of CHD can be delayed where treatment options are then 
limited. Currently, the only definitive treatment for CHD is valve surgery which can 
only be performed if the patient is fit enough to undergo a major operation.  
 
A significant difference in the VAP-1 expression was seen in the CHD cohort 
compared to the control valve cohort. VAP-1 expression was present in both the 
carcinoid plaque as well as in the atrial/ventricular and fibrous valve layers. A 
reason for the increased VAP-1 expression seen in CHD could be that 
expression of VAP-1 is driven by an increase in circulating amines. Either the 
amines themselves or the breakdown products from monoamine oxidases (or 
other amine oxidases) can stimulate certain cell populations to produce VAP-1, 
and subsequent autocrine and paracrine activities perpetuate expression of the 
protein. I would hypothesis therefore that in the control valves the circulating 
levels of amines are below a certain threshold that is required to trigger the 
expression of VAP-1 by these cells.  
VAP-1 lined the vasculature both in the carcinoid plaque as well as in the 
underlying valve. The vascular areas seen within the underlying valve could be 
a result of hypoxia secondary to valve injury leading to neovascularisation, or 
may occur as a granulation repair response driven by VAP-1 present in the 
carcinoid plaque. 
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VAP-1 expression varied according to the CHD valve area. There was no VAP-1 
expression seen in the chords of the CHD valve, with increasing VAP-1 
expression evident with increasing degrees of fibrosis as revealed by EHVG 
staining. Increasing expression was seen in the myxoid area, collagen area and 
elastin area of the valve where fibrosis is most mature in the elastin area. The 
carcinoid plaque may contribute to a change in the nutrients, vascular supply and 
oxygenation to the plaque which then leads to development of the myxoid layer, 
and as the fibrosis matures, the collagen and the elastin layer then form. A scoring 
system for VAP-1 expression could be proposed, reflecting expression present in 
chords, myxoid, collagen and elastin area respectively. 
 
Collagen I and collagen III were expressed in both the CHD and control valve 
groups. Collagen III stained more selectively than collagen I, with collagen I 
expression seen in both the cells producing collagen I as well as in the stroma 
surrounding the cells, whereas collagen III was seen in the cells producing it and 
not in the surrounding stroma. The positive staining seen in the control valves is 
probably because the control valves are not completely normal valves and 
therefore will have some pathology associated with them. CD45 positive staining 
was present in the CHD and control valves, and VAP-1 may have a role in the 
immune cell recruitment seen. In the control valves, the positive staining could be 
explained by the underlying valve injury that has occurred with the activation of 
VICs. Positive CD31 staining was seen in the CHD valves but not in the control 
valves, and this could be attributable to the angiogenesis role of VAP-1 leading to 
neovascularisation.  
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Another reason for the fibrosis and inflammatory cell recruitment seen in CHD 
could be that the products released by VAP-1 including hydrogen peroxide lead 
to further valvular damage which then results in the activation of VICs to enable 
valvular remodelling and repair. In the diseased CHD valves, the VICs stay in a 
continuous activated state leading to fibrosis, calcification and inflammation.  
 
The dual fluorescent staining showed that VAP-1 was associated with a dense 
stromal and collagen network in the CHD group. Co-localisation of both VAP-
1/collagen III and VAP-1/-SMA were present but with reduced expression 
compared to the individual areas of -SMA or collagen III and VAP-1 seen. This 
highlights that cells producing both VAP-1 and either collagen III or -SMA are 
possibly present in these valves, but individual cell types also produce each 
marker independently. Certain areas of VAP-1 expression was present with no -
SMA / collagen III expression, which could suggest circulating soluble VAP-1 
adhering to the carcinoid plaque and underlying valve matrix. Therefore more 
advanced techniques such as single cell RNA sequencing or laser capture 
microdissection may allow us to identify different stromal cell populations within 
these tissues, e.g. VAP-1+-SMA- or VAP-1--SMA+, which have discrete 
functions. 
 
The cell type producing VAP-1 displays a stellate appearance. This is also seen 
in cardiac myxomas where single stellate cells are embedded in a myxoid 
stroma.(362) S100 is a marker that has been shown to be positive in this cardiac 
tumour.(363) The cells producing S100 in CHD also displayed a stellate 
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appearance. S100 positive cells were also present in the control valves, which is 
not surprising given that S100 is a marker for one cell type of the valvular pVICs 
which is a source for activated valve interstitial cells following valvular 
injury.(253) Interestingly, the myxoma tissue also stained positive for VAP-1, 
and therefore could also be a potential treatment target in this group of patients.  
 
6.5 Conclusion 
CHD valves are associated with a dense collagen and stroma network with strong 
VAP-1 expression and the development of neovascularisation. VAP-1 may be a 
key driver of the cardiac fibrotic complication seen in NETs. Treatment options for 
CHD are limited at present, and diagnosis may be delayed if patients are 
asymptomatic or current biochemical markers used in clinical practice are normal. 
VAP-1 can therefore be utilised in various ways for CHD: it can be tagged with 
imaging, including both functional and anatomic imaging to diagnose the degree 
of fibrosis present, and it can also be used as a potential treatment target. 
Additionally, it can have a non-invasive role in the measurement of serum VAP-1 
levels in this group which can then lead on to further investigations, diagnosis and 
treatment in a timely manner. This would therefore enable patients with CHD to 
have an additional treatment offered, which could potentially be given to those 
unsuitable for cardiac surgery, with an overall aim of improving their quality of life 
and overall survival.   
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7.1 Overview 
At present there can be a delay in diagnosing cancer at an early stage and 
detecting complications associated with the underlying tumour. This can then lead 
to limited treatment options available to patients once the cancer or associated 
complications have progressed to a certain stage or when the patient is physically 
not well enough to undergo invasive treatment, thereby increasing their morbidity 
and mortality.  
 
Accurate biomarkers that assist clinicians in identifying and diagnosing early 
cancer correctly are ideal and beneficial. The prompt identification of 
complications associated with cancer is also necessary. Early cancer diagnosis 
and the recognition of the presence of complications associated with the 
underlying cancer both allow further investigations to be performed, with more 
treatment options available and the early commencement of treatment which in 
turn will improve patients’ overall quality of life and survival.  
 
7.2. Summary of principal findings 
7.2.1 PIVKA-II in early HCC 
PIVKA-II has been widely studied mainly in Asia and has been incorporated into 
the Japanese guidelines as part of HCC surveillance in their at-risk groups.(364) 
However, there is limited published data in Europe looking at the role of PIVKA-II 
in diagnosing early HCC. No studies in the UK have yet directly compared the role 
of PIVKA-II in diagnosing early HCC with AFP and evaluating which marker has 
a better sensitivity and specificity. Two scores (GALAD and BALAD-2) evaluated 
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in the UK have been shown to optimise the sensitivity and specificity in diagnosing 
HCC as well as showing a clear differentiation in the four different BALAD-2 score 
categories in the UK median survival.(48, 306) However, PIVKA-II’s association 
with prognosis and the response of PIVKA-II with ablation treatment remain 
unknown.  
In the data shown in chapter 3, PIVKA-II was not found to be superior to AFP in 
diagnosing early HCC and the combination of both markers was only marginally 
superior to AFP alone. These findings differ from previous studies where PIVKA-
II was found to be a better marker in diagnosing early HCC compared to AFP,(98, 
119), and the combination of both makers has a better performance in diagnosing 
HCC including in the early stages.(121, 365) Previous studies have shown similar 
results to these findings where AFP is superior to PIVKA-II in diagnosing early 
HCC.(22, 120) PIVKA-II was found to be superior in advanced stages of disease 
and showed a better performance in larger tumours, in keeping with previous 
studies.(130, 131) On explant histology, pre-transplant PIVKA-II levels were found 
to be significantly higher in the presence of MVI and in moderately- or poorly-
differentiated HCC, which was not seen with AFP. Previous studies have also 
shown similar results with increased PIVKA-II levels seen in MVI, in moderately- 
or poorly-differentiated HCC, and has also been found to independently predict 
the presence of MVI.(122, 123) In this longitudinal analysis where samples were 
taken pre- and post-ablation, results showed that those who developed 
recurrence tended to have higher AFP and PIVKA-II levels that increased over 
time. There was a 100% vs 0% estimated recurrence rate in those with a pre-
ablation PIVKA-II of 125 mAU/mL vs <125 mAU/mL. However, a weaker 
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association was seen with the pre-ablation AFP and estimated recurrence rate. 
Therefore, these findings do raise the need to consider whether AFP should be 
incorporated back into clinical guidelines in the surveillance of HCC in patients 
with cirrhosis. A meta-analysis published in 2018 found that in HCC patients 
treated with ablation and had elevated PIVKA-II levels, this was significantly 
associated with a poorer overall survival and recurrence-free survival.(139) A 
Japanese group showed that the cumulative survival rate, recurrence-free 
survival rates and staying within the MC were significantly lower in patients treated 
with ablation who had a PIVKA-II 100 mAU/mL compared to a PIVKA-II <100 
mAU/mL.(141) 
Compared to other biomarkers that have been studied, the sensitivity of PIVKA-II 
was found to be superior in this study compared to previous study findings of the 
sensitivity of AFP-L3 in diagnosing early HCC, but similar to GPC3.(11, 37) OPN, 
GP73 and molecular biomarkers were found to have a higher sensitivity in 
diagnosing early HCC compared to PIVKA-II.(28, 39, 44) A higher specificity in 
diagnosing early HCC was seen with a AFP-L3, GPC3 and molecular biomarkers 
compared to PIVKA-II.(22, 37, 44)  
PIVKA-II could be a prognostic marker in HCC and may support patient 
stratification for therapy, in particular when a decision for ablation vs 
transplantation is being considered. PIVKA-II does also show a promising role in 
the surveillance of recurrent HCC post-ablation. A multi-centre analysis would 
validate PIVKA-II in patient cohorts in the UK. Additionally, assessing the use of 
the GALAD score and comparing this to individual markers would be beneficial in 
the UK to determine which method has the greatest sensitivity and specificity in 
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diagnosing early HCC. Increasing numbers in the longitudinal analysis and across 
various UK centres would also help to evaluate the role of PIVKA-II in the UK as 
a surveillance marker of developing recurrent HCC post-ablation, thereby 
enabling patient stratification for therapy. 
 
7.2.2 VAP-1 in NETs 
Despite NETs being generally slow-growing tumours, they can be associated with 
significant GI and cardiac valve pathology related to the underlying fibrosis.(196) 
This can then lead to complications that include intestinal obstruction and bowel 
ischaemia / infarction, CHD and heart failure. When GI complications occur, 
surgery is the only effective treatment. However, patients need to be fit enough to 
undergo surgery, and side-effects following surgery may also be problematic. 
CHD is the major cause of mortality and morbidity in patients with NETs and valve 
surgery is the only treatment that can be offered to patients and again, the patient 
has to be physically fit enough to have the operation.(213, 245) CHD can be 
asymptomatic, leading to a delayed diagnosis when the disease is at an advanced 
stage and treatment options are limited. Current biomarkers that are used in NETs 
are primarily used for monitoring of cancer, treatment response and to help 
determine overall prognosis. These include CgA, CgB, 5-HIAA and NT-proBNP. 
Higher levels of CgA correlate with tumour bulk (202) and 5-HIAA represents the 
hormone secretion by the tumour with elevated levels likely to be present in 
CS.(204, 210) NT-proBNP is a marker used to screen for CHD.(216) However, at 
present, there are no biomarkers that may indicate the presence of fibrosis which 
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will allow further investigations to be performed and treatment to be commenced 
at an earlier opportunity.  
 
Circulating sVAP-1 have been shown to be higher in chronic liver disease, with 
levels correlating with the degree of fibrosis present.(277) Increased levels have 
also been found to be associated with a poorer liver transplant-free survival (either 
death or liver transplant).(291) There are trials that are targeting VAP-1 in their 
treatment, by either using a monoclonal antibody or a small molecule inhibitor of 
VAP-1.(323, 324)  
I have therefore assessed the role of VAP-1 in NETs and CHD both as a 
circulating form as well as the tissue expression of this molecule, to see whether 
this marker could be associated with the presence of fibrosis seen in NETs.  
 
7.2.2.1 The role of circulating sVAP-1 in NETs 
The data in chapter 4 has shown significantly higher levels of sVAP-1 in 
pancreatic NETs, midgut NETs and CHD vs healthy controls. Analysing the 
midgut NET, CHD and healthy control groups alone, a significant difference in 
sVAP-1 levels was found between the midgut NET vs healthy controls, CHD vs 
healthy controls and midgut NET vs CHD. Interestingly the pancreatic NETs only 
showed a significant difference in sVAP-1 levels compared to the healthy controls 
and there was no significant difference in levels between the pancreatic NETs vs 
midgut NETs, nor the pancreatic NETs vs CHD groups. Despite the presence of 
CHD in pancreatic NETs being uncommon, circulating sVAP-1 levels did not differ 
significantly between both groups.  Analysing the midgut NET and CHD groups 
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together, neither the presence of liver metastases, nor having surgery pre-sample 
collection influenced sVAP-1 levels. These findings differ from previous studies 
which have shown levels of sVAP-1 in other malignancies including colorectal 
cancer decreasing with disease progression.(297, 320) However, there have 
been similar findings with raised sVAP-1 seen in HCC.(322)  
The longitudinal analysis demonstrated no significant change in sVAP-1 post-
treatment, similar to the markers currently used in clinical practice. Similarly, no 
significant differences were seen in sVAP-1 levels in patients who underwent 
surgery prior to the first sample being taken compared to those who did not 
undergo surgery. Despite these results, a significant reduction was observed in 
the carcinoid syndrome symptoms experienced. Therefore, this highlights that 
sVAP-1 levels do not resemble the carcinoid symptoms experienced, and the 
symptoms improve after treatment when a reduction in hormone levels is the likely 
factor for this, whereas the underlying fibrous stroma is not affected by the 
treatment. Another possible reason is that the half-life of the circulating sVAP-1 
levels is currently not known, and therefore serial measurements are required at 
the same timepoints for each patient in order to further assess the role of 
circulating sVAP-1. 
 
Overall across the three disease groups, significant correlations were found 
between sVAP-1 and BMI (significant negative correlation), and sVAP-1 and 
HbA1c (significant positive correlation). Various studies have shown different 
correlations between sVAP-1 and BMI. A previous study has shown similar results 
with BMI correlating indirectly with sVAP-1 levels in women.(325) However, 
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another study showed no correlation between sVAP-1 levels and BMI (366), 
whereas a different study showed a direct correlation between sVAP-1 levels and 
morbid obesity in non-diabetics.(367) A study has shown that sVAP-1 levels are 
increased in type 1 diabetics, and that the elevated glucose levels did not increase 
sVAP-1 levels, but instead, circulating insulin concentrations indirectly correlate 
with sVAP-1 levels.(368) Increased levels of sVAP-1 are also thought to be a 
response to hyperglycaemia (369) and, through the SSAO activity of VAP-1 
regulates glucose homeostasis by increasing glucose uptake and glucose 
transporter-4 expression.(370) 
 
Circulating sVAP-1 levels could be an effective stratification marker for patients 
with NETs to predict outcomes and where to escalate therapy.  Multi-centre 
evaluation of sVAP-1 levels within the UK and internationally would be 
important to validate this not only as a biomarker but also as a prognostic 
marker. My work has helped us collaborate with another large NET centre in 
Manchester, and we will also be receiving serum samples from their cohort of 
patients for sVAP-1 analysis. Immunohistochemistry analysis of pancreatic 
NETs is required to assess in further detail the tumour microenvironment and 
analyse the presence of fibrosis seen in this group. 
 
7.2.2.2 Tissue expression of VAP-1 in NETs 
Knowledge of the tumour microenvironment is important to gain an 
understanding of potential mechanisms occurring in the tumour stroma that may 
lead to tumour growth, survival and metastases.(333)  Previous findings have 
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shown that there is predominantly a desmoplastic reaction with limited 
leucocyte presence in midgut NETs, therefore differing to other cancer 
microenvironments.(330) Limited knowledge is known on the exact ECM 
composition in midgut NETs but these tumours are known to highly express -
SMA in the tumour stroma.(336) 
In CHD, the exact pathogenesis leading to this fibrotic complication is not fully 
understood. Exposure of high levels of serotonin and other vasoactive 
substances are thought to be involved in the pathogenesis and development of 
CHD.(355)  
 
Tissue expression of VAP-1 was analysed in both midgut NETs and CHD with 
the data shown in chapters 5 and 6. In summary, the presence of VAP-1 is 
seen associated with a dense stromal and collagen network in both midgut 
NETs and CHD. An immune cell involvement can be appreciated with positive 
CD45 cells in a similar area to the presence of VAP-1. However, this is an 
observational finding and a previous study has shown the adhesive function of 
VAP-1 which drives the immune cell infiltration.(277) A similar underlying 
mechanism may also be present in midgut NETs. Staining midgut NET tissue 
sections with -SMA and VAP-1 showed that the fibroblasts were in a very 
similar distribution to VAP-1, therefore suggesting that a similar cell type 
produces both markers. This is in keeping with previous findings of increased 
expression of -SMA in the tumour stroma of midgut NETs.(336) Additionally, 
liver myofibroblasts have been shown to control both lymphocyte recruitment 
and positioning (351), and VAP-1 may have a similar role in controlling the entry 
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and retention of immune cell populations via either its adhesive function or 
enzymatic activity. Co-localisation of both VAP-1 and -SMA, and VAP-1 and 
collagen I/III in both midgut NETs and CHD was present but with very low 
expression compared to areas of individual markers seen. Areas without 
overlap may be due to the presence of sVAP-1 associating with additional 
undefined cell types, and cells that have secreted VAP-1 into the media or 
downregulated VAP-1 protein production. Further studies using confocal 
microscopy with z-stack images and a broader cell marker panel are required to 
determine the extent of co-localisation. VAP-1 was seen in the ECM evident in 
midgut NETs, which may be the circulating sVAP-1 adhering to this area. 
Significantly higher tissue expression of VAP-1 was noted in the CHD valves 
compared to the control valves. Interestingly, increasing VAP-1 expression was 
seen through increasing fibrotic areas of the CHD plaque. This could be 
incorporated into a scoring system to help grade the severity of fibrosis in CHD.  
The fibrosis and inflammatory cell recruitment seen in CHD could also be a 
result of the products released through the enzymatic activity of VAP-1 including 
hydrogen peroxide leading to further valvular damage, with resulting activation 
of VICs in response to valvular injury.(253) Positive CD31 staining was found in 
the CHD valves but not in the control valves. This could be the result of the 
angiogenesis role of VAP-1 resulting in neovascularisation which may be seen 
in tumour.(371) In order to confirm these possible explanations the mechanistic 
role of VAP-1 in CHD needs to be performed in future work. The cell type 
producing VAP-1 in CHD displayed a very similar appearance to the myxoma 
cells seen in cardiac myxomas.(362) To assess this further, S100 staining was 
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performed in both control and CHD valves, with positive staining seen in both 
groups. The cells producing S100 did appear to have a stellate appearance 
similar to VAP-1. Myxoma tissue was also stained with VAP-1 with positive 
expression seen, therefore suggesting VAP-1 could also be a future treatment 
target in cardiac myxomas.  
 
Therefore, the tissue expression analysis of VAP-1 has shown that this molecule 
may play a role in the fibrosis seen in midgut NETs and may be involved in the  
pathogenesis and development of CHD. A previous study has suggested that 
there are discrete populations of fibroblasts that may be activated by different 
factors (296) and VAP-1 positive fibroblasts also expression the transcription 
factor NKX2-3, and therefore, this may also be a similar reason for the VAP-1 
expression seen in NETs and CHD with expression being driven by certain 
mediators or the tumour ECM. In CHD, VAP-1 may also be a receptor to the high 
levels of circulating amines that then drives the fibrotic process and activates the 
VICs present in cardiac valves, accentuating the production of a fibrous stroma 
and a rich ECM seen in CHD. The association of VAP-1 and ECM in other tumours 
and fibrous tissue has not been fully explored and sVAP-1 may be trapped either 
on or in the ECM and then influence the immune and other cells function. Future 
trials comparing using a VAP-1 antibody vs. an enzyme inhibitor would be 
worthwhile looking into. The VAP-1 antibody solely blocks the VAP-1 receptor and 
the adhesive function of VAP-1 and does not have any effect on blocking the 
catalysis of small molecule amines. Therefore by comparing both the antibody 
with the enzyme inhibitor will allow us to understand if it is only the adhesive 
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function which is required to drive the fibrotic process or immune cell recruitment 
or if the enzyme function of VAP-1 is also necessary for this to take place. 
 
7.3 Study limitations and study strengths 
In this thesis, the biggest limitation for both projects are the low numbers of study 
participants for serum analysis, particularly in the longitudinal analyses. 
Additionally, in the longitudinal analyses, exact time-points for sample collections 
have not been taken for each patient with either a variable number of follow-up 
samples being taken or just one measurement post-treatment analysed. 
Therefore the timing and number of follow-up samples for all patients have not 
been consistent in either project. Serum samples taken for both projects were only 
from one centre. Having a multi-centre participation would not only increase 
patient numbers in both studies, but would also validate VAP-1 as a potential 
biomarker in NETs and CHD.  
 
A limitation in the VAP-1 project is that the circulating sVAP-1 samples were not 
matched to the tissue sections analysed, and therefore no direct correlation 
between circulating sVAP-1 and tissue VAP-1 expression could be done. With the 
tissue sections stained in both the midgut NETs and CHD groups, no clinical 
information on the patients was known, and therefore correlating tissue 
expression of VAP-1 with demographics and various clinical factors could not be 
done. Additionally, the enzymatic function of VAP-1 is not known in these samples 
nor the levels of circulating amines present which may be driving the 
pathogenesis and expression of VAP-1. The findings of the tissue VAP-1 
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expression in NETs and CHD in this thesis are purely observational findings, and 
therefore do not suggest the underlying mechanistic role of VAP-1 in this group 
of tumours nor in CHD. 
 
There are a number of strengths in both studies. Firstly, for both projects, this is 
the first time PIVKA-II has been analysed in the UK and compared it to AFP as a 
potential marker for diagnosing early HCC as well as a treatment response marker 
following ablation. Similarly, for the first time, the role of VAP-1 in NETs and CHD 
has been assessed both as tissue expression and also as a circulating form. 
Another strength of the PIVKA-II project is that pre-transplant serum PIVKA-II 
levels were matched with explant histology for all patients, and therefore allowed 
prognostic factors to be assessed according to serum PIVKA-II levels. In the VAP-
1 project, the Queen Elizabeth Hospital Birmingham is one of the largest CHD 
centres, which allowed a good size CHD cohort to be recruited into the study. 
 
7.4 Suggested future work 
The PIVKA-II data presented in this thesis is very interesting and the suitability of 
PIVKA-II as a potential surveillance marker for recurrent HCC post-ablation is 
promising. Expanding numbers overall and having a multi-centre analysis would  
greatly strengthen the analysis of PIVKA-II in the UK. Further assessment in 
comparing PIVKA-II to other biomarkers discussed earlier (AFP-L3, GPC3, OPN, 
GP73, nucleic acids and miRNAs), in addition to the combination of biomarkers, 
is required in different centres in the UK to establish the optimal biomarker(s) 
required to diagnose early HCC. Additionally, comparing individual markers to the 
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GALAD score would allow us to evaluate which combination or marker(s) is the 
optimal way to diagnose early HCC in at-risk patients to enable an early diagnosis 
to be made so potentially curative treatment can be offered.  
The role of VAP-1 in NETs and CHD shown in this thesis are observational 
findings. Evaluating the mechanistic role of VAP-1 in pre-clinical models would 
allow us to understand the pathways and mechanisms involved in the 
pathogenesis of fibrosis and development of CHD. Increasing numbers of study 
participants from various NET specialist centres would allow us to validate VAP-
1 as a biomarker and a prognostic marker in NETs and CHD, and collaborations 
with The Christie Hospital are already underway. Additionally, at present NT-
proBNP is the most effective biomarker used to screen for CHD.(218) 
Comparisons between sVAP-1 and NT-proBNP would be interesting to see which 
of these two markers is the best way to detect and diagnose CHD. Using reagents 
that target VAP-1 could be conjugated with either anatomic or functional imaging, 
which could both diagnose the presence of fibrosis and be used as treatment 
target in patients. VAP-1 has been shown to be expressed under normal 
conditions in vascular endothelial cells, adipocytes and smooth muscle cells.(371) 
Therefore targeting VAP-1 in NETs or CHD, may also affect VAP-1 expressed in 
non-target cells and have detrimental effects on normal tissue homeostasis. The 
precise role of VAP-1 in the modulation of ECM is not entirely known, and if VAP-
1 is associated with the deposition and/or maturation of elastin, blocking VAP-1 
may also disrupt the development of ECM components potentially leading to 
adverse events. It is known that genetic knockout of lysyl oxidase, a related amine 
oxidase that contributes to cross-linking of collagens and elastin (372) in mice 
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leads to perinatal death from weakening of the arterial walls.(373, 374) Therefore, 
a similar effect may also occur in humans by blocking VAP-1 if the timing and 
dosing is not chosen carefully. The circulating soluble form of VAP-1 may also 
have an undescribed beneficial role in human biology, and by removing this 
protein pool from the circulation may lead to increased potential for systemic 
inflammatory responses. A previous study has shown that using conjugated 
siglec-9 (lymphocytic ligand to VAP-1) with 68Ga-DOTA imaging showed positive 
uptake in areas of tumour and inflammation.(284) Finally, plans are underway to 
enable a scoring system of fibrosis in NETs using radiological imaging which 
could then be matched to circulating sVAP-1 levels to enable an earlier 
recognition of fibrosis present, so treatment can then be offered at an appropriate 
time, thereby improving overall morbidity and mortality in this group of patients. 
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